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ABSTRACT 
GH acts through its specifie receptor, GHR. In the human liver, more than 
twelve hGHR mRNAs are transcribed from unique 5'UTR exons, seven of 
which are found in two small clusters: module A (V2,V9,V3) and module B 
(V7,Vl,V4,VB). While module A mRNAs are ubiquitously expressed, 
module B transcripts are restricted to normal postnatalliver, suggesting 
developmental- and liver-specific regulation of the hGHR gene. 
To begin characterising the elements regulating module B mRNA 
expression, 1 studied the promoter region of the Vl exon, the most 
abundantly expressing variant in liver. A LB kb region upstream of the Vl 
transcriptional start site (TSS) was actively repressed in transient 
transfection assays (TIAs). However, 5' or 3' deletions relieved the 
suppression, suggesting the presence of multiple negative and positive 
regulatory elements. Two sites for growth factor independence-l (Gfi-l) 
and Gfi-lb and a GAGA element were identified in the most 3' 300 bp 
regulatory region. Gfi-l was detected by western blot in human foetal and 
postnatalliver. Gfi-l and Gfi-lb strongly repressed while the Drosophila 
GAGA factor (GAF) stimulated Vl transcription through their specifie sites, 
as determined by lTAs and site-directed mutagenesis (SDM). Six putative 
sites for hepatic nuclear factor-4 (HNF-4) were also identified in the LB kb 
region. HNF-4a is developmentally regulated in human liver: HNF-4a2 
and aB proteins are expressed in foetal hepatocytes but only HNF-4a2 is 
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detected postnatally. TIAs and SDM demonstrated that HNF-4a2 and 
HNF-4a8 have a similar dual effect on V1 transcription: activation via site 
#1 in the proximal promoter and repression through site #6, ~1.7 kb 
upstream of the TSS. Results from EMSA/EMSSA/ChIP analyses suggest 
these sites are bound by HNF-4a. 
Thus, V1 transcriptional activity is repressed by Gfi-1/Gfi-1b, stimulated 
through a GAGA element by GAF, and repressed or stimulated by HNF-4a 
(2+8) depending on the site. Similar sites are present in homologous 
regions of the bovine, ovine and mouse GHR genes suggesting that their 
regulatory roles are conserved. However, none of these factors 
individually appear to be responsible for the postnatal hepatic-specific 
expression of V1 mRNA. To define the specifie regulatory mechanisms, 
future studies should examine their interactions with additional liver-
enriched factors (e.g. C/EBPa). 
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ABRÉGÉ 
L'hormone de croissance (GH) agit à travers son récepteur spécifique, le 
GHR. Dans le foie humain, on compte plus que douze ARNm qui sont 
transcrits à partir d'uniques exons 5'UTR, dont sept ont été trouvés 
répartis sur deux petits clusters: le module A 012,V9.V3) et le module B 
(V7,V1,V4,V8). Si les ARNm du premier module sont exprimés d'une 
manière ubiquitaire, les transcrits du deuxième module sont, cependant, 
spécifiques au foie postnatal normal. Ceci suggère une régulation du 
gène hGHR spécifique au développement et à la régulation hépatique. 
Pour ainsi caractériser les éléments régulant l'expression des ARNm du 
module B, j'ai étudié la région du promoteur de l'exon V1, la variante la 
plus exprimée dans le foie. La région à 1,8 kb en amont du site de 
transcription (TSS) a été activement réprimée dans les essais de 
transfection transitoire (lTA). 
Toutefois, des délétions 3' et 5 ' relâchent cette suppression, suggérant la 
présence de plusieurs éléments régulateurs positifs et négatifs. En effet, 
deux sites de facteurs de croissance independence-1 (Gfi-1), Gfi-l et Gfi-
lb, et un élément GAGA ont été identifiés dans la région régulatrice 3' 300 
bp. Le Gfi-1 a été détecté par western blot dans le foie humain fœtal et 
postnatal. Comme il a été déterminé par mes expériences de TTAs et de 
mutagenèse site-dirigée (SDM), Gfi-1 et Gfi-1b répriment alors que le 
facteur GAGA de drosophile (GAF) stimule, via leurs spécifiques sites, la 
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transcription du Vl. Six sites potentiels pour le nuclear factor-4 (HNF-4) 
ont été également identifiés dans la région 1,8 kb. HNF-4a est régulé, au 
cours du développement, dans le foie humain: les protéines HNF-4a2 et 
a8 sont exprimées dans les hépatocytes fœtaux, mais seulement HNF-4a2 
qui est détectée à l'état postnatal. 
TTAs et SDM ont démontré que HNF-4a2 et HNF-4a8 ont un effet dualiste 
similaire sur la transcription de V1 : d'une part, une activation via le site 
#1 dans le promoteur proximal et, d'autre part, une répression à travers 
le site #6, environ 1,7 kb en amont du TSS. Les résultas des analyses 
EMSAjEMSSNChIP suggèrent que HNF-4a s' s'attache à ces sites. 
Aussi, l'activité «transcriptionnelle» du V1 est-elle réprimée par Gfi-1jGfi-
lb, stimulée par GAF à travers l'élément GAGA et désactivée ou activée 
par HNF-4a (2+8), dépendamment du site. 
Des sites similaires sont présents dans des régions géniques GHR 
homologues chez les bovins, les ovins et chez la souris, indiquant que 
leurs rôles régulateurs ont été conservés. Toutefois aucun de ces facteurs 
ne semble être responsable, d'une manière individuelle, de l'expression 
postnatale spécifique du ARNm V1 pour définir de tels mécanismes 
régulateurs, les analyses ultérieures devront examiner de plus près les 
interactions de ces sites avec d'autres facteurs hépatiques (ex. CjEBPa). 
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CHAPTER 1: INTRODUCTION AND LITERATURE 
REVIEW 
1.1. Growth Hormone (GH) 
GH is weil known as a major regulator of postnatal growth and 
metabolism (1). GH was first isolated from rat pituitary extracts, and 
subsequently from bovine (2;3). Studies with porcine and bovine GH 
showed that monkeys and humans did not respond to subprimate GH, 
suggesting species specificity [reviewed in (4)]. In the 1950'5, GH was 
isolated from human and monkeys and tested in humans. It was 
discovered in the 1960'5 that GH could be used to treat GH-deficient 
children. Subsequently, GH was extracted from human cadavers and used 
in treating GH deficiency. However in 1985, Creutzfeldt-Jakob disease 
was diagnosed in severa 1 patients who had been treated with extracted 
pituitary hGH, thus the treatment was withdrawn from the North American 
market. At that time, a budding North American pharmaceutical 
company, Genentech, developed recombinant GH (rGH). The FDA (Food 
and Drug Administration) quickly approved Genentech's rGH (Protropin) 
for treatment in 1985 [reviewed in (4)]. Severa 1 other companies now 
produce rGH including Eli Lilly and Serono. rGH remains the chosen mode 
of treatment for GH deficiencies to this day. 
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1.1.1. Structure of GH 
GH, a 191 amino acid polypeptide, belongs to the helix bundle peptide 
(HBP) hormone family that includes the closely related hormone, prolactin, 
and severa 1 haematopoietic cytokines (5). As the name suggests, HBP 
hormones are composed of four a-helices that run in an anti-parallel 
fashion (5;6). 
The hGH gene consists of five exons, and four introns and is part of a 
highly conserved five gene cluster spanning ---66 kb on chromosome 
17q22-24 (7;8). The five genes are in the order 5' to 3': pituitary GH 
(GHN), Placentallactogen-L (PL-L), PL-A, GH variant (GHv) and PL-B (9). 
GHN, or GH1 as it is sometimes known, is expressed primarily in the 
somatotropic cells of the anterior pituitary; PL-A, PL-B and GHv are 
produced in the syncytiotrophoblastic cells of the placenta. PL-L is 
considered a pseudogene even though mRNA transcripts have been 
detected (10). GHv is produced by the placenta beginning ---6 weeks post 
conception and secreted only into maternai circulation, gradually replacing 
GHN in the mother (10). 
GHN is the major circulatory form of GH. Secretion in the foetus has been 
detected from ~6 weeks, rising to 120-150 ngjml at midgestation, 
followed by a slow decline although levels remain high into the first few 
weeks of postnatallife [reviewed in (11-13)]. It drops thereafter to ---10 
ngjml in children and adults. Alternative splicing of exon 3 of GHN 
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transcripts produces two variants, 22 kDa (191 aa) and 20 kDa (176 aa), 
and an exon 3 deficient form, 17.5 kDa. The major forms (22 kDa and 20 
kDa) account for 75-85% and 15% of circulating GH, respectively. Both 
isoforms have somatotrophic and lipolytic actions, although the 20K 
isoform has been shown to have weaker anti-insulin-like effects [reviewed 
in (11)]. 
1.1.2. Regulation of GH secretion 
GH is secreted from the pituitary somatotrope in a pulsatile manner, with 
7-10 episodic bursts per day, and a nocturnal surge (14). For severa 1 
years, trough and peak patterns of GH release have been known to be 
primarily under the control of two hypothalamic hormones: the 
stimulatory GH releasing hormone (GHRH) and the inhibitory somatostatin 
(SST) (15;16). Both of these regulatory hormones are released into the 
median eminence and travel to the anterior pituitary via the hypothalamic-
hypophyseal portal system. A third more minor regulatory factor, Ghrelin 
was identified a few years ago (Figure 1) (17). 
GHRH, from the arcuate nucleus of the hypothalamus, interacts with its G-
protein coupled receptor (GPCR), GHRHR, on the somatotropes of the 
anterior pituitary and causes the release of pre-packaged GH secretory 
granules by increasing intracellular cAMP concentrations and activating L-
type calcium channels and, stimulates transcription of GH gene to increase 
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a readily releasable pool of GH. In vitro studies of foetal pituitary explants 
and clinical studies of premature babies have shown that the human 
foetus responds positively to GHRH [reviewed in (11)]. 
On the other hand, the SST inhibition of GH is not effective until after 
birth. SST is produced in the periventricular nucleus. There are five SST 
receptor genes (SSTRl-5), located on different chromosomes [reviewed in 
(18-20)]. The five receptors are GPCRs. SSTR5 is the predominant type 
in rodent and human somatotropes and mediates actions of SST on GH 
secretion [reviewed in (20)]. SST reduces intracellular cAMP byactivating 
inhibitory G-proteins (Gi) and inhibits L-type calcium channels by Go 
activation; it inhibits release of GH but has no effect on GH gene 
transcription [reviewed in (21)]. It has also been shown to reduce GH 
binding to hepatocytes, thereby inhibiting GH-activated pathways in 
hepatocytes (22). 
Ghrelin was identified as an endogenous agonist of the GH secretagogue 
receptor (GHS-R), another member of the GPCR family (17). The major 
form of ghrelin, an n-octanoylated 28 amino acid peptide, was first 
purified from rat and human stomachs (17;23). A minor form, with a 
deletion of glycine 14, des-Gln14-ghrelin, was subsequently purified in 
both species (24;25). 
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Figure 1: Hypothalamic-GH-IGF-l-target organ axis. 
Release of GH from the anterior pituitary is primarily regulated by the 
hypothalamic hormones GHRH and SST. Ghrelin, a third and more minor 
regulating hormone, is mainly produced in the stomach and stimulates GH 
release by acting on the hypothalamus and anterior pituitary. 
GH: Growth Hormone, GHRH: Growth Hormone Releasing Hormone, SST: 
Somatostatin, IGF-1: Insulin-Like Growth Factor. Adapted from (17;26). 
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Ghrelin stimulates GH secretion by interacting with somatotrope GHS-R 
and increasing intracellular Ca2+ concentration through IP3. This increases 
GH levels through GHRH stimulation of somatotropes (27;28). Maximal 
stimulatory effect of ghrelin is 2-3 fold higher than GHRH, however the 
synergistic effects of GHRH and ghrelin are greater than either factor 
alone [reviewed in (29)]. GHS-R, the receptor for ghrelin has been shown 
to be constitutively active. Pantel et al. described patients that presented 
with short stature (30). The patients had a missense mutation in the 
GHS-R that affected its constitutive activity. However the mutant GHS-R 
maintained its responsiveness to ghrelin. Thus the physiological role of 
ghrelin in GH secretion is still unknown. Other effects of ghrelin include 
appetite regulation through effects at the level of the hypothalamus 
[reviewed in (29)]. 
GH and IGF-l negatively feedback on the hypothalamus and anterior 
pituitary to regulate GH secretion (Figure 1). High levels of IGF-1 inhibit 
GH secretion by direct inhibition of the somatotrope and, indirectly, by 
stimulating SST production from the hypothalamus. GH inhibits GHRH 
secretion from the hypothalamus and GH release from the somatotropes 
[(31) and reviewed in (26)]. 
Other factors that affect GH secretion include sleep, feeding, exercise, 
steroids (glucocorticoids, sex steroids, thyroid hormone), stress and 
obesity (1). 
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1.1.3. Gender differences 
GH secretion is sexually dimorphic in rats, mice and, to a lesser extent, 
humans (32-34). In rodents, the sex differences in GH secretion are 
strikingly different. The amplitude of GH bursts is characterised by higher 
peaks and deeper troughs in males than in females. In humans, the 
patterns of GH secretion become gender dependent only after puberty 
and are not as markedly different as in rodents (35-37). In addition, 
women have 2-3 fold higher levels of GH than males due to the frequent 
and irregular pulses of GH release. However, IGF-1 levels are roughly the 
same in both sexes suggesting a relative insensitivity of the GHR-IGF-l 
axis in females (38;39). Neonatal exposure to sex steroids sets the 
patterns of pituitary GH secretion that are later manifest in puberty 
(40;41). The sexual dimorphic pulsatile pattern of GH secretion is 
important in stimulating postnatal growth. This has been shown in GH-
deficient animais where pulsatile rather than continuous GH infusion is 
more effective in restablishing growth (42). 
1.2. Actions of GH 
GH has major actions on growth and metabolism either directly or 
indirectly through IGF-1. GH stimulates longitudinal bone growth, glucose 
transport and metabolism in liver, lipolysis in adipose tissue and liver, and 
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protein synthesis and amino acid metabolism and transport in muscle, 
adipose tissue and liver (Figure 2). 
1.2.1. Growth 
Effects of GH on bone growth and bone minerai density (BMD) are weil 
known even though studies, especially in BMD area of research, are 
limited. Long bone growth occurs at the epiphyseal growth plate by a 
series of finely controlled steps. In the first few weeks of life, the skeletal 
system of the foetus forms as cartilage and connective tissue. 
Endochondral ossification, a process by which cartilage tissue is gradually 
replaced by bone tissue, begins around the eighth week of conception. 
The epiphyseal growth plate lies between the epiphyses and the 
metaphyses of long bones. Chondrocytes in the growth plate are split into 
four zones of progressive chondrocyte maturation: resting or germinal 
zone, proliferative (upper and lower), hypertrophie and calcifying. The 
most distal region is the transitional zone from cartilage to bone. 
Longitudinal bone growth cornes to a hait during late puberty, when the 
growth plate becomes completely ossified. Sex steroids and GH are 
among the hormones that influence bone growth. Initially the 
somatomedin hypothesis suggested that GH stimulated longitudinal bone 
growth through liver production of IGF-l that then circulated to the 
epiphyseal growth plate as an endocrine factor (43;44). 
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Figure 2: Effect of GH on target organs. 
GH, secreted by the anterior pituitary exerts its effects on target cells both 
directly and indirectly (through the production of IGF-l) in the majority of 
cells. 
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This theory was later challenged by the dual-effector hypothesis: GH was 
found to accelerate growth of the rat tibia epiphyseal plate when directly 
injected into the growth plate, suggesting that it can have direct effects 
on longitudinal bone growth (45). In agreement with this, GH has been 
observed to stimulate bone growth both directly and indirectly through 
local IGF-1 production (46). The direct role of GH on bone growth is 
demonstrated by the presence of functional GH receptors (GHRs) on 
chondrocytes of rat, rabbit and human growth plates and the fact that GH 
treatment in igf-1 null mice leads to the normal expansion of the germinal 
(resting) zone (47;48). 
GH also affects bone minerai density: it stimulates both bone formation 
and resorption (49). Bone resorption is carried out by osteoclasts and 
formation of new bone by osteoblasts. Net decreases in bone minerai 
density occur when bone resorption exceeds bone formation as is the case 
in post-menopausal women due to a deficiency in oestrogen. GH 
treatment enhances bone turnover in post-menopausal women with 
osteoporosis, improving their bone mass (50;51). GH also stimulates 
bone turnover in young healthy males (52). GH deficient patients have a 
decrease in their bone minerai density and this condition is reversed by 
GH treatment [(53;54) and reviewed in (55)]. 
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GH, GHR and IGF-l deficiencies ail result in severe growth retardation as 
weil as changes in BMD. The effects of GH and GHR deficiencies are 
discussed in more detail in sections 1.2.7 and 1.4.1. 
1.2.2. Metabolism 
GH exerts a range of metabolic effects on target tissues (Figure 2). The 
metabolic effects depend on the length of exposure to GH. When 
administered acutely, GH has insulin-like effects and stimulates glucose 
uptake and lipogenesis. The effect of chronic exposure to GH is quite the 
opposite: anti-insulin-like effects are observed. This is especially evident 
in acromegalics that may also develop type II diabetes (26). In the 
upcoming sections of the literature review, the major focus of GH 
metabolic effects will be on the liver as the experimental work of this PhD 
thesis is focused on hepatic GHR expression. 
1.2.2.1. Effect of GH on glucose metabolism in the liver 
The effects of GH on glucose metabolism were evident even before its 
isolation in the 1940'5 (56). Anti-insulin-like effects of GH were first 
observed in experimental diabetic dogs in the 1930'5 by Houssay and 
Biasotti: hyperglycaemia was reduced in these animais following 
hypophysectomy (57). The factor responsible for this action was later 
isolated from the pituitary and identified as GH (2;3;56). Much of the 
known and documented effects of GH are in the postnatal individual. 
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However, there is evidence to suggest that GH plays a role in glucose 
metabolism in the foetalliver as weil. In the developing foetus, the liver 
is a major site for haematopoiesis, until late gestation, when the site of 
haematopoiesis moves to the bone marrow and the liver begins to adopt 
the metabolic functions that are seen in the adult. Receptors for GH are 
present on hepatocytes from as early as 8 weeks of foetal life in the 
human (58-60). Furthermore, these receptors are similar in structure and 
size to those present on adult hepatocytes (59). The functionality of 
foetal GHRs is shown by stimulation of glucose uptake by primary cultures 
of hepatocytes from 15-20 week old foetuses in response to GH (59). In 
addition, newborns with GH deficiency are often born with hypoglycaemia, 
indicating an important role for GH in glucose metabolism of the late 
gestation foetus (61). 
GH effects on glucose metabolism have been studied in detail in healthy 
individuals and type 1 diabetics [reviewed in (62)]. GH increases fasting 
glucose levels by stimulating gluconeogenesis and glycogenolysis in 
hepatocytes. It also decreases use of glucose in peripheral tissues by 
inhibiting glycogen synthesis and oxidation of glucose [reviewed in (62)]. 
PEPCK and GLUT-2, two proteins involved in glucose metabolism and 
transport, have been shown to be regulated by GH in the mouse (63). 
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1.2.2.2. Effect of GH on lipid metabolism in the liver 
The liver is the main site of cholesterol (lipid) metabolism, which involves 
cholesterol synthesis, breakdown and transport. GH regulates lipid 
metabolism in both rodents and humans, however sorne species 
differences exist in the mode of action [reviewed in (64)]. Very low 
density lipoprotein (VLDL) is produced in the liver and transports esterified 
cholesterol from the liver to peripheral tissues. While in circulation, 
triglycerides and sorne apolipoprotein components are removed, 
converting VLDL into IDL (intermediate) and LDL (Iow). HDL (high) 
scavenges cholesterol from other tissues and transports it to the liver. 
VLDL, IDL, HDL and LDL are sequestered by the LDL receptor (LDLR) on 
the surface of cells and, through receptor-mediated endocytosis and 
degradation of the lipoproteins by Iysosomal lipases, release amine acids, 
cholesterol and fatty acids into the cell (65). 
In humans, LDLR is required for the lipid lowering effects of GH. GH has 
been shown to increase hepatic LDLR in cholecystectomy patients and 
cultured HepG2 cells, and to lower circulating plasma levels of LDL in 
healthy subjects (66-68). However, patients with familial 
hypercholesterolaemia (FH) do not express functional LDLRs and their 
plasma levels of LDL cholesterol do not decrease following GH treatment 
(69). GH is also required for the full restoration of stimulatory effects of 
oestrogen on LDLR expression in hypophysectomized animais. This is a 
direct effect of GH as IGF-l does not produce the same effect (64). In 
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mice, however, GH action on lipid metabolism is LDLR independent, as GH 
is able to reduce plasma levels of LDL cholesterol in LDLR knock out mice 
by stimulating cholesterol 7-a hydroxylase (cyp7a1), the rate limiting 
enzyme in the breakdown of cholesterol into bile acids (70). 
Apolipoproteins (apo) are the protein components of lipoproteins that 
transport lipids in various forms throughout the body. Of the nine known 
apolipoproteins, apo B100 (fuillength), apo B48 (truncated form of apo 
B100) and apo E are involved in cholesterol clearance (65). GH stimulates 
expression of apolipoprotein B (full length) and E in both the rat and 
humans (64;71). RNA editing of full length apoB mRNA by a multiprotein 
editosome complex produces apoB48 which has a higher affinity for the 
LDLR than apoB100 and results in faster clearance of lipoproteins (64;72-
74). Unlike the rat where apoB editing occurs in both the liver and 
intestine, apoB editing occurs only in the intestine in humans (75;76). 
Excess cholesterol is cleared from the body through the liver through 
conversion to bile acids by the neutral or acidic pathway, and faecal 
excretion of the salt conjugates (65). In rats and mice, GH stimulates the 
expression of cyp7a1, the rate-limiting enzyme of the neutral pathway, 
thereby stimulating bile acid synthesis and subsequent excretion 
(64;70;77). In contrast, GH does not stimulate bile acid synthesis in 
humans (69). 
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1.2.2.3. Effects of GH on amino acid metabolism and protein 
synthesis 
GH is weil known to increase uptake of amine acids in liver, skeletal 
muscle and adipose tissue in both rodents and humans [reviewed in (78)]. 
As an anabolic hormone, GH increases nitrogen retention by a 
combination of both increased protein synthesis and/or inhibition of 
protein degradation (79;80). In the liver, GH promotes positive nitrogen 
balance by decreasing degradation of amine acids through the urea cycle, 
resulting in increased protein synthesis (81). In light of the positive 
effects of GH on nitrogen balance, GH has been used to treat protein 1055 
in a variety of patients: for example, GH prevents muscle wasting in AIDS 
patients, promotes protein synthesis in cholecystectomy patients, and 
stimulates protein synthesis and promotes wound healing in burn victims 
[(82-85) and reviewed in (86)]. Inhibition of lipolysis has been shown to 
block GH-induced protein retention, suggesting that lipid metabolites are 
required for GH promotion of nitrogen retention (87). 
1.2.3. Detoxification: GH regulation of the P450 
cytochrome family 
ln addition to its fuel metabolic functions, the liver also acts as a 
detoxifying organ, metabolizing endogenous steroids, fatty acids and 
foreign substances su ch as drugs and environmental carcinogens. This 
function is carried out by haem-containing, membrane-bound P450 
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enzymes (CYPs), in rodents and humans. CYP1, 2 and 3 are highly 
expressed in the liver and subject to transcriptional regulation by several 
factors including environ mental insults (e.g. carcinogens) and hormones 
(e.g. GH). 
Certain members of the CYP family are expressed in a sexually dimorphic 
manner, such as the male-specifie testosterone 2a- and 16a-
hydroxylases, cyp2c11 and cyp2d9, and the female-specific steroid 
sulphate 1S~-hydroxylases, cyp2c12 and cyp2a4 [reviewed in (88)]. The 
sex differences in the expression of CYPs are attributed to the influence of 
sexually dimorphic GH secretory patterns and, in rodents, StatSb has been 
identified as the intracellular mediator of these GH-mediated sexual 
dimorphic effects [reviewed in (88)]. In the liver of pubertal male rats, 
tyrosine phosphorylation and nuclear translocation of StatSb is high during 
a GH pulse and knock out male mice models of STATSb lose the distinct 
adult growth pattern and the expression of male-specifie eyps seen in 
normallittermates (89-91). The reverse is observed in the liver of female 
rats: 90% of StatSb activation is suppressed by the eontinuous exposure 
of female rats to GH (92). Although there is an inereased expression of 
more female CYPs in the liver of the male StatSb knock out mice, changes 
are not as pronouneed in StatSb female knoek out miee (92). 
Studies have also shown that StatSb is not the sole determinant of the 
sexually dimorphic expression patterns of CYPs in the liver: severalliver 
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enriched transcription factors (LETFs) have been implicated. Cyp2c12 is 
upregulated by HNF-6 and HNF-4a in the female rat liver (93). GH 
stimulates HNF-6 expression via STAT5b and HNF-4a (94). 
Hypophysectomy reduces HNF-6 mRNA and protein levels in rats, and is 
only restablished by continuous infusion of GH (95). 
Male specifie cyp4a12 and female specifie cyp2bl0, cyp2b13, cyp3a41 and 
cyp3a44 are also regulated by both GH and HNF-4a in mice (96). 
Gender differences in the expression of CYPs also exist in the human. 
CYP3A4, a major CYP expressed in human liver and intestine is found at 2 
fold higher levels in females than males (97). In addition, its activities 
su ch as the inactivation of cortisol and metabolism of certain drugs (e.g. 
erythromycin) are more rapid in women [reviewed in (88)]. GH regulation 
of CYP3A4 was shown by increased levels in response to the female 
pattern of GH secretion, and suppression by pulsatile GH treatment of 
primary human hepatocytes (98;99). 
1.2.4. Pathologie conditions associated with GH 
Clinical manifestations of GH undersecretion are known collectively as GH 
deficiency (GHD) and overexpression of GH as acromegaly or gigantism. 
GHD includes isolated GHD (IGHD) where only GH secretion is affected, 
and combined pituitary hormone deficiency (CPHD), where other anterior 
pituitary hormones as weil as GH are affected. Four classes of IGHD exist 
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(Table 1) [reviewed in (12)]. The majority of IGHD are a result of 
molecular defects in the GHN (GH) gene. CPHD is caused by mutations in 
different transcription factors and their binding sites that regulate the 
development of the anterior pituitary hormone secretory cells. These 
factors include PIT-l, PROP-1, HEX1, LHX-3 and -4 [reviewed (12)]. GH 
deficiency can also be acquired following head trauma or brain surgery. 
Patients with GH deficiencies are phenotypically short, they accumulate fat 
around the waist area, and have reduced muscle mass and energy. 
Biochemical analyses show that they have low to absent circulating levels 
of GH but respond to exogenous GH which leads to an increase in IGF-l, 
Excessive production of GH by GH-secreting pituitary adenomas leads to 
two clinical disorders of GH that are distinguished by the age of onset. 
Pre-pubertal onset of GH overexpression is rare and causes gigantism. 
Postpubertal onset of GH overproduction results in acromegaly, 
characterised by overgrowth of soft tissues. In both cases, biochemical 
characteristics include elevated levels of GH and IGF-1 as weil as 
decreased insulin sensitivity [reviewed in (100)]. 
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Table 1: Classification of Isolated Growth Hormone Deficiency (IGHD). 
There are four classes of isolated growth hormone deficiency (IGHD). 
IGHD-1A patients are completely GH1 deficient while IGHD-1B, IGHD-II 
and IGHD-III patients produce low levels of GHl. IGHD-III is associated 
with hypogammaglobulinaemia, an immunity disorder; however, no 
mutations have been identified in the GH1 gene. IGHD patients have 
severe growth defects, corresponding to GH function in the postnatal 
individual. Table from (12). 
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Type Mode of Features Etiology 
inheritance 
IGHD-IA Autosomal recessive • Total • GHl 
deficiency deletions 
• Development • Nonsense 
of anti-GH mutations 
antibodies 
IGHD-IB Autosomal recessive Partial deficiency Splicing 
mutations 
IGHD-II Autosomal dominant Partial deficiency Missense and 
splicing 
mutations 
IGHD-III X-Ii n ked Partial deficiency Unknown 
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Acromegalies are treated by surgery (tumour excision), radiation and 
pharmacological interventions, including pegvisomant, the GHR 
antagonist, dopamine agonists and long acting analogs of SST (octreotide 
LAR and lanreotide SR) [reviewed in (101)]. 
1.3. Growth Hormone Receptor (GHR) 
1.3.1. Cytokine Receptor Family 
Most members of the cytokine receptor superfamily are single 
transmembrane proteins that lack intrinsic kinase activity and share 
certain structural motifs, including multiple paired cysteine residues in the 
extracellular domain and box 1, an eight residue proline-rich sequence 
located 10-20 amine acids intracellular to the transmembrane domain 
(102). There are two classes of cytokine receptors. Class 1 receptors are 
distinguished by the presence of a conserved WSXWS motif extracellular 
to the transmembrane region which is involved in ligand binding and 
subsequent signalling (103). The GHR is a class 1 receptor and other 
family members include receptors for prolactin (PRL), leptin and 
erythropoietin (Figure 3). Interleukin-10 (IL-la) and IL-12 act through 
class II receptors. 
The GHR contains a YGEFS motif in place of the WSXWS motif (Figure 4). 
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Figure 3: Cytokine Receptor Family 
Diagram depicting members of the cytokine receptor family and their 
structural domains. The receptors are identified by their ligand. The 
intracellular domain is in blue; fibronectin type III module in pink; 
cytokine receptor module in yellow; immunoglobulin module is in light 
blue; and the fibronectin type III spacer is green. The conserved disulfide 
bonds are indicated in the cytokine receptor module and the position of 
the WSXWS box is also indicated in the fibronectin type III module. 
GH, growth hormone; PRL, prolactin; IL-4, interleukin 4; IL-7, interleukin-
7; Epo, erythropoietin; G-CSF, granulocyte colony-stimulating factor; IL-2. 
interleukin 2; IL-3, interleukin 3; IL-S, interleukin 5; GM-CSF, granulocyte-
macrophage colony-stimulating factor; IL -6, interleukin 6; LIFjOSM, 
leukemia inhibitory factorjoncostatin M; CNTF, ciliary neurotrophic factor; 
MPL, the cellular counterpart of the viral mploncogene product. ECD: 
extracellular domain; TMD: transmembrane domain; ICD: intracellular 
domain. Figure and text of legend from (104). 
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Figure 4: Structural and functional features of GHR. 
The key structural features of GHR and their relation to GH function are 
shown in this diagram. The main protein domains; ECD, TMD and ICD are 
indicated. Five potential aspargine (Asn)-linked glycosylation sites (N), 
the YGEFS motif and seven cysteine residues (C) (six of them paired) are 
located in the ECO. Boxes 1 and 2, and tyrosine (Y) residues are 
indicated. ECO: extracellular domain; TMO: transmembrane domain; ICD: 
intracellular domain. Figure modified from (105). 
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Even though this motif does not directly interact with GH, alanine 
mutagenesis studies of the YGEFS motif have shown that it is important 
for ligand binding and signal transduction of GH (103). The ECD contains 
five potential N-linked glycosylation sites and seven cysteine residues. 
The ICD contains box 1 and box 2. Box 1 interacts with JAK2 and is 
required for the activation of GH signalling (106). The serine rich box 2 is 
40 amine acids downstream of box 1 and is involved in internalisation of 
the GHR (26). There are several tyrosine residues in the ICD that are 
phosphorylated upon GHR activation by GH, and are involved in GH 
stimulation of lipogenesis and protein synthesis (107;108). 
Upon ligand binding, cytokine receptor associated protein kinases are 
activated which, in turn, activate the receptors themselves as weil as 
latent cytoplasmic proteins by phosphorylation. The phosphorylated 
proteins either phosphorylate other cytoplasmic proteins (e.g. the adaptor 
protein, IRS-l) and activate various signalling pathways or translocate into 
the nucleus (e.g. STATs) and affect gene transcription. Members of the 
cytokine receptor family activate similar signalling pathways due to the 
common structural motifs. 
1.3.2. GHR Isoforms 
Severa 1 isoforms of the GHR have been identified. A circulating form, the 
growth hormone binding protein (GHBP), exists in ail animais, identical in 
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sequence to the extracellular region of the full-length receptor (109). The 
mou se and rat have an alternative exon, 8A, which introduces a 
premature stop codon; thus, two GHR mRNAs are produced by alternative 
splicing, one of which encodes the GHBP (110). In man, the cow and the 
rabbit, the GHBP is produced by proteolytic cleavage of the GHR at the 
cell surface (109). Both mechanisms of generating GHBP exist in the 
rhesus monkey (111). Cleavage of GHR by the metalloprotease 
TACEjADAM 17 produces GHBP (ECD) and a remnant (TMD and ICD) 
which is cleaved further by y-secretase (112-116). The major role of the 
GHBP seems to be to enhance the effects of GH by increasing its 
circulatory half-life. 
Other variable forms of the hGHR have been detected exclusively in 
human tissues. Exon 3 of the GHR gene codes for 22 amino acids in the 
N-terminal region of the receptor. An exon-3 deleted GHR isoform is 
present in about 30% of individuals (117). Initially, studies from this 
laboratory and others reported that exon 3 deleted GHR isoforms are 
produced as a result of alternate GHR mRNA splicing in tissues and that 
expression is individual-specific (118;119). Subsequently, it was 
determined that individuals expressing the exon-3 deleted isoform do not 
have exon 3 of the hGHR in their genomic sequence as a result of a 
retroviral deletion mechanism (117;120). 
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Whether the exon 3 deleted isoform is functionally different from the exon 
3 retaining isoform is still controversial. Both isoforms of the GHR (exon 
3+ and 3-) have been shown to have similar binding properties and the 
presence of a single copy of either the exon 3 deleted or exon 3 retaining 
isoform has been shown to be sufficient for growth (121-123). A 
nonsense mutation in exon 3 affecting it's splicing has been identified in a 
patient with Laron syndrome. The other GHR allele of this patient has 
another mutation in exon 4, whilst the parents are heterozygous for each 
mutation and are of normal height (120). Thus, there is considerable 
evidence that having one normal GHR allele (3+ or 3-) is sufficient for 
normal function. 
Three recent clinical studies of final adult height and growth responses to 
GH treatment in idiopathie short stature, SGA (small for gestational age) 
and GH deficient children, and Turner syndrome patients suggest that 
individuals homozygous for exon 3 retaining hGHR isoforms are less 
responsive to GH (124-126). In contrast, two groups have recently 
reported that the presence or absence of exon 3 of the GHR does not 
affect height in children with idiopathie short stature or CGD (127;128). 
Thus, the exon 3 controversy remains unresolved. 
Two truncated (GHR277 and GHR279) forms resulting from alternate 
splicing of exon 9 are present as <1-<10% of ail GHRs in GH target 
tissues (129; 130). GHR279 is produced by the use of an alternative 3' 
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acceptor splice site 26 bp into exon 9 (Figure 5), while exon 9 is 
completely excluded from the GHR277 isoform. Both isoforms lack the 
necessary domains required for signalling but can heterodimerise with full 
length GHR and, therefore, act as dominant negative forms of the 
receptor (129). The truncated isoforms are highly resistant to 
internalisation and produce large amounts of GHBP (129-132). The actual 
mechanisms governing the physiological production of these alternate 
GHR isoforms are not yet known. However, relative amounts appear to 
be involved in GH insensitivity (GHIS). Three patients presenting with 
GHIS, characterized by high GHBP levels and partial responses to 
exogenous GH, were found to be heterozygous for a mutation in the 
don or splice site of intron 9 that resulted in the skipping of exon 9 (133). 
GHR 277, normally <1% of expressed GHR, was now at least 50% of 
expressed GHR in the lymphocytes of these patients (133). This unusually 
large proportion of the truncated GHR accounts for the high serum levels 
of GHBP, and the presence of one normal GHR allele allows for a partial 
response to GH administration (133;134). Aylin et al. have also reported 
mutations that result in exon 9 skipping and familial GHIS (131;132). 
1.3.3. GH signalling pathways 
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Figure 5: Schematic representation of hGHR and the 
alternatively spliced truncated hGHRtr (GHR 279). 
Frame-shifting bya 26-bp deletion results in a novel translation of 6 
intracellular amino acids and an early termination, truncating 97.5% of 
the intracellular sequence. Box 1 is interrupted and Box 2 is deleted. The 
changed amino acids are indicated in bold. K: lysine; Q: glutamine; R: 
arginine; 1: isoleucine; M: methionine; L: leucine; 5: serine; D: aspartic 
acid. Figure and text of legend from (135). 
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Figure 6: Hypothetical model of GHR dimerization. 
Dimerization of GHRs occurs in the endoplasmic reticulum (ER) and the 
GHRs are transported to the cell surface as dimers. GH binding induces a 
conformational change in the GHR, activating JAK2. Figure from (136). 
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1.3.3.1. Receptor dimerization 
For many years, it has been proposed that GH binding causes GHR 
dimerization. However, a recent report has challenged this, showing that, 
in the absence of ligand, GHR exist as preformed dimers both in the 
endoplasmic reticulum (ER) and at cell surfaces (Figure 6) (136). 
One molecule of GH binds to a dimer of its specifie membrane bound 
receptor. Site 1 of the GH molecule binds to one molecule of GHR while 
site 2 of GH interacts with a second receptor. The heterotrimer complex 
results in conformational change of the receptor and activation of a 
cascade of signalling pathways that mediate the effects of GH on a cell 
(Figure 7) (137). 
lAK activation 
Following receptor activation, Janus kinases (JAKs) are recruited to box 1 
of GHRs. In turn, they transphosphorylate each other as weil as the 
tyrosine residues within the intracellular domain of GHR (105). To date, 
experiments suggest that GH signalling mainly involves JAK1, JAK2, JAK3 
and Tyk 2, a JAK related protein, but JAK2 is preferentially recruited 
(138; 139). Apart from JAK 3, that is highly abundant in haematopoietic 
cells, ail of the JAK family proteins are ubiquitously expressed [reviewed in 
(140;141)]. JAKs are required for cytokine signalling and are essential for 
severa 1 biological functions as determined by studies in knock out mice 
and natural mutations in humans [reviewed in (141)]. JAK 1 is an 
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important determinant in early development as disruption in mice is 
perinatally lethal (142). Targeted disruption of JAK2 in mice causes 
defective haematopoiesis and is also embryonically lethal (143;144). JAK3 
-/- mice and humans with JAK3 mutations suffer from severe combined 
immunodeficiency (SCID), where Iymphopoiesis is defective while 
myelopoiesis seems normal (145). As the mice age, defective 
myelopoiesis becomes apparent and mice have enlarged spleens and an 
increase of myeloid progenitors in peripheral blood (146). Thus JAK1 and 
JAK2 are important in early development, while JAK3 is involved in 
haematopoiesis. Information from studies of Tyk2 knock out mice 
suggest that it is most important in responses to IL-12 and LPS [reviewed 
in (141)]. 
JAK-STAT pathway 
Many pathways have been described that are activated following 
phosphorylation by the JAKs. However, the most weil characterised 
pathway involves the signal transducers and activators of transcription 
(STATs). Following activation of the GHR, depending on the cell type 
involved, STATs l, 3 or 5 are recruited to the receptor and tyrosine 
phosphorylated by JAK2. STATs 1 and 3 interact with phosphotyrosine 
residues on JAK2 via their src homology (SH2) domains, while STAT5 
associates with JAK2 as weil as the phosphorylated GHR. Homo- and 
hetero-dimers of the phosphorylated STATs then translocate to the 
55 
nucleus where they bind to their specifie response elements, namely 
gamma interferon activated sequences (GAS) and GAS-like (GLE) 
response elements found on GH responsive genes such as IGF-1, the early 
genes c-fos and c-jun, serine protease inhibitor 2.1 (spi 2.1) and j3-casein 
[reviewed in (147)]. In liver, JAK2 preferentially phosphorylates tyrosine 
residues of STAT5 in response to GH. 
Mitogen Activated Protein Kinase (MAPK) pathway 
The MAP kinase family of proteins are serine-threonine protein kinases 
that mediate cellular responses to several factors, including GH. They 
include MAPKK kinase, MAPK kinase and MAPK. p38 MAPK is required for 
GH action on cytoskeletal organisation of the ce" and cell proliferation 
(148). p44/42 MAPK and c-jun N-terminal kinase (JNKjSAPK) are also 
activated by GH (149;150). In 3T3-F442A ceUs, GH has been shown to 
activate the Ras-Raf-MEK pathway by the SHC-Grb2-S0S complex (151). 
The MAPK pathway involves several cytoplasmic adaptor and docking 
proteins that are common to other pathways, enabling cross-talk with 
severa 1 other pathways [reviewed in (150)]. 
Phosphatidylinositol-3-Kinase (PI3K) pathway 
Insulin-like effects of GH include stimulation of lipogenesis, amine acid 
and glucose transport, protein synthesis, rearrangement of the 
cytoskeleton and mitogenesis (152). 
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Figure 7: GH activated signalling pathways. 
Signal transduction pathways of GH. GH binds to its surface receptor, 
GHR, and, through the activation of JAK2 proteins, stimulates a series of 
signalling pathways. See text for details. Adapted from (147). 
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In common with signal transduction pathways activated by both factors 
are the insulin receptor substrates-1 and -2 (IRS-1 and -2). Tyrosine 
phosphorylation of IRS-1, -2 and -3 is stimulated by several cytokines, 
including GH, IL-2, IL-4 and oncostatin M (QSM) [reviewed in (153)]. GH 
stimulates tyrosine phosphorylation of IRS proteins via JAK2 activation of 
the docking protein, SH2-B (154). IRS proteins act as docking molecules 
for several proteins, including Grb-2, Nck, Csk and p8S (regulatory subunit 
of PI3K). Effects of GH mediated by PI3K include GH-induced 
organisation of actin cytoskeleton and anti-apoptotic actions through PI3K 
dependent phosphorylation of Akt (155; 156). The Akt pathway also 
mediates GH actions on glucose transport by inducing GLUT-4 membrane 
translocation, and C/EBP~-dependent regulation of c-fos by glucose 
synthase kinase 3 (GSK-3) (157;158). 
Phospholipase C (PLC)/Protein kinase C (PKC)/Ca2+ pathway 
Ali members of the cytokine receptor superfamily activate the PLC 
pathway. PLC hydrolyses phosphotidylinositol 4,5-bisphosphate into 
l,4,5-triphosphate (IP3) and diacylglycerol (DAG) (65). IP3 increases 
intracellular Ca2+ concentrations, while DAG activates PKC. In addition, 
PLC-y binds to and is tyrosine phosphorylated by GHR/JAK2 complexes 
(150). Effects of GH mediated through the PLC/PKC/Ca2+ pathway include 
lipogenesis, c-fos gene regulation, GHR internalisation and proteolytic 
cleavage (159-161). 
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GH activation of L -type calcium channels is JAK2-independent but requires 
the (-terminus (amino acids 454-506) of the GHR (162). 
1.3.4. Regulation of GH signalling 
Fine tuning of the GHjGHR signalling axis is dependent on the availability 
of GHR molecules on the cell surface as weil as by both negative and 
positive regulation of signalling pathways (Figures 8, 9 and 10). 
1.3.4.1. Hormonal regulation of GHR levels 
Sex steroids, glucocorticoids, thyroid hormones and GH regulate the 
expression and availability of the GHR. GH-mediated postnatal growth is 
modulated by oestrogen in females and androgens in males [reviewed in 
(163)]. Hepatic GHR and GHBP protein levels are higher in female rats 
compared to their male counterparts (164-166). Studies in the rat have 
shown that ovariectomy or treatment with an oestrogen antagonist lead to 
a reduction in hepatic GHR and GHBP proteins, while they are increased 
by oestrogen treatment (167). However the effects of oestrogen are GH-
dependent as the oestrogen receptor has been shown to be regulated by 
GH (168-170). In mice and humans, GHR protein levels are highest in the 
liver of the pregnant female (164;171). Oestrogen also regulates GHR at 
the transcriptional level, possibly through an ERE (oestrogen response 
element) on the mouse L1 promoter (172). In extra-hepatic tissues, 
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oestrogen regulation of GHR mRNA expression is cell-type specifie: it 
increases GHR expression in osteoblasts but not in the uterus (173;174), 
Glucocorticoids generally stimulate GHR expression, A cortisol surge in 
the late gestational foetus increases hepatic GHR expression and cortisol 
treatment of human osteoblast-like cells increases GHR expression 
(175;176), However, dexamethasone has been shown to have dose-
related effects on GHR expression in rat hepatocytes: stimulation at low 
levels and inhibition at high (> 10-8Ilm) doses (177), 
Thyroid hormones increase the transcription of GHR in ovine hepatic 
tissue, human hepatoma cells (Huh7) and porcine hepatocytes (178-180), 
GH upregulates its own receptor in hepatocytes, epiphyseal chondrocytes, 
mesangial cells and adipose tissue (181-188), 
1.3.4.2. Bioavailability of GHR molecules 
GH induces the internalisation and degradation of GHR via a proteasome-
ubiquitination system, 
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Figure 8: Regulation of GHR bioavailability. 
GHR are synthesized in the endoplasmic reticulum (ER) (1), sorted in the 
Golgi complex and transported to the cell surface (2). Receptors are shed 
into the extracellular space (3) or endocytosed into the cells (4) and 
transported to the lysosomes for degradation (5). Availability for GH at the 
cell surface is determined by: the rate of endocytosis by the ubiquitin-
prateasome pathway (75%), the rate of shedding (10%), and other 
(unknown) mechanisms (15%). Figure and text of legend fram (189). 
61 
., . 
. F 
. Degradation 
('''';'\ . :"., 
. il! 1· 
.'-:",/ . 
.~: 
. '",.' ./'":,,,\.., 
.... .......... l\:.g.,l . 
~ ........ ' .' 
.. ,: .. it. . ..... 
. 1iIfiL. "fi. '. .:~ . 
. '$" 
ts 
GH Receptors at Cel! Surface 
,'" " :'):~:rr~;); 
.----~: 
,~End'?.~~toSiS 
~.,.o., .( ·4·) 
t ............. ). ~:> ............. 
. . Jf:ffi~~ 
.;;: .... :.: .... . 
. :-. . .. ':" .... . 
':." ..• : ....... . 
DegradaUon .' 
···.lysosomê 
R Degradation . 
Ubiquitination is a three-step process: 1) El, the ubiquitin-activating 
enzyme, activates ubiquitin, a 67 amine acid protein; 2) E2, the ubiquitin-
conjugating enzyme, receives ubiquitin from the E1-ubiquitin complex; 3) 
E3, a ubiquitin Iigase, catalyses the transfer of ubiquitin to the amine 
group of a lysine residue on the receptor [reviewed in (189-191)]. 
Polyubiquitinated substrates are then recognised and degraded by the 26S 
proteosome complex (190). A 10 amine acid UbE motif is located within 
box 2 of GHR (192). Mutation of the UbE motif increases the half-Iife of 
GHR (189). 
However ubiquitination of GHR is dispensable in the internalisation of GHR 
by the proteosome: the internalisation of a truncated GHR lacking the UbE 
motif and having ail 10 lysine residues in the ICD mutated is still 
dependent on the ubiquitin-proteosome pathway even though it is not 
ubiquitinated (192). Internalisation of GHR has been shown to occur in 
c1athrin-coated pits and to involve association with caveolin (193-195). 
In addition to preventing STAT5b binding to the GHR, cytokine-inducible 
SH2-containing protein (CIS) also targets GH-GHR-JAK2 complexes for the 
proteosome-ubiquitination pathway (See section 1.3.4.2) (196). 
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Figure 9: Negative regulation of GH signalling. 
Cytokine stimulation activates the JAK-STAT pathway, leading to induction 
of CIS, SOCS1, SOCS2 and SOCS3. These SOCS proteins then inhibit the 
signalling pathway that initially led to their production. (A) SOCS1 binds to 
JAK and inhibits its catalytic activity, as does SOCS3 (B) after binding to 
the activated receptor. (C) CIS blocks STAT binding to the cytokine 
receptor thereby preventing STAT activation. The inhibitory mechanism of 
SOCS2 involves binding to two phosphorylated tyrosines on the ICD of the 
GHR. Figure and text of legend from (197). 
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1.3.4.3. Additional Negative Regulation by Intracellular 
Molecules. 
Additional proteins that negatively regulate GH signalling are either 
constitutive or induced. Tyrosine phosphatases and protein inhibitors of 
activated STATs (PIAS) are constitutive regulators, whereas suppressors 
of cytokine signalling (SOCS) are inducible (198). 
socs 
Four of the eight members of the SOCS superfamily are involved in the 
regulation of GH signalling, namely SOCS1, SOCS2, SOCS3 and CIS. 
Interestingly, ail four proteins are induced in rat liver by GH, via STAT 
binding (199). 
SOCS3 is rapidly and transiently induced, the production of SOCS2 is slow 
and sustained while the effect on CIS is rapid and prolonged [reviewed in 
(200)]. 
SOCS proteins suppress GHR signalling by interacting with JAK2 and 
inhibiting its activity, by binding to tyrosine residues of GHR usually 
phosphorylated by JAK2 or required for STAT interaction, or by targeting 
bound signalling molecules for degradation (201). SOCS1 and SOCS3 
inhibit JAK activity by interacting with the activation loop of JAK2 and the 
receptor, respectively, whereas SOCS2 and CIS interact with the 
phosphorylated receptor and prevent access to STAT 
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proteins (Figure 9) (201). CIS interacts with the GH-GHR-JAK2 complex 
and targets them for degradation by the proteosome (Figure 10) (196). 
The physiological role of SOCS proteins has also been studied by their 
targeted disruption in mice. SOCS1 -j- mice die around 3 weeks after 
birth of multiple organ failure (202;203). SOCS2 -j- mice develop 
gigantism whilst overexpression of SOCS2 leads to only mild gigantism 
(204). Titration studies of SOCS2 suggest a dual role in regulation of GH 
signalling: low protein concentrations of SOCS2 inhibit about 50% of GH 
induced STAT5 activation, whereas high levels enhance GH signalling 
possibly by inhibiting the activity of other members of the family (205). 
SOCS3 -j- is embryonically lethal: mice die from placental insufficiency 
and defective erythropoiesis (206;207). SOCS3 mRNA is more highly 
expressed in rat foetalliver than in adult tissues (206;208). 
Tyrosine phosphatases 
SH-2 domain containing protein-1 (SHP-1) and SHP-2 have been 
implicated in the regulation of GH signalling. SHP-1 is activated GH and 
binds to JAK2 (209). GH also causes SHP-1 to be translocated into the 
nucleus where it binds to STAT5b and attenuates signalling (209). SHP-2 
has both negative and positive effects on GH signalling. It acts as a 
negative regulator of GH activated signalling pathways by attaching to the 
GHR (210). 
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Figure 10: Regulation of GHR internalization by CIS. 
One of the pathways of GHR internalization involves CIS. CIS interacts 
with GH-GHR-JAK2 complexes and targets them for degradation by the 
proteosome. Transfection of CIS-R107K, the dominant-negative SH2 
domain mutant form of CIS into cells inhibits GHR internalization. The 
proteosome inhibitor MG132 also inhibits GHR internalization. Once 
internalized, the GH-GHR-JAK2 complex continues to phosphorylate Stat5 
proteins. Figure from (196). 
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Mutating the tyrosyl residues of GHR that are recognised by SHP-2 results 
in prolonged GH-induced tyrosine phosphorylation of GHR, JAK2 and 
STAT5b (210;211). 
Protein inhibitors of activated STATs (PIAS) 
The PIAS family of proteins was identified as interacting with STAT 
proteins using the yeast two hybrid assay (212;213). PIAS proteins have 
an N-terminal LXXLL motif also present in nuclear receptors and required 
for cofactor interaction, a putative zinc binding motif, an acid rich region 
and a serine/threonine rich region (214). 
Recently a PINIT motif has been identified as being essential for the 
nuclear retention of PIAS (215). PIAS proteins have been shown to bind 
activated STAT1 and STAT3 dimers, to inhibit their DNA binding and to act 
as a corepressor of STAT4 (212;216;217). PIAS regulation of STAT 
activity has been shown in prolactin activated signalling pathways, 
although it remains to be determined whether it has the same effect on 
GH signalling (213). 
Growth factor receptor bound protein-l0 (Grb-l0) 
Grb-10 is an SH-2 and pleckstrin homology (PH) adaptor protein that 
regulates GH signalling by interacting with phosphorylated tyrosine 
residues 454-620 of GHR. In Huh7 cells, Grb10 inhibited GH-induced 
stimulation of c-fos and spi 2.1 promoter constructs via the SRE and 
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GHRE2 elements, respectively. Although it is known that Grb10 does not 
inhibit the phosphorylation of GHR, JAK2 or Stat5, the mechanism of 
action has not yet been determined (218). 
1.3.4.4. Positive regulators 
SHP-2 
As mentioned earlier, SHP-2 has a dual role in the regulation of GH 
signalling. SHP-2 is tyrosine phosphorylated in response to GH and 
associates with Grb2 and SIRPa (211). The mechanism by which SHP-2 
exerts a positive effect is unknown. It has been speculated that 
interaction with Grb2 willlead to activation of the Ras-Raf-MAPK pathway. 
Also, phosphorylated SHP-2 may dephosphorylate certain substrates such 
as the negative regulator, SIRPa (211). 
SH2-B 
SH2-B is an adaptor protein that contains both an SH-2 and a PH domain. 
Of the three splice variants (a, B, y), SH2-BB has been shown to interact 
with JAK2 via its SH-2 domain (150;219). It has been shown to 
specifically increase GH-stimulated tyrosine phosphorylation of JAK2 and 
the tyrosine phosphorylation of STAT5b by JAK2, thereby enhancing 
activation of the downstream signalling pathways (220). 
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Figure 11: The GHR gene, coding exons and protein domains. 
The hGHR is coded for by exons 2-10. (A) The ECD is coded for by exons 
3-7, the TMD byexon 8, and ICD by exons 8 (part), 9 and 10. 
(B) The hGHR gene is located on the short arm of chromosome 5 near the 
centrosome. Thirteen non-coding exons have been reported within the 
300 kb upstream of exon 2 in the 5' UTR. Seven of the non-coding exons 
are clustered in 2 small regions defined as Module A (1V1.6 kb) and 
Module B (1V2 kb); VA-VE and V3a/b are found between the two modules. 
VS is located adjacent to the first coding exon, exon 2. hGHR: human 
Growth Hormone Receptor; ECD: extracellular domain; TMD: 
transmembrane domain; ICD: intracellular domain (102;221-224). 
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1.4. GHR gene 
The hGHR gene has been mapped to chromosome 5p12-13, where a 
cluster of other receptors for growth factors such as PRLR, IL-SR, IL-3R, 
C5F-2R, GM-C5FR and POGFR have also been localized (221). The gene 
locus spans approximately 300 kb (Figure 11B). 
The coding region of the GHR gene consists of 9 exons (exons 2-10) that 
code for a 620 amine acid protein: exon 2 codes for 18 aa of the signal 
sequence and the first five amine acids of the extracellular domain (ECO), 
exons 3-7 code for the majority of the ECO, exon 8 for the last three 
amine acids of the ECO and the 24 amine acid transmembrane region 
(TMR) and exons 8 (part), 9 and 10 for the 350 amine acid intracellular 
domain (ICO) (Figure 11A) (102). 
1.4.1. Growth hormone insensitivity: Defects of GHR (coding 
region) 
Laron dwarfism, idiopathie short stature (155) and constitutional growth 
delay (CGO) are three classes of clinical defects associated with GH 
insensitivity (GHI), a term used to describe a condition characterised by 
low to non-detectable levels of circulating IGF-1 in parallel with (and in 
response to) normal or supraphysiologicallevels of GH (225). 
1.4.1.1. Laron syndrome 
In 1958-59 Laron et al. first described three Israeli siblings with marked 
short stature and hypoglycaemia (226). In the years following, the 
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purification of hGH and development of specifie hGH radioimmunoassays 
(RIA) enabled them to define the biochemical reason for this disorder 
(227;228). Patients had elevated levels of GH, low circulating levels of 
IGF-1 and their hepatic membranes did not bind radiolabelled GH. 
Patients also failed to produce IGF-1 in response to GH stimulation (229). 
These observations suggested a primary defect in the GHR. Two years 
after cloning of the human and rabbit GHR, a partial gene deletion 
(resulting in the loss of part of the GHR ECD) in two patients with Laron-
type dwarfism was characterised (102). Current nomenclature of this 
autosomal recessive disorder in the literature includes Laron dwarfism, 
Laron syndrome (LS), GH insensitivity (GHI) and GHR deficiency (GHRD). 
In addition to short stature and the biochemical abnormalities, patients 
have craniofacial abnormalities, sparse hair, blue sclerae (in 
Mediterranean and Middle-Eastern patients), high pitched voices in certain 
children and adult females, profuse sweating and hypoglycaemia in 
newborns and infants, delayed sexual maturation and hypogonadism 
(more pronounced in males), and obesity. To date severa 1 defects, 
including missense, nonsense and splice site mutations as weil as whole 
gene deletions, have been found in the GHR coding sequence of patients 
with Laron syndrome [reviewed in (226;230)]. GHBP levels are low to 
undetectable in 80% of GHR-deficient patients (231). Patients with 
normal to high circulating levels of GHBP have GHR mutations that allow 
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for the production of high levels of binding protein (229;232). The only 
form of treatment available for these patients is exogenous recombinant 
IGF-l. Patients have been identified ail over the world, and include 
patients from Ecuador, Brazil, South Africa, USA, various parts of Europe 
and the middle East (233). 
The Laron syndrome mouse model is similar to the human in that it 
exhibits low IGF-l levels, elevated levels of GH in serum, growth 
retardation and delayed sexual maturation (234). However, mice models 
do not present with hypoglycaemia, obesity or elevated levels of insulin as 
is seen in humans with Laron syndrome (235). 
Only rare cases of mutations «2%) in the GHR coding regions have been 
described in patients with ISS or CGD; thus the classification of these 
disorders remains "idiopathie". 
1.4.1.2. Defects in GH signal transduction pathways 
Defects in tyrosine phosphorylation of STAT5 have been observed in two 
patients with GHI, although no molecular mutation was identified (236). 
The patients were short and had elevated levels of GH and low IGF-l and 
IGBP-3 levels (237). Kofoed et al. have recently reported the first patient 
with a homozygous autosomal molecular defect in her JAK-STAT pathway 
(238). The patient presented with severe growth retardation, 
immunodeficiency and low serum concentrations of IGF-l, IGFBP-3 and 
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ALS. A missense mutation at residue 630 in the SH-2 domain of STATSb 
affected its tyrosine phosphorylation following GH binding to GHR 
(238;239). More recently, a complete absence of STATSb in a GHI patient 
has been reported (240). The patient, who presented with short stature, 
also had normal to high GH levels whereas IGF-1, IGFBP-3 and ALS levels 
were barely detectable (240). 
1.4.2. GHR 5'UTR mRNA isoforms 
The S'UTR of the hGH R gene locus is highly complex in that it contains 
severa 1 non-coding exons each of which gives rise to different mRNA 
transcripts [V1-VS, V7-V9, V3ajb, VA-E (223;224;241;242)] (Figure 11B). 
V6, initiallY described by Pekhletsky et al, has now been reported to be 
an experimental artifact (241;243). Transcripts derived from these non-
coding exons ail splice into exon 2, eleven nucleotides upstream of the 
translational start site and, thus, encode the same protein. Seven of the 
S'UTR exons are clustered in two small regions (1.6 kb and 2 kb), which 
we have named Module A and Module B, respectively (223). 
V1, V4, V7 and V8 form the module B cluster which is 16-18 kb upstream 
of exon 2, as identified by 5' rapid amplification of cD NA ends (RACE), 
RNAse protection (RPA) and primer extension (PE) assays (223). V1, the 
major transcript in the human liver, has two TATA boxes and two 
transcriptional start sites (TSS) that are unique to the human, while the 
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second and downstream TATAjTSS complex is conserved across species 
(Figure 12) (223). The end of V7 is just 60 bp upstream of the first TSS 
start site for VI. Module A contains V2, V3 and V9 and is, according to 
the most recent Human Genome Map (NCBI), ~ 140 kb upstream of exon 
2 (224). Module A exons are dominated by CpG islands that suggest 
possible regulation by methylation. V2, a highly GC rich exon produces 
the second major transcript in the liver and the most abundant transcript 
in non-hepatic tissues (223;224). Two VS mRNA transcripts have been 
detected in human tissues: the longer transcript is continuous with exon 2 
and more abundant than the shorter transcript (223;241). Wei et al. have 
shown that transcripts from exons VA-VE are ubiquitously expressed 
(224). 
1.4.2.1. Modules A and B: Ubiquitous versus tissue- and 
developmental-specific expression of the GHR 
The hGHR mRNA isoforms are expressed in bath tissue- and 
developmental- specifie patterns: mRNAs derived from the exons of 
Module A (V2, V3, V9), VS and VA-E are ubiquitously expressed, whereas 
transcripts arising from Module B exons (V1, V4, V7, V8) are found only in 
normal human postnatal liver, where V1 is the most abundant transcript 
(Figure 12) (223;224;244). 
74 
Figure 12: Comparing the 5'UTR of GHR in human and other species. 
Comparison of V2, V9, V3, and V5 (A) and of V7, V1, V4 and V8 (B) 
sequences of the human GHR gene (GenBank AJ002175 and AJ131868) 
with their equivalents in ovine, bovine, mouse and rat GHR genes. Figure 
from (59). 
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1.4.2.2. Expression of GHR and its mRNA variants in other 
species 
GHR genes have been identified in many species including the rabbit, 
mou se, rat, sheep, cow, chicken, pig, dog, monkey, fish, birds and turtles 
[NeBI and reviewed in (245)]. 
The complexity of the 5' UTR of GHR is not restricted to the human gene. 
Five 5' UTR exons have been identified in the rat and mouse, two in sheep 
and chicken, nine in the cow, and three in the rabbit and monkey (Figure 
12 & data not shown) (222;246-252). Rat (GHR1), cow (b1A) and sheep 
(olA) homologues of V1 are found exclusively in the liver (249;253;254). 
In rats, the expression of the liver-specific GHR1 is sexually dimorphic 
(255). GHR1 accounts for 30% and 2% of total hepatic GHR in female 
and male rats, respectively. Following gonadectomy, GHR1 levels are 
elevated to 7% in male mice and reduced to 16% in female mice (255). 
Furthermore, continuous infusion of GH to mimic the female GH secretory 
pattern results in a further increase in GHR levels in male rats to 17%, 
equivalent to females (255). In the mouse, the L1 variant is expressed 
only in the liver of the pregnant female (172;256). Th erefore , although 
there is a certain degree of conservation in dynamics of GHR expression, 
there are also speCifie species differences. 
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The downstream TATA/TSS complex of the human V1 is conserved across 
species and has been described as the functional TATA for the ovine olA, 
bovine b1A, and mouse L1 exons (256-258) (Figure 13). A V4 homologue 
is found in the baboon while V7 and V8 are, at present, unique to the 
human (252). Similar to V1, ovine olA is ",17 kb upstream of the 
translational start site in exon 2 (246). 
The human V2 mRNA variant is ubiquitously expressed, the most 
abundant transcript in non-hepatic tissues, and the second most abundant 
in normal postnatalliver. The V2 exon is located '" 140 kb upstream of 
the translational start site (224). The region immediately upstream of the 
V2 exon is '" 79% GC rich and does not contain a TATA box; instead it 
contains ETS1 and C/EBPa-CHOP sites and a CCMT box. 
The ovine equivalent, olB, is at least 27 kb upstream of exon 2 and is '" 
78% GC rich (247). The putative promoter region is TATA-Iess, but it has 
a CCMT box, an E-box, a GC box and a putative C/EBP site. The b1B 
promoter is '" 75% GC rich and contains a single putative binding site for 
C/EBP, CTF/NF-1 and severa 1 Sp1 sites that are functional (259). Mouse 
L2 constitutes 50-80% of total hepatic transcripts in the liver of the non-
pregnant mouse (260). The L2 exon is located at >26 kb upstream of the 
translational start site (245). Two GC boxes and a CCMT box are found 
upstream of the 71% GC promoter region of the TATA-Iess L2 exon. L2 
transcriptional activity has been shown to be regulated by Sp1 and Sp3, 
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and a repressosome complex containing NF-Y, BTEB1, HMG-YjI and sin3b 
(260;261). 
Interestingly, the level of expression of each mRNA transcript may not 
reflect the amount of GHR protein translated from it. The presence of 
multiple open reading frames (ORF) in the 5'UTR of several of the non-
coding exons suggests there may be control of the GHR gene at the 
translationallevel (241;259). Translational efficiency studies have only 
been carried out in the bovine and have shown that, of the major isoforms 
in the liver (b1A, b1B and b1C), b1B is the least translated (249). This 
inhibition of translation could be caused by formation of a secondary 
structure due to the high Ge content in the promoter region. 
Indeed this might be the case in other species as weil since tissues that 
express this isoform or its equivalent as the major transcript have low 
levels of the protein receptor, as determined by binding assays"(249). 
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Chapter 2: OBJECTIVES 
Previous findings in the laboratory of Dr. Cindy Goodyer have shown that 
the levels of hGHR mRNA and hGH binding in the liver are dramatically 
increased after birth (Figure 12) (223). These increases can be partially 
explained by the postnatal onset of expression of the module B liver-
specifie variant mRNAs (223;244). 
The overall goal of the Cindy Goodyer laboratory is to characterise the 
tissue- and developmental-specific mechanisms regulating the hGHR 
gene. The objectives of my PhD project have been 
1) to do a preliminary characterisation of the hGHR gene promoter 
regions; and 
2) to identify developmental- and liver-specific transcription factors 
that regulate expression of the V1 variant. 
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Figure 13: Tissue- and developmental-specific expression of the 
hGHR. 
Severa 1 human foetal and postnatal tissues were analysed for (A) total 
GHR mRNA and (8) hGH binding. The sample number is indicated in 
parentheses. Both total hGHR mRNA expression and hGH binding were 
significantly increased in human postnatal liver. F: foetal; P: postnatal; 
Int: small intestine. Figure from (223). 
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Chapter 3: MATE RIALS AND METHODs 
3.1. Materials 
The following antibodies were obtained from Santa Cruz Biotechnology Inc 
(Santa Cruz, CA): HNF-4a C-19 (sc-6556 and sc-6556X), HNF-4a H-171 
(sc-8987X), Gfi-1 N-20 (sc-8558X), Gfi-1b (sc-22795X), anti-goat-HRP (sc-
2020), goat IgG (sc-2028), rabbit IgG (sc-2027). Calnexin antibody 
(C45520) was obtained from Transduction Laboratories (Lexington, KY). 
Anti-mouse-HRP and anti-rabbit-HRP were purchased from NEN (NEN Life 
Sciences Products Inc., Boston, MA). An antibody to the Drosophila GAF 
protein was kindly provided by Dr. Carl Wu (National Cancer Institute, 
NIH, Bethesda, MD). CV1 (African Green Monkey Kidney fibroblasts), 
HEK293 (human foetal kidney epithelial cells) and HepG2 (human 
hepatoma cells) were obtained from the American Type Culture Collection 
(ATCC, Manassas, VA), while Huh7 (human hepatoma cells) were kindly 
provided by Dr. Ken K Ho (Garvan Institute of Medical Research, Sydney, 
New South Wales, Australia). 
Expression vectors: HNF-4a1 was kindly provided by Dr. Elly Holthuizen 
(University of Utrecht, Netherlands), HNF-4a2 and a8 by Dr. Bernard 
Laine (U 459 INSERM, France), Gfi-1 and Gfi-1b by Dr. Lee Grimes 
(University of Louisville School of Medicine, KY), and GAF by Dr. Greti 
Aguilera (NICHD, Bethesda, MD). sp64 and pSV-~-galactosidase were 
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purchased from Promega Corporation (Madison, WI), and pA31uc was 
kindly provided by Dr. Jacques Drouin (IRCM, Montreal, QC) (262). 
3.2. Tissues 
Human foetal livers were obtained at the time of therapeutic abortions 
(n=ll, 13.5-19.5 wk), foetal age being determined by foot length (263). 
Normal human postnatallivers (n=5, 11-66 yr) were obtained 4-10 hr 
after the removal of a donor liver for paediatric transplantation and 
following perfusion to remove ail blood cells. Tissues were collected 
following written consent and with the a pprova 1 of the local ethics 
committees in compliance with CIHR guidelines. Tissues collected for RNA 
and protein studies were frozen at -80°C until processed. Tissues for 
hepatocyte isolation were immediately processed, as detailed below. 
3.3. Hepatocyte Isolation 
Foetal hepatocytes were prepared as previously described (118). 2.5 mg 
of fresh human foetal liver were minced in 10 ml of warm filter-sterilised 
solution 1 (10 mM HEPES, 0.142 mM NaCl, 6.7 mM KCI, 1 mM EDTA.4Na). 
Minced tissues were washed 2X with warm sterile solution l, and 
transferred into a sterile scintillation vial with a mini-stir bar. 10 ml of 
filter sterilised warm solution II (100 mM HEPES pH 7.4, 67 mM NaCl, 6.7 
mM KCI, 4.8 mM CaCb.2H20, 2 mg/ml collagenase type 1 [Invitrogen 
Corporation, Carlsbad, CA], 0.2 mg/ml DNAse 1 [Roche Diagnostics 
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Corporation, Indianapolis, IN]) was added to the minced tissue and stirred 
at 37°C, in 5% C02 for 20 min; the mixture was allowed to settle by unit 
gravity for 20 min and the supernatant discarded. This step was 
repeated. Cells were then resuspended in 5 ml of warm filter-sterilised 
solution III (0.96 9 Minimum Essential Medium [Invitrogen]/100 ml of 
solution III (4.8 mM EDTA.4Na, 0.22 9 NaHC03, 0.16 mg/ml DNAse l, pH 
7.4) and centrifuged at 1000 RPM for 10 min. The cells were washed 
twice with warm sterile solution III and allowed to settle by unit gravity 
for 20 min. The final cell pellet was resuspended in William's Medium E 
(Invitrogen) supplemented with 10% FBS, 100 lU/mi penicillin G, 16 
)..tg/ml gentamycin sulphate (Garamycin) and 39.2 )..tg/ml dexamethasone. 
Cells were then plated on 100 mm collagen-coated tissue culture dishes 
(BD Biosciences, Mississauga, ON) and cultured for 2 hr at 37°C in 5% 
C02. The cells were then washed 5-6X with warm sterile lX phosphate 
buffered saline (PBS), until there was no trace of blood cells. Media were 
replenished and the cells were cultured overnight in the same conditions. 
This preparation gives a > 95% hepatocyte yield. Cells were washed 
twice with lX PBS, scraped and centrifuged at 1000 RPM. The resulting 
pellets were immediately extracted for protein and RNA or frozen at -80°C 
until required. 
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3.4. RNA Extraction 
1 ml of Trizol (Invitrogen) was added to cells (5-10 x 106) or ground 
tissue (200 mg) in an eppendorf tube and incubated at room temperature 
for 5 min to allow for complete dissociation of nucleoprotein complexes. 
0.2 ml of chloroform was added to the Trizol mixture and tubes vigorously 
shaken for 15 sec and subsequently incubated for a further 20 min at 
room temperature. The mixture was th en centrifuged at 13,000 RPM for 
15 min at 4°e. The aqueous phase (clear upper layer) was transferred to 
a new eppendorf tube, 0.5 ml 100% isopropanol added, mixed, incubated 
at room temperature for 10 min and centrifuged for 10 min at 4°C at 
maximum speed. The resultant pellet was washed with 75% ethanol (1 
ml/1 ml Trizol), dried for 5 min and resuspended in 20 ~I DEPC-treated 
water. The sample was heated at 55°C for 5 min before being stored in 
aliquots at -80°e. 
3.5. Reverse Transcription (RT) and Polymerase Chain Reaction 
(PCR) Assays 
5~g of total RNA was transcribed in the presence of 200 U of Superscript 
II (Invitrogen), 200 ng of random primers (Invitrogen) or 5 ~M specific 
antisense primers (Table 2) 0.1 M DTT, 10 mM dNTP and lX first strand 
buffer (Invitrogen) in 20 ~I of reaction mix. RNA and specific antisense 
primer solution were heated at 65°C for 5 min before the reverse 
transcription reaction. 
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Table 2: Primers used in RT-PCR assays of hGHR variants. 
PriIœrNmœ Sequence 
Vlseme 5' -CGCCI'GCI'OCTGACDIOJG.3' 
V3seme 5' -GGAGAŒITGGAGGGACAGAG-3' 
V9seme ATGGAAŒo::;a::rrCAGrAGAGIG-3' 
V7seme 5' -GrAATMcn::crCATGAGAŒCCA-3' 
Vlseme 5' -AGATTGAGAATGAŒGATITCn:iAG-3' 
V4seme 5' -GAGrA<rAAAGATGGAITAGrGAG-3' 
vs seme 5' -TAGCTATGACAGCACGrATGAOC-3' 
V5seme 5' -TCGITrC:nGfGAGGfGITCfAT-3' 
lSseme 5' -CIœIGITG\.ccrrcn::Acrcn:-3' 
Exon4sense 5' -ATICACCMGTCnJJ1TCActTGA-3' 
Exon 5 antiseme 5' -TMTCA<nrATTCI1TCrATT-3' 
1A2 antisense 5' -AGGTATCCAGATGGAGGTMAffi3' 
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Table 3: Primers used in RT-PCR assays of HNF-4a isoforms 
lN'-4aexmIDsense 
lN'-4aexm tAsense 
lN'-4aexm1'4aIiiseŒe 5' 
HNF-4aexon3 aIiismse 1.>J'~J. -3' 
lN'-4aexon 7 sense -3' 
HNF-4aC-temimI tnuctroaIiismse (iItron8) 
lN'-4aexm9 sense#1 5' 3' 
lN'-4aexm9 sense#}. 5' 
HNF-4aexon 10 aIiismse #1 ~JL<~,-,3' 
HNF-4aexon 10 sense#1. 
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The RT was performed at 42°C for 50 min and the reaction inactivated at 
70°C for 15 min. For reactions involving random primers, the primers 
were heated at 25°C for 10 min prior to the 42°C step. Products were 
stored at -20°e. 
PCR assays were performed with Taq DNA polymerase (Invitrogen) and 3 
JlI of cDNA from the RT reactions. Primers (Tables 2 and 3) were 
purchased from Alpha DNA (Montreal, QC). PCR conditions were as 
follows: one cycle of 2 min at 94°C followed by amplification for 35 cycles 
at 94°C for 2 min, GO-70°C for 1 min, 72°C for 1.5 min, ending with 72°C 
for 5 min. Products were resolved on a 1.5% agarose gel, using ethidium 
bromide. 
3.6. DNAse 1 Treatment of DNA-contaminated RNA 
To ensure that PCR amplified RNA products were not contaminated with 
genomic DNA, total RNA was treated with DNase 1. 9 U of DNase 1 
(Invitrogen) was added to 10 Jlg of total RNA (100 ng/Jll) and heated at 
37°C for an hour, then at 70°C for 5 min to inactivate the DNase 1. The 
DNA was ethanol precipitated overnight at -80°e. The DNA-ethanol 
mixture was spun at 13,000 RPM for 15 min at 4°e. The supernatant was 
discarded and the pellet was washed in cold 75% ethanol, and centrifuged 
for 15 min at 4°C at 13,000 RPM. The pellet was dried for 15 min at room 
temperature and resuspended in 15 JlI DEPC water. 
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3.7. Cell Culture . 
eV1 and HepG2 cells were cultured in low glucose (1 g/L D-glucose) 
Dulbecco's Modified Eagle's Medium (DMEM) (Invitrogen, cat # 11885-
084) supplemented with 10% foetal bovine serum (FBS), 100 lU/mi 
penicillin G, 1.6 mg/ml gentamycin sulphate (Garamycin) and 25 mM 
HEPES. HEK293 cells were grown in low glucose (1 g/L D-glucose) DMEM 
(lnvitrogen), supplemented with 10% FBS:newborn calf serum (NeS) 
(1: 1), 100 lU/mi penicillin G, 1.6 mg/ml gentamycin sulphate and 25 mM 
HEPES. Huh7 cells were cultured in Earle's salts MEM (lnvitrogen), 10% 
FBS, 500 lU/mi penicillin Gand 12.5 mM HEPES. Ali cells were maintained 
at 37°C in 5% e02. 
3.8. Plasmid Construction 
2.7 kb (Module A) and 4 kb (Module B) of hGHR genomic DNA were 
subcloned from a Bac clone (hcit.102E14) into the Bluescript (pSK+) 
vector (223). Various restriction enzymes were used to digest the DNA 
and specifie fragments were subcloned upstream of pA31uc (262), a 
luciferase reporter vector (Figure 14). Deletion constructs were created 
from V2V3P2 (Module A) and V1P1 (Module B) to study the putative 
promoter regions of the exons in the two modules (Figures 14 and 15). 
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Figure 14: Promoter constructs for modules A and B. 
Human genomic DNA from a Bac clone (hcit.102E14) was digested using 
restriction enzymes and the fragments were cloned upstream of a 
luciferase vector, pA3luc. Promoter constructs were created to study the 
promoter regions upstream of the exons in (A) module A (V2 and V3) [V9 
has already been studied (223)]and (B) module B (V7, V1, V4 and VS). 
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Figure 15: V1 deletion promoter constructs 
In order to study the V1 promoter region in more detail, S'and 3' deletion 
constructs were created from V1P1 (2 kb) using specifie restriction 
enzymes sites as indicated. ~ = known transcriptional start sites. Kb 
numbers indicate distance from the translational start site in exon 2. 
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3.9. Site directed mutagenesis 
Mutations were introduced into plasmids using the Quikchange Site 
Directed Mutagenesis kit (Stratagene, La Jolla, CA). In a PCR reaction, 20 
ng of template DNA, 10 JlM of sense and antisense primers carrying the 
desired mutations, 10 mM dNTPs, lX Pfu turbo buffer and 2.5 U of Pfu 
turbo triplemaster Taq polymerase (Stratagene) were cycled under the 
following conditions: 1 cycle of 950 C/30 sec, 16 cycles of 950 C/30 sec, 
550 C/60 sec and 68°C/ (2 min per kb of plasmid). The presence of the 
mutations was verified by sequencing. The primers used are listed in 
Tables 4-6. 
3.10. Transient transfection assays 
Two modes were used to deliver DNA into the cells for transient 
transfection assays: calcium phosphate and Polyfect (Qiagen, Mississauga, 
ON). 1 x 105 cells were seeded into 12-well plates (BD Biosciences) 24 hr 
prior to transfection. 
Calcium phosphate method (for CV1, HEK293, HepG2 and Huh7 cells): 
DNA-mixes (2.5 Jlg of reporter luciferase plasmid, 0.5 Jlg RSV-~­
galactosidase, and sufficient sp64 (empty) vector to bring the total DNA 
per weil up to 5 Jlg) were prepared for triplicate wells in 5 ml 
polypropylene tubes. For HNF-4a1 studies in HEK293 and HepG2 cells, 1 
Jlg of HNF-4a1 expression vector (per weil) was added to the DNA mixes. 
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Table 4: Primers for site-directed mutagenesis of Gfi-ljlb sites. 
Mutated nucleotides are in bold and small letters. Gfi-ljlb sites are 
underlined. 
Primer name Sequence 
Gfi-l/lb mutant sense 1 5'-GAGAGAGA lTGAGM TGACTGAglTG 
(proximal site) GGAGGGA1TTTC-3' 
Gfi-l/lb mutant antisense 5'-CMMTCCCTCCCMcTCAGTCAlTCT 
1 (proximal site) CMTCTCTCTC-3' 
Gfi-l/lb mutant sense 2 5'-GAGACMTGGTCTGATGTGAglTMlT 
(second site) TACTCC-3' 
Gfi-l/lb mutant antisense 5'-GGAGTAMlTMcTCACATCAGACC 
2 (second site) AlTGTCTC-3' 
Table 5: Primers for site-directed mutagenesis of GAGA sites. 
Mutated nucleotides are in bold and small letters. The GAGA element is 
underlined. 
Primer name Sequence 
GAGA mutant sense 1 5'-TGTGTGTGTGCATGtcAccGAttGtlT 
GAGMTGACTGATlT -3' 
GAGA mutant antisense 5'-AMTCAGTCAlTCTCMaCa aTCggT 
1 flaCATGCACACACACA-3' 
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Table 6: Primers for site-directed mutagenesis of HNF-4 sites. 
Mutated nucleotides are in bold and smailletters; the HNF-4 sites are 
underlined. 
Primer name Sequence 
HNF-4 site 1 (112) 5'-AGAGCCCAGAGATGTACTtcaagMGGT 
mutant sense ÇAGGGATTTATTATATG-3' 
HNF-4 site 1 (112) 5'-CATATMTAAATCCCCTGACCTTcttgaAG 
mutant antisense TACATCTCTGGGCTCT -3' 
HNF-4 site 1 mutant 5'-GCCCAGAGATGTACTaGGCMcGGTaAG 
sense GGGATTTATTATATGAGA-3' 
HNF-4 site 1 mutant 5'-TCTCATATMTAAATCCCCTtACCgTT 
antisense GÇCtAGTACATCTCTGGGC-3' 
HNF-4 site 6 mutant 5'-AGGGGATGCTCAggGÇCCTGMGGATG-3' 
sense 
HNF-4 site 6 mutant 5'-CATCCTTCAGGGCccTGAGCATCCCCT-3' 
antisense 
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Sterile water was added to the mix and 75 III of 4X CaClz (500 mM CaCIz, 2 
mM Tris-HCI, 0.2 mM EDTA) was added dropwise to each tube. 150 III of 
2X HBS (50 mM HEPES, 280 mM NaCl' 1.5 mM NazHP04) solution was 
introduced into the bottom of the tube and bubbles created into the 
mixture 5-6 times, using a pipette. The DNA-mixture was incubated at 
room temperature for 30 min to allow the precipitate to form. The cells 
were washed once with lX PBS and fresh media was added. 100 III of the 
DNA precipitate was added dropwise to each weil. The cells were 
incubated at 37°C in 5% COz for 48 hr. 
Polyfect method: HEK293 cells were transfected with 0.5 Ilg of promoter 
reporter or empty reporter vector,O.lllg of pSV-~-galactosidase 
(Promega), 0.001-0.02 Ilg of Gfi-l or Gfi-1b expression vectors, 0.025-0.1 
Ilg of GAF expression vector or 0.05-0.2 Ilg of HNF-4a1, a2 or a8 
expression vectors; total DNA per weil was made up to 1 Ilg with sp64. 
150 III of DMEM and 6 III of polyfect reagent were added to triplicate weil 
DNA mixes in 5 ml polypropylene tubes. The tubes were vortexed and 
complexes left to form at room temperature for 10 min. Media of cells 
was replaced with 1 ml of fresh complete media. 900 III of complete 
media was added to the polyfect-DNA complex and 356 III evenly 
dispersed in each weil. The cells were then incubated at 37°C in 5% COz 
for 48 hr. 
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3.11. J3-Galactosidase and Lu ci fe ra se Assays 
48 hr after transfection, cells were washed twice with ice-cold lX PBS and 
Iysed for 15 min on a rotating platform at room temperature in 200 III Iysis 
buffer (0.5 mM DTT, 0.1 M Tris HCI, 0.005% NP-40). 
6-galactosidase assay: 10 III of Iysate was added to the wells of a 96-well 
microtiter plate (Corning Inc., NY) and 100 III of f3- galactosidase solution 
composed of 0.5 III of 13- galactosidase and 99.5111 of reaction buffer 
diluent (100 mM Na2P04 pH 7.5, 1 mM MgClz, and 5% sapphire-II 
enhancer [Tropix Galactonstar, Bedford, MAD was added to the Iysate. 
The plate was covered with a clear lid and the reaction incubated at room 
temperature for an hour. 
Luciferase assay: 100 III of Iysate was added to the wells of a 96-well 
microtiter plate (Corning). lX luciferin solution was prepared in 0.1 M Tris 
Hel (pH 7.9) from a 10X luciferin concentrate (2.5 mM ATP [Amersham 
Biosciences, Baie D'Urfe, QC], 0.1 mM Coenzyme A [Roche], 1 mM 
luciferin [BD Biosciences], 5 mM MgClz, 0.5 M Tris HCI pH 7.9) stored at-
20°e. 
Both f3-galactosidase and luciferase activities were measured in relative 
light units (RLU) using an EG&G Berthold MicroLumat Plus 
bioluminometer. Luciferase data were normalised to the f3-galactosidase 
activity and expressed as a fold change relative to the empty vector, 
pA3luc. 
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3.12. Protein Extraction 
Tissue: 500 mg of frozen liver tissue was minced in 1-2 ml of lX 
radioimmunoassay immunoprecipitation (RIPA) buffer (1 % NP-40, 0.5% 
sodium deoxycholate, 0.1% SDS, 150 mM NaCI) [modified from a protocol 
provided at www.upstate.com]. The solution was then homogenised in 
lX RIPA buffer supplemented with phosphatase and protease inhibitors 
(50 mM NaF, 0.2 mM Na3V04, 1 mM PMSF, 1 mM DTT, 1 ~g/ml each of 
aprotinin, leupeptin and pepstatin) in a Dounce homogeniser. The Iysate 
was centrifuged at 12,000 RPM for 50 min at 4°e. 
Cells: HEK293, Huh7 and HepG2 cells were trypsinised and centrifuged at 
1000 RPM for 10 min at 4°e. Pellets were resuspended in 10X pellet 
volume of lX Iysis buffer (50 mM Tris HCI pH 7.5, 0.1% Triton-X 100, 2 
mM EDTA) supplemented with phosphatase and protease inhibitors (50 
mM NaF, 1 mM Na3V04, 1 mM PMSF, 10 ~g/ml each of aprotinin and 
leupeptin) and incubated on ice for 15 min. The cell suspension was then 
spun at 13,000 RPM for 10 min at 4°e. 
Supernatants from tissue and cell preparations were stored in aliquots at 
20°e. Protein concentrations were determined by the Bradford assay 
(Biorad Laboratories Inc., Hercules, CA). 
3.13. Nuclear Protein Extraction 
Nuclear extracts were prepared from both cells and tissues using the NE-
PER kit (Pierce Biotechnology Inc., Rockford, IL), following the 
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manufacturer's instructions. After resuspension in NER (nuclear extraction 
buffer), supplemented with protease inhibitors (Roche), the nuclear 
extra ct was dialysed (Slide-a-Lyser, Pierce) in ice cold PBS and stored in 
aliquots at -80°e. Protein concentrations were determined by the 
Bradford assay (Biorad). 
3.14. Western blot 
1-75 ~g of whole cell or nuclear protein extra ct were boiled in lX SOS 
loading buffer (0.1% bromophenol blue, 0.1 M OTT, 10% glycerol, 2% 
SOS and 50 mM Tris pH 6.8) for 3 min, separated on a 12% SOS-PAGE 
gel and transferred onto Immobilin-P, a polyvinylidene difluoride (PVOF) 
membrane (Millipore Corporation, Mississauga, ON) using a wet transfer 
mini trans-blot cell (Biorad Laboratories Inc.). The blots were blocked in 
5% milk (PBS-T [PBS + 5% tween] or TBS-T [Tris-buffered saline + 5% 
tween]) and probed with various primary antibodies. The blots were then 
washed for cycles of lX 15 min and 3X la min with PBS-TjTBS-T before 
being incubated for an hour at room temperature with 1: 1000 fold dilution 
of corresponding secondary antibodies. The enhanced 
chemiluminescence (ECL) system (Perkin Elmer Life Sciences Inc., Boston, 
MA) was used to visualise the bands. In order to reprobe, the membrane 
was rinsed in double distilled water and rotated at 500C for 30 min in 
stripping buffer (2% SOS, 62.5 mM Tris pH 6.8, 100 mM /3-
mercaptoethanol). The membrane was rinsed in PBS-T and probed with 
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anti-calnexin (1:1000, BD Transduction Labs) and anti-mouse-HRP as a 
secondary antibody (1:1000, NEN), as a loading control. HNF-4a (1:1000, 
Santa Cruz) and GAF (1:3000) antibodies were probed for an hour at RT, 
and overnight for Gfi-1 (1:200) and Gfi-1b (1:100). The blot was treated 
with ECL kit reagents (Perkin Elmer) and visualised by autoradiography. 
Quantitation analysis of HNF-4a content were performed by densitometric 
analyses of the bands using the Biorad Gel Doc analysis system 
(Mississauga, ON), and data are expressed as a ratio of HNF-4a to 
calnexin. 
3.15. EMSA and EMSSA (Electromobility Shift and Supershift 
Assays) 
Double-stranded oligonucleotides were prepared by dissolving 
complementary oligonucleotides (Alpha DNA) (Tables 7-8) in annealing 
buffer (100 nM Tris HCI pH 7.5, 1 M NaCl, 10 mM EDTA) at a final 
concentration of 100 nmoljml, incubated at 65°C for 10 min, then at RT 
for 1-2 hr. The double-stranded oligonucleotides were end-Iabelled with 
[y32P] ATP using T4 polynucleotide kinase (Invitrogen). Alternatively, the 
double-stranded oligonucleotides were labelled (fill-in reaction) with 
[a32P] CTP using Klenow fragment (Invitrogen). Labelled probes were 
purified by G-50 spin columns (Amersham). 
6-10 Jlg of nuclear extra ct were preincubated on ice in lX binding buffer 
and 1 Jlg of polydI.dC (Sigma Aldrich) for 20 min on ice. 0.5 ng of 
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labelled probe was added to the mixture and incubated for a further 20 
min on ice. In supershift assays, 2 Ilg of antibody was added to the 
mixture after the 20 min incubation with the labelled probe and incubated 
for an hour at 4°C. In competition assays, 200X cold probe was added to 
the binding reaction. 
The 20 III reaction was then loaded on 5-10% pre-run polyacrylamide 
gels and electrophoresed at 100 V in cold 0.5X TBE. Gels were dried at 
BOoC for an hour and complexes detected byautoradiography. 
3.15.1. EMSA and EMSSA Binding buffers 
HNF-4 binding buffer: 20 mM HEPES, 5% glycerol, 100 mM KCI, 1 mM 
DIT, 1 mM EDTA, 113 mM MgCIz. 
GAGA binding buffer: 1.2 M KCI, 0.5 M Tris HCI (pH 7.9), 0.05 M EDTA, 
23% glycerol, 0.005 M DIT. 
3.16. Chromatin Immunoprecipitation (ChIP) 
ChIP was performed as previously described (264). Briefly, cells (1 X 106) 
cultured in a 100 mm dish were crosslinked in 1% formaldehyde (ICN 
Biomedicals Inc., Aurora, OH) for 10 min at room temperature. Cells were 
scraped and pelleted, and the pellets were resuspended in 300 III SDS 
Iysis buffer on ice and sonicated twice for 15 sec at 50% input (VibraCell 
Sonicator, Sonics, Betatek Inc., Toronto, ON). 
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Table 7: Oligonucleotides for EMSA probes (GAGA). 
Mutated nucleotides are in bold and small letters. GAGA element is 
underlined. 
Oligonucleotide name Sequence 
GAGA sense 1 5'- TGTGCATGAGAGAGAGAGATTGAG 
AATGACTG-3' 
GAGA antisense 1 5'-CAGTCATTCTCAATCTC-3' 
GAGA mutant sense 1 5'-TGTGTGTGTGCATGtcAccGAttGtTT 
GAGAATGACTG-3' 
GAGA mutant antisense 1 5'-CAGTCA TTCTCAAaCaa-3' 
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Table 8: Oligonucleotides for EMSA probes (HNF-4). 
Mutated nucleotides are in bold and small letters, HNF-4 sites are 
underlined. AS: antisense; Y2: half-site mutant. 
Oligonucleotide name Sequence 
H N F-4 site 1 sense 5'-GAGATGTACTGGGCAAAGGTCAGGG 
GA-3' 
HNF-4 site 1 AS 5'-TCCCCTGACCTTTGC-3' 
HNF-4 site 1 (112) S'-GAGATGTACTtcaagAAGGTCAGGGGA-3' 
mutant sense 
HNF-4 site 1 (112) 5'-TCCCCTGACCTT cttga-3' 
mutant AS 
HNF-4 site 1 mutant 5'-CTaGGCAAcGGTaAGGGGATITA-3' 
sense 
HNF-4 site 1 mutant AS S'-TCCCCTtACCgTTGC-3' 
H N F-4 site 5 sense 5' -GATGAAACAGGGGCAGAGGAGGAAG 
AAAAGAC-3' 
HNF-4 site 5 AS 5'-GTC 1 1 1 1 CTTCCTCCTC-3' 
HNF-4 site 5 mutant 5'-GATGAAACAttcGCAcAGGAGGAAGAAA 
sense AGAC-3' 
HNF-4 site 5 mutant AS 5'-GTC 1 1 1 1 CTTCCTCCTg-3' 
H N F-4 site 6 sense 5'-AGGGGATGCTCATTGCCCTGAAGGA 
TG-3' 
HNF-4 site 6 AS 5'-CATCCTTCAGGGCAATGAGCATCCCCT-3' 
HNF-4 site 6 mutant 5'-AGGGGATGCTCAggGCCCTGAAGGATG-3' 
sense 
HNF-4 site 6 mutant AS 5'-CATCCTTCAGGGCccTGAGCATCCCCT-3' 
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The suspension was centrifuged at 10,000 RPM for 10 min at 4°C. The 
lysa te was diluted 10-fold in ChIP dilution buffer and 500 ~I was kept 
aside as input. 2 ml of the remaining Iysate was supplemented with lX 
protease inhibitor cocktail (Roche) and precleared with 2 ~g of BSA (NEB, 
Beverly, MA), 4 ~g of sonicated herring sperm DNA (Sigma) and 45 ~I of 
protein A/G plus aga rose beads (Santa Cruz) for 30 min at 4°C on a 
rotating platform. The beads were pelleted and the supernatant 
immunoprecipitated for 3 hr at 4°C, rotating with 4 ~g of either goat IgG 
(control) or anti-HNF-4a. Complexes were pulled down by incubating the 
above solution overnight with 2 ~g of BSA, 4 !lg of sonicated herring 
sperm DNA, and 45 ~I of protein AjG plus agarose beads (Santa Cruz), 
rotating at 4°C. Beads were pelleted and washed sequentially with low 
salt buffer, high salt buffer, lithium chloride wash buffer and lX Tris-EDTA 
(TE) for 5 min each. Bound protein was eluted twice from the beads by 
vortexing at the highest speed for 15 sec and gently rotating for 15 min in 
ChIP extraction buffer, at room temperature. Crosslinks were reversed for 
4 hr at 65°C. DNA was purified with the Qiagen DNA purification kit 
(Qiagen). 2-5 !lI of the 50 ~I purified DNA in elution buffer was used per 
PCR reaction. PCR assays were performed with Taq DNA polymerase 
(Invitrogen) and 3 !lI of cDNA from the RT reactions. Primers (Table 9) 
were purchased from Alpha DNA (Montreal, QC). PCR conditions were as 
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follows: one cycle of 2 min at 94°C followed by amplification for 26-32 
cycles at 94°C for 30 sec, 58-62°C for 1 min, 72°C for 1 min, ending with 
72°C for 5 min. Products were resolved on a 2% aga rose gel, using 
ethidium bromide. 
3.16.1. ChlP buffers 
ChlP Iysis buffer: 1% SDS, 10 mM EDTA, 50 mM Tris-HCI (pH 8.1). 
ChlP dilution buffer: 1% Triton X-I00, 2 mM EDTA, 150 mM NaCl, 20 
mM Tris-HCI (pH 8.1). 
Low salt buffer: 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 150 mM 
NaCl, 20 mM Tris-HCI (pH 8.1). 
High salt buffer: 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 500 mM 
NaCl, 20 mM Tris-HCI (pH 8.1). 
LiCI wash buffer: 0.25 M LiCI, 1% NP-40, 1% deoxycholate (Na salt), 1 
mM EDTA, 10 mM Tris-HCI (pH 8.1). 
lX TE: 10 mM Tris-HCI (pH 8.1), 1 mM EDTA. 
Elution buffer: 1% SDS, 0.1 M NaHC03. 
3.17. Statistical analyses 
The significance of observed differences between groups was determined 
by ANOVA followed by Bonferroni's group comparison statistical test, 
using the Instat 3 program. 
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Table 9: Primers for ChIP analysis of HNF-4 sites #1, #5 and #6. 
Expected size of PCR products are indicated. 
Primer Name Sequence Product 
size (bp) 
ChlP site 1 HNF- 5'-GTAATAAGGCCTCATGAGACTCCA-3' 
4 sense 270 
ChlP site 1 HNF- 5'-AACCTTCACAAAATCCCTCCCA-3' 
4 antisense 
ChlP site 5 HNF- 5'-CCAAGTGGGAAATGGTGGCTA-3' 
4 sense 200 
ChlP site 5 HNF- 5'-TTCTAAAACTAAACTCAGTGGTCCA-
4 antisense 3' 
ChlP site 6 HNF- 5'-ATGTGTTCAGTGGTCCAGCCCA-3' 
4 sense 200 
ChlP site 6 HNF- 5'-TCCCATTTTCAGTTAGTAATAGAA-3' 
4 antisense 
ChlP control 5'-AAAGAACATTTTGCTGACAAT-3' 
sense 210 
ChlP control 5'-TTGGGAGGTGGGGGGAAA-3' 
antisense 
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CHAPTER 4: RESUL TS AND DISCUSSION 
4.1. Comparison of module A and B promoters 
4.1.1. GHR variant expression in human foetal hepatocytes, 
adult liver and cell lines 
Previous results from this laboratory have shown that module A mRNA 
variants are expressed in every tissue examined to date and at every 
developmental stage, including tumours (223;244). Module B mRNA 
variants, however, are expressed only in the normal postnatal liver; foetal 
liver, hepatocarcinomas and hepatomas do not express module B variants 
(223;244). These data suggested that hGHR expression is regulated by 
multiple promoters. To test this, the promoter activity of modules A and B 
exons were examined in two human hepatoma cell lines (HepG2 and 
Huh7) and two primate kidney cell lines (CVl and HEK293), using 
transient transfections. 
In order to determine the background expression of the hGHR variant 
expression in these cells as weil as in human foetal and adult hepatocytes 
(controls), we first designed primers specifie to the different hGHR 
variants for use in RT-PCR assays (Table 2). The results from the RT-PCR 
experiments show that both human foetal and adult hepatocytes and ail 
the four ceillines express GHR mRNA, although HepG2 cells have 
extremely low to undetectable levels (Table 10). Adult hepatocytes 
express ail known hGHR variants. Foetal hepatocytes express ail but 
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module B variants, confirming what is already known (223;244). The GHR 
variant profile of the cell lines is similar to foetal hepatocytes: they do not 
express module B variants. However, they ail express V5 and module A 
variants (V2, V3 and V9), except for HepG2 cells that have undetectable 
levels of V9, and CV1 cells that do not express V3 or V9. A recent 
publication has reported that V6 hGHR mRNA is an artifact and, therefore, 
it has not been studied further (243). 
4.1.2. Promoter activity of Module A and Module B promoters 
Promoter constructs were prepared to compare the individual promoters 
from modules A and B (Figure 14), and tested in ail four ceillines except 
for V9 which has already been studied (223). We hypothesized that 
module A constructs will be more active than the liver-specific module B 
promoter constructs, as the cell lines do not express the liver-specific 
variants. Indeed, module A promoter constructs ail showed very 
significant transcriptional activity, 30-200 fold over the promoterless 
vector in ail cell lines (Figure 16), the activity being 4-5 times higher in 
Huh7 cells, the GH responsive hepatoma ceilline (265), than in HepG2, 
CV1 and HEK293 cells. 
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Table 10: RT-PCR results of GHR mRNA variants in human adult liver and 
foetal hepatocytes, and four primate cell lines. 
HepG2, Huh7: human hepatoma ceillines, HEK293: human foetal kidney 
ceilline, CV1: African green monkey kidney ceilline. ++: present 
(strong), +: present, +/-: barely detectable, -: not detected. 
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Human Human 
Sample/ Adult Foetal HepG2 Huh7 HEK293 CVI 
Variant Liver Hepatocytes (n=3) (n=3) (n=3) (n=3) 
(n=2-4) (n=4-9) 
Total GHR ++ + +/- + + + 
(Module B) 
++ - - - - -V7NIN4N8 
1 
1 
++ + +/- + + + 1 V2 
V3 ++ + +/- + + -
VS ++ + +/- + + + 
V9 ++ + - + + -
Module B promoter constructs were ~2-4 fold lower in activity than 
module A promoter constructs in ail cell lines (Figure 16), as hypothesized. 
Surprisingly, V8, an hGHR mRNA variant that is not expressed in any of 
the cell lines, and is the least abundant mRNA variant in adult liver, was 
the most active, especially in Huh7 cells (mean±SE, n; 29.7±4.5, n=10) 
(Figure 16B). 
Thus, the information inferred from the cell lines, and in particular the 
hepatoma cell lines, may not always reflect what occurs in normal adult 
liver as the hGHR module B variant transcriptional profile is quite different. 
However from these data and the published V9 data, 1 can conclude that 
ail seven of the non-coding exons in modules A and B have individual 
promoter activity. 
4.2. Deletion analyses of the V7-Vl promoter 
V1 is the most abundant variant in the human postnatal liver 
(59;223;241). Because this expression pattern suggests both 
developmental- and tissue-specifie regulation, we decided to focus on 
characterising the elements controlling V1 transcriptional activity. The 
first objective was to characterise a 1.8 kb region upstream of the second 
transcriptional start site (TSS). In order to identify the regulatory 
domains, 5' and 3' deletional promoter fragments were cloned upstream 
of a luciferase vector and tested by transient transfection assays in the 
four cell lines (Figure 15). 
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Figure 16: Transcriptional activity of hGHR modules A and B promoter 
constructs. 
Module A (A) and module B (B) constructs were transfected into HEK293, 
CV1, HepG2 and Huh7 cells by the CaP04 method. Cells were harvested 
48 hr after transfection and assayed for luciferase and f3-galactosidase 
(internai control) activity. The relative luciferase activity is presented as 
fold change over the promoterless vector. Data are presented as mean ± 
standard error, n=3-10 experiments. 
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The longest construct, V1P1, containing the V7 exon and 46 bp of the V1 
exon, was strongly repressed in ail four cell lines (Figure 17). 
Wh en the 31 150 bp were deleted (V7VIPl construct, 1.85 kb), there was 
a significant increase in luciferase activity in HEK293 (3.9±1.3, n=4, p < 
0.05), HepG2 (7.2±1.8, n=5, p < 0.01) and Huh7 (11.5±0.9, n=7, p < 
0.05) cells (Figure 17A). Wh en another 3' 150 bp were deleted (V7P1 
construct: 1.7 kb), similar activities were observed. A further 3' 0.5 kb 
deletion (VXPB construct: 1.2 kb) led to an even greater increase in 
reporter activity in ail four ceillines: HEK293 (14.3± 3.2, n=4, p < 0.001), 
CV1 (14.8± 5.7, n=3, p < 0.01), HepG2 (7.88± 3.77, n=3, NS) and Huh7 
(76.3± 9.5, n=5, p < 0.001) cells (Figure 17A). The significant changes in 
the activities of the 31 deletion promoter constructs suggest that there are 
multiple inhibitory elements within the 310.8 kb region. When we 
analysed constructs with 51 deletions, we found that a construct with 
deletion of the 51 1.2 kb region (V1P2) showed a significant increase in 
transcriptional activity in HEK293 (4.4±1.0, n=ll, p< 0.001), HepG2 
(6.3±1.1, n=4, p< 0.001), and Huh7 cells (13.9±1.8, n=8, p< 0.001) 
(Figure 176). 
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Figure 17: Transcriptional activity of V1 hGHR deletional promoter 
constructs. 
(A) 3' deletion and (B) 5' deletion V1 constructs were transfected into 
HEK293, CV1, HepG2 and Huh7 cells by the Capo4 method. Cells were 
harvested 48 hr after transfection and assayed for luciferase and ~­
galactosidase (transfection control) activities. The relative luciferase 
activity is presented as fold change over activity obtained using the 
promoterless vector. Data are presented as mean ± standard error from 
n=2-11 experiments, VXPB in CV1 is an n=2 experiments. The significance 
of the observed differences (compared to V1P1) was determined by 
Bonferroni's statistical test following an ANOVA analysis. * p < 0.05, ** P 
< 0.01, *** P < 0.001. 
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A further 5' 1055 of 270 bp (V1P3) from V1P21ed to a general decrease in 
activity although levels were still higher than with V1P1 (HEK293: 2.7±0.4, 
n=7, NS; HepG2: 2.9±0.4, n=6, p< 0.01 and Huh7: 5.9±1.1, n=9, p< 
0.01) (Figure 178). Subsequent 1055 of another 230 bp (V1P4) resulted in 
a marked increase in activity in HEK293 (4.5±0.6, n=10, p < 0.001), 
HepG2 (5±0.3, n=5, p < 0.001) and Huh7 (13.2±1.4, n=5, p < 0.001) cells 
(Figure 178), similar to V1P2. The V1P5 construct, containing the 
conserved downstream TATA box and TSS, ~100 bp of its promoter and 
46 bp of the V1 exon, showed minimal promoter activity in HEK293 cells 
(1.7±0.9, n=7, NS) and CV1 cells (1.92±0.35, n=4, NS), and significant 
activity in HepG2 (2.7±0.3, n=6, p < 0.05) and Huh7 (6.6±0.7, n=8, p < 
0.01) cells. The promoter constructs were generally active in CV1 cells 
but the changes were only significant with VxPs. Data from the 5' 
deletional constructs suggests that there are additional inhibitory elements 
in the 5' 1.2 kb region. 
8ased on these 3' and 5' deletional construct studies, 1 have defined three 
negative regulatory regions within the 1.8 kb V1 promoter (NRR 1-3) 
(Figure 18). The first (NRR1) is the most 3' 300 bp end of the V1P1 
construct containing both TATA/TSS complexes of VI. NRR2 is defined as 
the 230 bp region immediately upstream and finally NRR3 is the 5' 1.2 kb 
region. Two positive regulatory regions (PRR 1-2) have also been 
identified in these studies: PRR1 is the 5' 150 bp region of NRR1 and 
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contains the upstream TATAjTSS complex as weil as '" 130bp of its 
proximal promoter. PRR2 is the 270 bp region between NRR2 and NRR3 
(Figure 18). Further investigations into possible repressor and activator 
response elements in these regions are discussed in sections 4.3, 4.4 and 
4.5. 
4.2.1. Discussion of the analyses of hGHR modules A and B 
promoter activity 
Publications from the laboratory of Dr. Cindy Goodyer were the first to 
report the differential (ubiquitous versus developmental- and tissue-
specifie) expression of GHR mRNA variants in humans (223;244). V3 
transcripts were detected in ail foetal and postnatal tissues tested, and 
hepatic tumours. Vl transcripts, on the other hand, were only detected in 
normal postnatalliver tissue (223;244). Studies in other species (ovine, 
bovine, mou se and rat) have also shown that expression of V1 
homologues are restricted to postnatal liver while the V2 homologues are 
ubiquitouslyexpressed (246;248;251;266). To date, none of the 
promoter analyses on these other species have identified what TFs are 
responsible for the developmental switch in GHR expression. However, 
promoter studies of the V2 equivalent in ovine, bovine and mouse have 
shown that Sp1, a ubiquitously expressed TF, has a major role in 
regulating ubiquitous GHR expression (247;259;260). 
113 
My comparative studies of putative promoters from modules A and B show 
that module A promoter constructs (V2, V3) are highly active in the cell 
lines. This was expected as ail the ceillines express V2 and V3. Promoter 
studies of V9 have already been published, showing similar results (223). 
It is likely that the ceU lines contain the necessary transcription factors to 
drive the ubiquitously expressing promoters and, thus, maintain a level of 
GHR expression. Module B variants on the other hand were 
understandably less active. It is assumed that the hepatoma ceillines do 
not express module B variants due to dysregulated hepatic function, which 
could include the presence of active repressors, the lack of transactivators 
and/or altered chromatin structure. 
From the deletion promoter analysis of the 1.8 kb region upstream of the 
Vl start sites, three major negative regulatory regions and two positive 
regulatory regions have been identified (Figure 18). 
NRR1: NRRl is the 300 bp region at the 3' end of V1Pl and includes the 
two TATA/TSS complexes. Very recently, Jiang et al have reported 
stimulatory activity bya ubiquitous TF, ZBP-89, through its binding site on 
the blA promoter, in a region similar to our NRRl (267). This interaction 
was first identified by yeast one-hybrid assays as traditional computer 
assisted-TF searches did not reveal any binding sites for known TFs (267). 
Studies of a similar NRR in the Vl promoter by other laboratories or in the 
equivalent regions in other species have not been reported. 
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Figure 18: Putative negative (NRR) and positive (PRR) regulatory regions 
of the hGHR V1 promoter. 
Regulatory regions of the V1 promoter as identified by deletion promoter 
studies. Kb numbers indicate distance from translational start site in exon 
2. Specifie restriction enzyme sites used in the cloning of the promoter 
constructs are indicated. 
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NRR2: By deletion promoter studies, Orlovskii et al also describe a 115 bp 
repressor region in the human V1 promoter region that is equivalent to 
our NRR2 (243). Footprinting analyses of the human V1 promoter using 
HepG2 nuclear extracts have uncovered 17 bp (F1) and 28 bp (F2) 
footprints that overlap with our NRR2 (268). A 23 bp footprint that 
overlaps with our NRR2 has also been demonstrated with bovine liver 
nuclear extracts ("446 - -469) (258). In the ovine olA, a rv 191 bp region 
homologous to the NRR2 was found to be stimulatory (253). 
NRR3: The most S' negatively regulated region, NRR3, occupies the S' 1.2 
kb region of V1P1. Using deletion promoter studies, Rivers et al describe 
a similar region (rv 900 bp) containing negative regulatory elements (268). 
The bovine b1A also has a 2.2 kb repressor region that overlaps with 
NRR3 (258). Ovine olA deletion studies also show a 125 bp repressor 
region overlapping with the S'end of the NRR3 (253). 
No further analyses of these NRRs in other species have been reported. 
Thus, data from other laboratories and in other species generally support 
our findings that NRR2 and NRR3 contain repressor elements that 
regulate the liver-specific expression of GHR. This study is the first to 
determine a third important NRR adjacent to the two V1 TSS. 
PRRs: PRR1 is the S' 150 bp region of NRR1, and PRR2 is the 270 bp 
region between NRR2 and NRR3. Previous studies of the human V1 
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promoter have not uncovered any positive regulatory regions 
(243;268;269). However, footprinting analyses show that a 32 bp region 
within PRR2 is bound byendogenous HepG2 nuclear proteins (268). Jiang 
et al have shown that HNF-4 al, HNF-4y and COUP-TFII stimulate blA 
promoter activity through an HNF-4 response element in a region 
homologous to our PRRl (258;270). This is discussed in more detail in 
section 4.7.13. Deletion promoter studies of the ovine equivalent of Vl, 
olA, have shown that a ,..., 150 bp region similar to our PRRl is also 
stimulatory (253). However our PRR2 overlaps with a ,..., 196 bp region 
found to be inhibitory. 
In summary, deletion promoter studies have led us to identify five major 
regulatory regions: two positive and three inhibitory. Regulation of the 
longest promoter construct (V1Pl) suggests that the inhibitory regions 
interact in order to markedly repress V1Pl in ail of the four cell lines. The 
most striking observation l made was the increase in the transcriptional 
activity of the Vl promoter construct in ail four cell lines once the 3' 150-
300 bp region (NRR1) was removed. Therefore l next investigated the 
possible transcriptional repressors in this region (sections 4.3 to 4.4.7). 
4.3. Putative binding sites of transcription factors in NRRI of 
the VI proximal promoter. 
Noticeably, across ail the ceillines, V1Pl was highly repressed. By 
removing 300 bp from the 3' end, the repressive element was lost. 
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Figure 19: Putative TF response elements in the NRRl. 
(A) Putative binding sites in the NRR1 for two related transcriptional 
repressors Gfi-1 (growth factor independence 1) and Gfi-1b, and a GAGA 
element were revealed by the MatInspector (www.genomatix.de) 
transcription factor binding site software. (B) Ovine and bovine 
equivalents of the human V1 have homologous sites for Gfi-1j1b and a 
GAGA element. Ll, the mouse equivalent of V1, has binding sites for two 
alternative transcriptional repressors (RP58 and RBP JK) as weil as a 
GAGA element in the same location. 
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Figure 20: Sequence comparison of human V1 to the ovine olA, 
bovine b1A and mouse Ll. 
500 bp of the human V1 sequence (AF322015) aligned with the ovine, 
bovine (U15731) and mouse (NT _039747) equivalents (223;256;258;271). 
Transcription start sites (bold and italicised), TATA boxes (bold), Gfi-1j1b 
sites (underlined), GAGA element (boxed), GT repeat (bold), ZBP-89 site 
(bold and italicised) and putative HNF-4 sites (bold) are indicated. The 
human V1 has two TATAjTSS complexes, the downstream TATAjTSS is 
conserved in the ovine, bovine and mouse. * represents conserved 
nucleotides. ~ : upstream transcriptional start site, +1: conserved 
transcriptional start site. 
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-1458 HNF-4 #3 -1516 
GATGTACAATGTGCTATCTTCTGGGCATTTGGGGTACTT-TAATGAGGTAGCAGTGAGTA 
---ATTTCACTTTCTATACTCTGGGTTCTTGGGATCTTT-CATGGAGATTCCAGC----A 
-------------------------TTCTTGGGATCCTT-CATGGAGATTCCAGC----A 
---TGGTACACCCCTTTAATCTCAATATTTGAGACAAAGACAGGTGGATCTTTGA----G 
*** * * * * * 
-1517 HNF-4 #2 -1575 
CCACAAATGGTCACTTCTGCCTTTGTTCTTATACT-CCTTAGAGAAGGGAAAGGACCAGA 
CCTCTGCC--CT---------TCCCTTCTTAAACT-CCTTAGTTGTGGAA-----TTATA 
CCTCTGCC--CTCCTGGAGCTTCCTTCCTTGAACT-CCTTAGCTGTGGGA-----TTAGA 
TTTGAGGCCAGCCTATTCTACAGAGTTCTAGAACAGCCAGGGCTACAAAGAGAAACCCAA 
* ** ** ** * * 
-1576 HNF-4 -1634 
TTCAGATACCCTA--TCACTGCTTTCTACCCATCCAGATCAGAGCCTTTGCTGAGTTCTA 
TTCAGATAACTC---TCACTGTCTTCAGCCCCTCCGGCTTATGGTCTTTGTCAAATTCTA 
TTCCGACAACTC---TCCCTGTCTTCAGCCCCTCTGGCGTATGGTCTTTGTCAAATTCTA 
TCTTAAAAACACAAGCAAAAAAAAAAAATCCAAATATTATATTCAATTTACTTAGATGAA 
* * * * ** * *** * * * 
-1635 -1688 
ACGCTTAGCCCTCTTCTCAGCTGATTTGGCTGCCTCCATTGTAATA----GGCCTCATG-
ATACATGGCC---TTCTCAGTTGATCTGGCTGGCTCCATCCTGATG----AGCCTCGTG-
ATACGTGGCC---TTCTCAGTTGGTCTGGCTGGCCCCATCCTGATG----AGCCTTGTG-
AAGCATAATCTGCCTTGAGTTTAACATTCAAGTCTCTTAAATGATCTTGTGGTCTCAGGT 
* * * * * * * * * * * ** * ** * 
-1689 HNF-4 #1 -1748 
AGACTCCAGCCTAGGCCTGGCCTTCAGTTCAGCAGGCAGAGCCCAGAGATGTACTGGGCA 
AGACTCCAACCCAGGCCTGGACTTCACTTCAGTTGGCAGAACCCAG-----CCCTGGGCA 
AGCCTCCAGCCCAGGCCTGGCCTTCACTTCAGTTGGCAGAACCCAG-----CCCTGGGCA 
AGACTCTAGCCCAGGG-TGGCCTTCACTTCAGCTGGAAGCCTCTAAAAATATTCTGGGCA 
** *** * ** *** *** ***** ***** ** ** * * ******* 
-1749 ~Gfi-1/1B -1802 
AAGGTCAG------GGGATTTATTATATGAGACAATGGTCTGATGTGATTTAATTTACTC 
AAGGTCGGGGGGGGGGGGTGCGTTATGTGAGGCAATGGGTTG-TATGTTCTAAT---CTT 
AAGGTCGG------GGGGTTCGTTATGTGAGGCAATGCGTTG-TGTGCTCTAAT---CTT 
AAGAGCAG------CAGCTGCATTAGATGAAGCAATCATCTGGGACAAT-TGATACACTC 
*** * * * * *** *** **** ** * * ** 
** 
-1803 -1834 
CTCTGGTACCAGAT-----------------------ATGTGTGTGTGTGCA~----­
TTCTGGTACCAGGTTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGA~ 
TTCTGGTACCAGGTTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGAC-~ 
TTCTGGAACCAGGT-----------------------GTGTG~GAGAGAGTGGG~-----
***** ***** * ****** * * * ** 
-1835 GAGA BOX Gfi-1/1B ZBP-89 -1889 
---pAGAGAGAGATTGAG~TG--ACTGATTTGGGAGGGATTTTGTGAAGGTTTATATAT 
IAGGGAGGAAGAGAGAGJ\lAAATGTAATTGATTTGGGGAGGACTI'GGGGAAGGTTTATATAG 
** *** ** ** * * **** 
-1890 +1 +36 
CAAAGCAGAAAGACCAAGAATTTAGAGATTAATACATGCCAAGTGGTAACCAAGAAACTT 
GAAGGCAGCAAGACCAAGAATCTACTGCCAAGCGGTGACCAAGAAACGTTCACCATATTC 
GAAAGCAGCAAGACCAAGAATCTACTGCCAAGCGGTGACCAAGAAACGTTCACCATATTC 
CCACACAACAACTTCTAGAAGCTACTGACCAAGACGCACCAAGAAATAACCAGGAAACGT 
** ** * **** ** * * ***** ** * * 
+37 +43 
CTGTGGG-------------------
CTCCT---------------------
CTCCTCCAACCCCGCACTGTTTGCCA 
CTACAA--------------------
The 300 bp NRR1 was analysed for putative response elements using the 
transcription factor scanning program MatInspector (Figure 19). 
Two putative binding sites for the transcriptional repressors, Growth factor 
independence 1 and lb (Gfi-1jGfi-1b), were identified. The most proximal 
site is conserved in the ovine and bovine while the mouse has different 
transcriptional repressors in the same region (Figures 19 & 20). The 
upstream site is unique to the human and is located at the upstream V1 
TSS (Figure 20). 
4.4. Gfi-l and Gfi-lb 
4.4.1. Protein domains 
Gfi-1 and Gfi-1b are two related zinc finger transcription factor proteins 
that are predominantly expressed in the haematopoietic system. They 
contain an identical 20 amino acid SNAG domain in the N-terminus and six 
C2H2 type zinc fingers in the C-terminus, and only differ in the intervening 
sequence (21% similarity in amino acids) between the two termini (Figure 
21) (272-274). Both factors bind to the same DNA sequence: 
TAAATCAC(A/T)GCA; however, only the core AATC sequence is required 
for binding (273). 
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Figure 21: Protein domains of Gfi-1 and Gfi-1b. 
Diagrammatic representation of Gfi-1 and Gfi-1b proteins indicating the 
SNAG (green) and C2H2 zinc-finger (blue) domains. Gfi-1 and Gfi-1b 
proteins differ in the length of the intervening sequence between the 
SNAG and zinc finger domains. Figure from (274). 
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4.4.2. Expression patterns 
Gfi-1 is predominantly expressed in the thymus, spleen, testis and bone 
marrow while Gfi-1b is expressed in bone marrow and spleen, specifically 
in haematopoietic stem cells, erythroblasts and megakaryocytes (275). 
Gfi-1b levels have been shown to be highest in human foetalliver and 
bone marrow (276). However, because the foetal liver is heavily 
populated with haematopoietic cells and this study did not differentiate 
between expression in hepatocytes versus blood cells, it was impossible to 
conclude whether foetal hepatocytes express Gfi-1b. 
Gfi-1 is also expressed in human neuroendocrine tumour cells, human 
prostate cancer cells and the cochlear hairs of the inner ear (277-279). 
Gfi-1 is required for inner ear hair cell development (279). One of the 
transcription factors that regulates Gfi-1 in this process is Pou4f3, which, 
when mutated, causes deafness in humans and mice (280). 
Mice homozygous for the Gfi-1 mutant allele have neutropaenia, lose their 
hearing and are sensitive to bacterial toxins (281). Interestingly, the body 
weight of these Gfi-1 null homozygous mice was 10-50% that of their 
normal littermates (281). Homozygous null Gfi-1b mice exhibit 
haemorrhaging, oedema and pallor and die by day E15 due to defective 
erythropoeisis (282). Humans with a defect in Gfi-1 are also neutropaenic 
but no hearing loss or susceptibility to endotoxins has been observed 
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(283). No growth or metabolic abnormalities resulting from Gfi-l and/or 
Gfi-lb mutations have been reported in humans. 
4.4.3. Repressor activity 
Gfi-l acts as a transcriptional repressor on the human cytomegalovirus 
major immediate-early (HCMV MIE), p2lCip/WAFl, Bax and 25 
hydroxyvitamin D la hydroxylase genes (278;284). Gfi-l represses 
transcription by interacting with the corepressors ETO, mSin3A and by 
direct interaction with histone deacetylases (HDAC-l, -2 and 3), thereby, 
modifying chromatin structure (Figure 22A) (284;285). Both the zinc 
finger and SNAG domains have been implicated in the repressive 
behaviour of Gfi-l. Grimes et al. showed that the SNAG domain was 
essential whereas McGhee et al. showed that the SNAG domain was 
dispensable, but the zinc finger domain was required for ETO-mediated 
repression (272;285). Gfi-l suppresses p2lCip/WAFl expression in an 
epigenetic fashion, by recruiting the histone methylase G9a and HDACl, 
independent of the SNAG domain (284). In addition, it binds and 
suppresses its own expression in Iymphoid cells (286). 
Targets of Gfi-lb include SOCSl and 3, the negative regulators of cytokine 
and GH signalling, Gfi-l and GATA-2, a major regulator of primitive 
erythropoiesis (286;287). SOCS proteins inhibit cytokine induced cell 
proliferation and, thus, the role of Gfi-lb in suppressing their expression 
correlates with its role in enhancing erythroid expansion. In response to 
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Epo stimulation of the myeloid 32D cells, Gfi-lb is downregulated through 
STAT5 induced de novo synthesis of intermediate, and as yet unidentified, 
proteins (287). A similar role cou Id be played by GH but this has not yet 
been investigated. 
4.4.4. Activator activity 
Gfi-lb has also been shown to act as a transcriptional activator on the CXl-
antichymotrypsin (pACT) promoter by interacting with PIAS (Figure 22B) 
(288). PIAS associates with STAT 3 making it inactive; binding of Gfi-l to 
PIAS releases STAT 3, enhancing its transactivating of the pACT promoter 
construct by ~ 5 fold (288). In addition, Gfi-l has stimulatory roles in the 
renewal and proper function of haematopoietic stem cells (HSCs), pre-T 
cell survival, guanylyl cyclase expression (in concert with CCMT binding 
factor) and erythroid expansion (275;289-292). The function of these 
transcription factors as repressors or activators appears to be both 
promoter and cell type specifie (Figure 22) (274). For example, Gfi-l is 
required for suppression of p21Cip/WAFl in Jurkat cells and for its 
expression in HSCs (289;292). 
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Figure 22: Two possible mechanisms of Gfi-l action. 
(A) Gfi-l as a repressor. Repression of Gfi-l target genes occurs by 
recruiting HDACs to the promoter sequence. De-acetylated histones result 
in a more tightly packaged chromatin that silences transcription. (B) Gfi-l 
as an activator. Gfi-l can enhance STAT3 mediated transcriptional 
transactivation by binding and sequestering the STAT3 inhibitor PIAS3. 
Figure and text of legend from (274). 
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Figure 23: Effect of Gfi-l and Gfi-lb on the transcriptional activity 
ofVl. 
Expression vectors for Gfi-l and Gfi-lb were cotransfected with two Vl 
constructs, VlP4 containing two sites and VlP5 containing only one, into 
HEK293 cells with polyfect. Cells were harvested 48 hr later and assayed 
as before. Data are presented as mean ± standard error, n=3-8 
experiments. The significance of the differences observed was 
determined by Bonferroni's statistical test. * p < 0.05. 
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4.4.5. Transient transfection assay studies on the effects of 
Gfi-1 and Gfi-1b on the V1 proximal promoter 
We hypothesized that Gfi-l and Gfi-lb would repress the activity of Vl. 
To test this, 1 carried out cotransfection experiments with a range of Gfi-l 
and Gfi-lb expression vector doses and Vl constructs containing either 
the most proximal and conserved site (V1P5) or both sites (V1P4) in 
HEK293 cells. The results showed up to 75% repression by very low 
amounts of these factors (Figure 23). V1P4, containing both sites, was 
significantly repressed by 10 and 20 ng of Gfi-l, and 5,10 and 20 ng of 
Gfi-lb. V1P5 showed inhibition that was not significant wh en multiple 
doses were tested (Figure 23) but was significant when only a 20 ng dose 
was used (Figure 24). 
4.4.6. Site-directed mutagenesis of two Gfi-1/1b sites 
In order to further evaluate the functionality of these putative Gfi-ljlb 
response elements, 1 mutated the sites in V1P4 and V1P5 (Table 4) and 
tested their responses to 20 ng of Gfi-l and Gfi-lb. Repression by both 
Gfi-l and Gfi-lb was abolished in the V1P5 mutant (Figure 24). Mutating 
the conserved Gfi-ljlb site in V1P4 diminished the response to Gfi-ljlb, 
however the repressed pattern was still present, likely due to the presence 
of the upstream site (Figure 25). This pattern is lost when only the 
upstream site was mutated. 
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Figure 24: Mutational analyses of the Gfi-ljlb binding sites in the 
proximal promoter of Vl (V1P5). 
V1P5 construct with the Gfi-ljlb binding site mutated (Table 4) was 
cotransfected with Gfi-l and Gfi-lb; non-mutated V1P5 construct was 
transfected as control. Data are presented as mean ± standard error, 
n=4-11 experiments. The significance of the differences observed was 
determined by ANOVA followed by Bonferroni's statistical test. *p< 0.05. 
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Figure 25: Mutational analyses of the Gfi-l/lb binding sites in the 
proximal promoter of Vl (V1P4). 
V1P4 constructs with either one or both of the Gfi-l/lb binding site(s) 
mutated (Table 4) were cotransfected with Gfi-l and Gfi-lb; non-mutated 
Vl P4 construct was transfected as control. Data are presented as mean ± 
standard error, n=3-17 experiments. The significance of the differences 
observed was determined by ANOVA followed by Bonferroni's statistical 
test. **p<O.Ol, ***p<O.OOl. 
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Figure 26: Detection of Gfi-1 immunoreactive protein in human liver by 
Western blot. 
75 Jlg of whole cell (human foetal hepatocytes) and tissue (human 
postnatal liver) Iysates were resolved on 12% SOS-PAGE and 
immunoblotted with anti-Gfi-l, 1 Jlg of nuclear Iysate from HEK293 cells 
overexpressing Gfi-1 was run as a control. Calnexin was used as a 
loading control. Another lab member, Gurvinder Kenth, carried out this 
experiment. 
HAL: human adult liver; HFH: human foetal hepatocytes; FBC: foetal 
blood cells. 
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In addition, loss of both sites resulted in a significant increase in basal 
activity (l6.2±3.4, n=5) compared to the wild-type (4.9±0.8, n=l7, 
p<O.OOl), upstream Gfi-ljlb (7.8±1.5, n=3, p<O.Ol) and proximal Gfi-
ljlb (5.5±1.5, n=8, p<O.Ol) mutants (Figure 25). 
Thus, by mutating the Gfi-ljlb sites, endogenous repressors, presumably 
Gfi-l andjor Gfi-lb, can no longer inhibit the activity of the VIP4 promoter 
construct. 
Protein expression of Gfi-l was detected in human foetal hepatocytes, 
human foetal blood cel/s, human foetal liver and adult liver by 
immunoblotting (Figure 26). We did not detect this transcription factor in 
the cel/ Iines (data not shown). However, Gfi-l expression in these cel/s 
may be below the detection level of our immunoblots, as the transfection 
data show that very smal/ amounts of both factors can cause significant 
repression and that endogenous Gfi-l-like proteins are present in HEK293 
cel/s. 
4.4.7. Discussion of Gfi-l and Gfi-lb data 
The restricted expression of Vl mRNA transcripts to normal postnatalliver 
has been intriguing and, thus, the mechanisms regulating it have been of 
great interest. From the deletion promoter studies of the Vl region, the 
transcriptional activity of VlPl was markedly repressed across the four 
cel/ lines. The fact that this was not cel/ type specifie suggests a common 
mechanism of repression. The 300 bp region (NRR1) contains two sites 
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for the transcriptional repressors, Gfi-1 and Gfi-1b: the proximal Gfi-1j1b 
site is conserved in the ovine and bovine GHRs but the upstream site is 
unique to the human. Using transient transfection assays and site-
directed mutagenesis, 1 have shown that both Gfi-1 and Gfi-1b strongly 
repressed V1 promoter activity. The inhibitory effect was more 
pronounced in a construct containing the conserved site as weil as the 
response element unique to the human V1 and promoter activity was 
significantly higher when both sites were mutated. This suggests that 
cooperation of the two sites is required for stronger repressive effects. 
Interestingly, NRR1 (the V1P4 construct), shows significant activity in ail 
four cell lines (Figure 178), and, therefore, the repressive effects of 
endogenous Gfi-1 and Gfi-1b (and other repressors) appear to be 
overridden by endogenous positive regulators acting within this region. 
Gfi-1 has been shown to repress transcription by interacting with the 
corepressor, Eto, and the recruitment of HDACs (285). It is also involved 
in epigenetic repression of p21Cip/WAF1 via interaction with the histone 
methylase, G9a (284). Regulation of GHR by DNA methylation seems 
unlikely as the V1 promoter has no CpG islands and few CpG 
dinucleotides. However, other epigenetic mechanisms may be involved. 
Initially the majority of the described targets of Gfi-1 and Gfi-1b were 
associated with the haematopoietic system [reviewed in (293;294)]. 
Since then, genes involved in deafness, prostate cancer and 
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neuroendocrine systems have also been described as targets [reviewed in 
(274)]. This is the first account of GHR as a target of both Gfi-1 and Gfi-
lb. In addition, Gfi-1 proteins were shown to be present in human foetal 
liver, blood cells and hepatocytes, and adult liver for the first time. This 
suggests a role for Gfi-1 in regulating hepatic genes, including the hGHR. 
It has recently been reported that ZBP-89 stimulates b1A promoter 
activity through a site just downstream of and overlapping the conserved 
Gfi-1j1b response element (Figure 20) (267). DNAse 1 footprinting 
studies with a 190 bp fragment (-169 to +21) of the b1A promoter 
showed that this region is bound byendogenous proteins in bovine liver. 
Yeast one-hybrid and EMSjSA studies confirmed that the interacting 
protein was ZBP-89 (267). Interestingly, the conserved Gfi-1j1b site also 
located in the 190 bp fragment was not protected from DNAse 1 digestion 
suggesting that the site is not bound in bovine liver (267). In addition, 
the yeast one-hybrid screen did not pick up Gfi-1 or Gfi-1b. Since the 
human Vl promoter sequence shows a non-consensus ZBP-89 site, it is 
likely that there are major species-specific differences in regulation of the 
V1 equivalent proximal promoter. 
In summary, my studies of two Gfi-1j1b sites in the proximal promoter of 
V1 have shown that V1 is a target of Gfi-1 and Gfi-1b repressive activity. 
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4.5. GAGA element 
Aiso of interest within the NRR1 site, and overlapping with the conserved 
Gfi-1j1b site, was a 4X GAGA repeat (Figures 19 & 20). This GAGA 
element is conserved in the ovine, bovine and mouse (Figures 19 & 20), 
suggesting that it is an important element in regulation of the liver-specific 
variant of GHR. More exciting is the fact that GAGA elements have been 
described as GHREs in several vertebrate genes. 
4.5.1. GAGA factor (GAF) in Drosophila 
GAGA elements were first identified in Drosophila genes and 
subsequently, in genes of other species, including mammals [reviewed in 
(295)]. The GAGA factor (GAF) was first isolated in Drosophila as binding 
to GAn repeats in the Ultrabiothorax (Ubx) promoter (296). GAF is 
encoded by the Trithorax-like gene, which is required for the regulation of 
severa 1 homeotic genes in Drosophila (297). Two alternatively spliced 
isoforms of GAF mRNA have been identified that translate into 519 and 
581 amine acid proteins ("" 70-90 kDa) (Figure 27) (298;299). These GAF 
proteins share the first 377 amine acids that encode the following 
domains: an N-terminal pox viruses and zinc fingerjbroad-complex, 
tramtrack, bric-a-bric (POZjBTB) domain and a single zinc finger DNA 
binding domain (DBD). 
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Figure 27: Protein domains of the GAGA factors. 
GAF proteins: (A) the 519 amino-acid isoform and (B) the 581 amino-acid 
isoform. The two proteins share the first 377 amino acids at which point 
they diverge. The glutamine rich regions (light and dark blue), BTB/POZ 
domain (black) and single zinc finger (red) are indicated. Figure from 
(300). 
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They differ in the length of the glutamine (Q) rich C-terminus. NMR 
studies of GAF showed that it binds to a GAGAG penta mer (301). 
However, gel shift analyses and immunoprecipitation assays demonstrated 
that GAF recognises a minimal GAG trinucleotide (302). The POZ/BTB 
domain is involved in protein-protein interactions and the Q domain is 
involved in DNA distortion and melting, as weil as multimerisation (303). 
Both isoforms form homo- and hetero-dimers, bind the same sequence, 
and have similar chromatin remodelling properties (298). DNA binding 
activity of the 519 GAF isoform is modified by the serine/threonine kinase, 
casein kinase 2 (CK2). CK2, phosphorylates 5378 and 5388 residues in 
the DBD of GAF and reduces its DNA binding activity (304). This region is 
absent in the 581 GAF isoform and, therefore, phosphorylation by CK2 is 
not common to the isoforms (304). 
Effects of GAF on heat shock gene transcription have been extensively 
studied in Drosophi/a. GAF activates transcription by counteracting the 
repressive effects of histones (305). Addition of GAF before or after 
nucleosome assembly on the hsp 70 promoter results in the disruption of 
chromatin structure and the appearance of hypersensitive sites (306). 
This process of chromatin remodelling requires ATP: the chromatin 
remodelling properties of GAF are facilitated by direct interaction with the 
ATP-dependent nucleosome remodelling factor (NURF) and FACT 
(facilitates chromatin transcription) protein (306-308). In addition to 
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chromatin disruption, GAF also maintains chromatin structure during the 
cell cycle as it is found associated with heterochromatin throughout the 
cell cycle (309). GAF and the GAGA element are also required for the 
enhancer blocking activity of the Frontoabdominal-7 (Fab-7), a boundary 
element in the bithorax gene complex (310). 
4.5.2. GAF studies in vertebrates 
In vertebrates, the Drosophila GAF has been studied as a classical 
transactivator on genes. An unusually large inverted GAGA element, a 
134 cr repeat, is found ~ 90 bp upstream of the transcriptional start site 
of the rat vasopressin lb receptor gene (VlbR) (311). Basal activity of a 
promoter construct was drastically reduced when the GAGA element was 
deleted. In addition, Drosophila GAF-519 stimulated a VlbR promoter 
construct containing the GAGA element by ll-fold. Endogenous VlbR 
mRNA expression in the hypothalamic cell line, H32, and the breast cancer 
ceilline, MCF-7, was induced 6-fold by GAF-519. Thus, the GAGA element 
is required for the basal activity of VlbR. No GAF homologue has been 
identified in mammalian systems. However, severa 1 GAGA binding 
proteins (GBPs) have been identified (see below). These proteins seem to 
be regulated by cytokines, GH being most weil studied. 
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4.5.3. GAGA element in vertebrates as a GH response element 
(GHRE) 
GAGA elements have been investigated in severa 1 vertebrate genes as 
GHREs. Promoter activities of the rat spi 2.1, carbamyl phosphate 
synthase 1 and the human type-1 angiotensin II (AT1) receptor genes 
were significantly increased upon GH treatment, mediated by the GAGA 
element (312-314). 
The rat spi 2.1 gene is one of the most weil studied of the GH-regulated 
genes. GH upregulates spi 2.1 mRNA both in vivo and in vitro (312;315). 
Two GHREs were identified: the more distal element, GHRE II, is a 
position independent enhancer and contains GLEs that interact with 
STATS upon GH stimulation (312;316-318). The more proximal element, 
GHRE l, includes a GAGA element just upstream of the transcriptional 
start site and is responsible for both basal promoter activity and 
stimulatory response to GH (312;314). In vitro transfection studies 
suggest that JAK2 and the C-terminus of GHR are required for GH-induced 
activation of the rat spi 2.1 promoter through the GAGA element (314). 
An EMSA probe containing the GAGA element of the spi 2.1 gene bound 
liver nuclear extracts (314). DNAse 1 footprinting experiments show that 
binding to the lower strand of the GAGA element was abolished in liver 
nuclear extracts prepared from rats either hypophysectomised or in whom 
LPS was used to induce inflammation, suggesting cytokine regulation of 
the GAGA binding proteins (GBPs) (314). 
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Two heat stable proteins, p38 and p40, have been identified as interacting 
with the GAGA box of spi 2.1 (319). These two proteins are rat 
homologues of the mouse CA-rich G box binding factor (mCBF-A) and the 
human Apobec-1-binding protein (hABBP-1) (320;321). Both mCBF-A and 
hABBP-1 are type A/B heterogenous nuclear ribonucleoproteins (hnRNPs) 
that interact with both RNA and DNA (320;321). mCBF-A binds both 
single and double stranded DNA and RNA (SP6 kappa gene) (322). 
hABBP-1 interacts with apobec-1, the catalytic subunit of the apoB mRNA 
editing complex and also with apoB mRNA, and is thus involved in the 
editing of apoB (321). As discussed in section 1.2.4, GH stimulates editing 
of apoB in rats by as yet unidentified mechanisms. Though the effect of 
GH on the binding of the two proteins was not investigated in the study, 
the same group has shown that GH affects the binding of GBPs through 
an as yet unidentified JAK2 activated pathway (314). 
It would be of great interest to know whether p38/40 are indeed 
regulated by GH, and whether GH regulation of apoB editing is through 
these proteins. Although the rat p38/40 proteins have no sequence 
homology to the Drosophila GAF, they may have similar functions in 
mammals. As type A/B hnRNPs with a potential ATP/GTP binding site, 
these GBPs may be involved in ATP-dependent chromatin remodelling. 
However they are unlikely to be involved in DNA melting as it was 
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demonstrated that they did not bind single strands (plus or minus) of the 
GAGA element (319). 
The GAGA element from the promoter of the rat vasopressin V1b receptor 
interacts with endogenous proteins of a size similar to the 75 kDa GAF: 
dimers of a 70 kDa protein were identified by size-exclusion 
chromatography (311). This protein is likely different from the single zinc 
finger GAF, as it is not recognised by an antibody against the whole 
Drosophila GAF protein (311). The effect of GH on the binding activity of 
this protein has not been studied. Promoter activity of the ATl receptor 
gene is enhanced by GH treatment in LRCC8 (human epithelial tubular 
kidney) cells. Binding of an 18 kDa protein to a GAGA element in the ATl 
receptor gene was rapidly induced (2.5 min) by GH in these cells. This is 
probably due to post-translational modifications, su ch as phosphorylation 
of the GBP. Inhibition of protein synthesis by cyclohexamide did not 
abolish binding but rather increased it, suggesting that de nova synthesis 
was important in destabilizing the GBP (313). The 18 kDa and the 70 kDa 
proteins are yet to be sequenced and characterised. Thus, although 
severa 1 GBPs have been described, no known mammalian homologues of 
the Drosophila GAF have been identified. 
4.5.4. Transient transfection assay studies on the effect of 
Drosophila GAF on the Vl proximal promoter 
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The ability of the GAGA element in the proximal promoter of V1 to 
respond to the Drosophila GAF factor was tested in cotransfection 
experiments using V1P5, the smallest GAGA containing construct, in 
HEK293 cells. GAF significantly stimulated V1P5 activity, although 
increasing doses> 25 ng to 100 ng of GAF made no significant difference 
on the activity of V1 [25 ng GAF: 12.5±2.8 fold (n=4, p<0.05); 50 ng GAF: 
13.8±3.7 fold (n=7, p<O.Ol) and 100 ng GAF 14.8±3.6 fold (n=, p< 
0.001)] (Figure 28). The control construct, VXPA, showed no significant 
response to GAF. Overexpression of GAF in HEK293 cells was verified by 
western blot analyses (Figure 29). 
4.5.5. Site directed mutagenesis of the GAGA element. 
In order to confirm that the GAGA element is responsible for the response 
to GAF, the GAGA element was mutated and tested in cotransfection 
experiments with the Drosophi/a GAF (Table 5). The response to 25 ng 
GAF was completely ablated in the V1P5 GAGA element mutant 
(3.24±0.25, n=3) (Figure 30). However basal activity of the GAGA 
element mutant construct (2.75± 0.45, n=4) was comparable to the wild-
type (2.65±0.35, n=7), suggesting that while GAF can act through the 
GAGA element in the V1 proximal promoter, HEK293 cells appear to be 
devoid of a protein with similar activating ability. 
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Figure 28: Effect of GAGA binding factor (GAF) on the transcriptional 
activity of Vl. 
Expression vector for GAF was cotransfected with VlP5 (containing the 
GAGA element) and VXPA was transfected as a control, in HEK293 cells 
with polyfect. Cells were harvested 48 hr later and assayed as before. 
Data are presented as mean ± standard error, n=4-7 experiments. The 
significance of the differences observed was determined by Bonferroni's 
statistical test. * p< 0.05, **p<.O.Ol, ***p<.O.OOl. 
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Figure 29: Western blot analyses of GAF overexpression in HEK293 cells. 
8 Ilg of Drosophi/a GAF expression vector was transfected into HEK293 
cells in a 100 mm tissue culture dish using the polyfect reagent. Cells 
were harvested 48 hr after transfection using the Pierce NE-PER nuclear 
extraction kit. 5 Ilg of nuclear extra ct from HEK293 cells and 20 Ilg of 
HEK293 whole cell extra ct were resolved on 12% SDS-PAGE and 
immunoblotted with an antibody directed against the whole Drosophi/a 
GAF protein. The immunoblot shows the overexpressed GAF protein at ~ 
75 kDa. The faint band seen in HEK293 cells is non-specifie as normal 
rabbit immune serum produces the same result. 
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Figure 30: Mutational analyses of the GAGA element in the proximal 
promoter of Vl. 
Constructs with the GAGA element mutated (Table 5) were cotransfected 
with 25 ng of GAF; non-mutated constructs were transfected as controls. 
Data are presented as mean ± standard error, n=3-7 experiments. The 
significance of the differences observed was determined by ANOVA 
followed by Bonferroni's statistical test. *** p< 0.001. 
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4.5.6. EMSA 
A radioactively labelled probe encompassing the GAGA element bound 
endogenous nuclear proteins in HEK293 cells. A similar band was seen 
when the probe was incubated with nuclear extracts from HEK293 cells 
overexpressing Drosophila GAF 519, but the band was at least 50% less 
intense. The mutant probe did not show binding to nuclear proteins or 
GAF suggesting that the protein-DNA interaction is specific (Figure 31). 
4.5.7. Interaction of Gfi-l/lb site and GAGA element in the 
100 bp proximal promoter region of Vl 
Because of the overlap of the GAGA element with the Gfi-l/lb site in 
NRRl (Figure 19), we studied the effect of increasing doses of the 
transcriptional repressors on GAF activation of V1P5, using Gfi-l as both 
factors (Gfi-l and Gfi-lb) have shown similar effects on the Vl promoter 
(Figure 23). Gfi-l (10 ng) repressed GAF (25 ng) activation of V1P5 by 
~75%. Increasing doses of Gfi-l (25 and 50 ng) did not cause any further 
repression of the Vl construct although the level of significance increased 
(Figure 32). This suggests that, in a cell system where both factors are 
present, there will be competition of the two transcription factors for the 
same locus, and, thus, the levels of the two transcription factors will be 
critical in the regulation of Vl. 
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Figure 31: Analyses of the binding of GAF and endogenous proteins to the 
GAGA element in the V1 promoter region by EMSA. 
A double stranded oligonucleotide encompassing the GAGA site (Table 7) 
was radioactively labelled Ca P32-CTP) and incubated with nuclear 
extracts from HEK293 cells and HEK293 cells overexpressing GAF. Mutant 
oligonucleotides (Table 7) were used to determine the specificity of 
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Figure 32: Interaction of GAF and Gfi-1 on the proximal promoter of Vl. 
Constructs with the GAGA element were cotransfected with 25 ng GAF 
plus 0, 10, 25 and 50 ng of Gfi-l. Data are presented as mean ± standard 
error, n=3-7 experiments. The significance of the differences observed 
was determined by ANOVA followed by Bonferroni's statistical test. * p< 
0.05, ** p< 0.01, *** p< 0.001. 
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4.5.8. Discussion of the GAGA element data 
l have investigated the response of the GAGA element to GAF. The 
Drosophila GAF-519 protein strongly stimulates the activity of the proximal 
V1 promoter through the GAGA element and mutation of this element 
resulted in 1055 of GAF activation. Although the stimulatory mechanism is 
not known, the hGHR, rat V1bR, rat spi 2.1 and human AT! receptor 
genes ail contain TATA boxes in very close proximity to the GAGA element 
and endogenous proteins binding to the GAGA element could possibly 
interact with transcriptional machinery and enhance transcription. 
However, at least in HEK293 cells, the proximal GAGA element is not 
. required for basal transcriptional activity of V1 as is seen in the rat V1bR, 
rat spi 2.1 and human AT! receptor genes (311-313). These differences 
may be due to the fact that different test cel! systems were used and the 
level of endogenous GBPs may differ significantly. It would be of interest 
to know whether the effect of GAF on V1 transcriptional activity is similar 
in other cell types (e.g. Huh7 cells) and whether there are coactivators 
and corepressors that can affect its activity depending on the cell type. 
In addition, the single GAGA element in the proximal promoter may not be 
sufficient for regulation of the basal activity of VI. There are two other 
GAGA elements within V1 that may be required as weil: a 3X GA repeat "" 
1.5 kb upstream of the conserved TSS and/or another "" 70 bp 
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downstream of the conserved TSS within the V1 exon. Finally, the 
proximal GAGA element could be important in growth factor-mediated 
stimulation of V1 by other than GH. This has been shown to be true for 
the human ATl receptor, rat spi 2.1 and rat V1b receptor genes (311-
314). For example, EMSA studies of the human AT! receptor GAGA 
element showed increased binding to endogenous GBPs following 
treatment of the test cells with insulin, PDGF and EGF (313). Due to the 
time constraints of this PhD project, the effect of GH or any other growth 
factor on V1 transcriptional activity has not yet been investigated. 
Endogenous protein (s) in HEK293 cells formed a smiliar sized complex 
with the V1 GAGA element to that seen with nuclear extracts from 
HEK293 cells overexpressing the GAF protein, suggesting that there are 
endogenous GBPs interacting with the GAGA element. An antibody 
directed against the entire Drosophi/a GAF protein immunoreacted with 
endogenous proteins in HEK293, Huh7 and HepG2 cells, and shifted 
protein complexes formed between the GAGA element in the V1 promoter 
and HEK293 nuclear extracts. However, normal rabbit immune serum 
also caused a supershift in EMSA analyses. Thus, the question as to 
whether endogenous GAF-like proteins are expressed in the ceillines and 
whether the contribution of the GAGA element to the regulation of V1 is 
cell type specifie remains unanswered. 
149 
ln summary, 1 have shown that the Drosophila GAF-519 protein stimulates 
the activity of the Vl proximal promoter in HEK293 cells through the 
GAGA element. 1 have also demonstrated that Gfi-l repressed the activity 
of GAF. The fact that the sites are adjacent and the transcription factors 
interact, suggests tight control of Vl transcriptional activity within the 50 
bp proximal promoter of the conserved TATA/TSS complex. 
4.6. Regulation of the longer 1.8 kb promoter of Vl 
4.6.1. Putative binding sites of liver-enriched transcription 
factors (LETFs) in the 1.8 kb Vl promoter region 
1.8 kb of the hGHR genomic sequence upstream of the first TSS for Vl 
was analysed by MatInspector and Signal Scan computer based 
transcription factor scanning programs. Putative binding sites for several 
LETFs were identified, including CCAAT enhancer binding protein (C/EBP), 
hepatocyte nuclear factor-l (HNF-l), HNF-4, HNF-6 and D-binding protein 
(DBP) within the 1.8 kb promoter region of Vl (V1Pl) (Figure 33). 
4.6.2. Liver enriched transcription factor (LETFs) 
Members of the LETF family that include C/EBP, HNF-l, HNF-3, HNF-4, 
HNF-6 and DBP cooperatively regulate expression of hepatic-specific 
genes. 
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Figure 33: Module B Vl Promoter: Putative binding sites for liver enriched 
transcription factor sites. 
Severa 1 putative liver enriched transcription factor (LETF) binding sites 
were identified by MatInspector (www.genomatix.de) in the 1.8 kb 
promoter of VI. HNF: hepatocyte nuclear factor; DBP: D-binding protein; 
C/EBP: CCAAT enhancer binding protein. 
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No single LETF family member is solely responsible for the transcription of 
a liver-specific gene as they form a complex network of transcriptional 
factors that define hepatic development as weil as function (Figure 34) 
[reviewed in (323-325)]. 
In addition, it is weil known that, in the rodent liver, GH regulates several 
members of the LETF family (Figure 35) and LETFs are involved in GH 
regulation of severalliver genes [(326) and reviewed in (323;325;327)]. 
In addition, GH has been shown to regulate GHR mRNA levels in the liver 
but not in skeletal muscle of GH deficient mice (328). Thus, although my 
primary focus for the study of the hGHR Vl promoter by LETF family 
members has been HNF-4, it is important to understand the relationship 
between HNF-4, GH and other members of the LETF family. 
C/EBP 
C/EBP is part of a large family of basic leucine zipper (bZIP) transcription 
factors that include CCMT response element binding protein (CREB) and 
AP-l (c-fos and c-jun) [reviewed in (323)]. There are multiple isoforms of 
C/EBP (a, B, y, 0, E and Ç), that are involved in regulating metabolism, 
(acute phase) immune response, cellular differentiation, apoptosis, 
development, liver generation and liver tumour biology [reviewed in 
(323)]. C/EBPs contain an N-terminal activation domain, a bipartite 
dimerization domain and a leucine zipper DBD C-terminal domain (329). 
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Figure 34: Hierarchy of the expression of liver enriched transcription 
factors (LETFs) during rat liver development. 
HNF-3a, HNF-3f3, HNF-la, HNF-lf3, HNF-4 and HNF-6 are expressed in 
the developing liver whereas C/EBPa, C/EBPf3 and DBP are expressed in 
the mature rat liver. Figure adapted fram (325). 
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Figure 35: GH regulation of LETFs. 
GH stimulates the expression of DBP, HNF-6, HNF-3B, HNF-3y and HNF-4, 
and suppresses C/EBPa expression in the rat and bovine liver. GH 
regulates HNF-6 and HNF-3y by inducing STATS binding to their 
promoters. The mechanism by which the other LETFs are regulated by 
GH has not been reported (326). Figure adapted from (327). 
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bZIP enhancing factor (BEF) interacts with C/EBPs to stabilise their 
binding to response elements and enhance their transactivating abilities 
(330). The highest levels of CjEBPa are in the placenta, and high levels 
are also found in the blood leukocytes, lung, liver, fat, adrenal gland, 
pancreas, small intestine, colon and skeletal muscle (331). 
Hepatic expression of C/EBPa is restricted to terminally differentiated 
hepatocytes (332). Mice that are homozygous null mutants for CjEBPa 
die soon after birth due to failure to accumulate glycogen in hepatocytes 
and lipids in adipocytes, suggesting major defects in gluconeogenesis and 
adipogenesis (333). Adult mice that are liver specifie null mutants for 
CjEBPa develop jaundice due to high levels of unconjugated bilirubin. 
In addition, the expression of several key enzymes involved in 
gluconeogenesis, such as PEPCK, were reduced (334). In a more recent 
study, mice with liver-specific deletion of CjEBPa have reduced serum 
levels of cholesterol, hyperammonaemia and impaired tolerance to 
glucose suggesting that C/EBPa regulates hepatic glucose, lipid and 
ammonia metabolism (335). Thus CjEBPa is required for the 
development of the liver, proper hepatic metabolic function and survival. 
There are four forms of CjEBP~ due to the use of alternative translation 
initiation codons. Liver-enriched inhibitory protein (LIP), a 20 kDa isoform 
of CjEBP~ lacks the activation domain and acts to inhibit transcriptional 
activation of CjEBPs (336;337). Half of the CjEBP~ null homozygous mice 
155 
die before birth, and those that survive to birth die in the first few weeks 
of life (338). Thus, CjEBPP is critical for development and survival of the 
foetus. CjEBPy, like LIP, lacks the activation domain that is present in a 
and P isoforms (339). CjEBPô is expressed during an acute phase 
response. CjEBPÇ, also known as GADD (growth arrest and DNA 
damage), is ubiquitously expressed and is induced during growth arrest; it 
does not interact with DNA since it lacks the basic leucine zipper DBD 
(340). 
Members of the CjEBP family heterodimerise with each other, with LIP, 
CjEBPy and ç acting as dominant negative factors. CCMT displacement 
protein (CDP), an antagonist of CjEBP transactivation, is highly expressed 
in dedifferentiated cell types and down-regulated in terminally 
differentiated epithelial cells (341). It competes with CjEBPs for similar 
binding sites, and has been shown to negatively regulate cholesterol 7 a-
hydroxylase (CYP7A1) gene in HepG2 cells by displacing CjEBPa and HNF-
la from their binding sites in the intron 1 of CYP7A1 (342). There are 
three putative CjEBP sites within the 1.8 kb V1 promoter region. 
HNF-l 
HNF-1 is a homeodomain TF and exists as two isoforms: HNF-1a and 
HNF-1p (also known as HNF-1v) (343;344). HNF-1 proteins contain an N-
terminal dimerization domain that allows for homo- and heterodimer 
formation between the isoforms, a POU A domain, a homeodomain and a 
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C-terminal activation domain that is not conserved between the two 
isoforms (345). They can act as transactivators by interacting with 
coactivators that have intrinsic histone acetylase (HAT) activity (e.g. CBP, 
p300 and p/CAF), or directly as repressors of gene transcription by 
undefined mechanisms [reviewed in (323)]. Liver contains predominantly 
HNF-la dimers; however, repression of hepatic specifie genes in certain 
ceillines is correlated with liver expression of HNF-1J3. Expression of HNF-
lJ3 is important in early development as it is expressed before HNF-la 
(346;347). Mice knock outs for HNF-1J3 are embryonically lethal and thus 
studies have only been conducted on embryonic stem (ES) cell embryoid 
bodies (346). These ES embryoid bodies have decreased levels of HNF-
4al, HNF-la and HNF-3y suggesting that HNF-1J3 is required for their 
expression in the visceral endoderm (346). Mice lacking HNF-la have 
multiple organ dysfunctions and die araund time of weaning (348;349). 
Metabolic defects include non-insulin dependent diabetes (NIDDM), 
hyperlipidaemia, hepatomegaly and fatty livers (348). They also show 
grawth retardation and, in certain strains of mice, Laran dwarfism (348). 
Humans with mutations in HNF-la and J3 genes develop Maturity Onset 
Diabetes of the Young (MODY) -3 and -S, respectively, inherited diseases 
characterised by an early onset of Non-insulin dependent diabetes mellitus 
(NIDDM) due to defective pancreatic J3-cell insulin production [reviewed in 
(350)]. 
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HNF-4a has been shown to be essential for HNF-1a expression in 
embryonic liver and hepatic cell lines, and in pancreatic cells the hierarchy 
is reversed (351-353). Studies have shown that HNF-1a expression is not 
regulated by GH (326;327). Three putative HNF-1 binding sites have 
been identified within the 1.8 kb V1 promoter region. 
HNF-6 
HNF-6 belongs to the one-eut family of transcription factors; the other 
known member of this family is OC-2. Both contain a single eut domain 
and a homeodomain (354). The HNF-6 gene is made up of 3 exons, 
where exon 1 codes for the N-terminus and the one-eut domain, exon two 
for 26 amino acids found only in the /3 isoform and exon 3 for the 
homeodomain and the C-terminus (355). Alternative splicing of exon two 
produces two forms: HNF-6a and /3 (355). Both are expressed during 
development of the pancreas and liver, and in differentiating neuronal 
cells (356). 
HNF-6 is regulated by GH through induced STAT5b binding to its response 
element (GLE) in the promoter region of the HNF-6 gene (94). GH also 
indirectly stimulates HNF-6 transcription by increasing HNF-4a 
transcription and binding, and by decreased transcription of its negative 
transcriptional regulator, C/EBPa, both of which have response elements 
in the promoter of the HNF-6 gene (94). Expression of HNF-6 is sexually 
dimorphic: normal female mice express higher levels of HNF-6 than their 
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male counterpart, whereas HNF-4a null male mice express HNF-6 at 
normal female liver levels suggesting that HNF-4a negatively regulates 
HNF-6 in male mice (96). 
HNF-6 regulates genes encoding plasma proteins (e.g. protein C), 
enzymes involved in glucose metabolism (e.g. 6-phosphofructo-2-kinase) 
and CYPs (e.g. cyp2c12, as discussed in section 1.2.6) (95;354;357-359). 
There is one putative HNF-6 binding site in the 1.8 kb V1 promoter region. 
DBP 
DBP is a basic leucine zipper LETF and belongs to the proline and acidic-
rich (PAR) family of proteins (360). DBP mRNA transcripts are detected in 
both foetal and postnatal rat liver and severa 1 non-hepatic tissues, but the 
protein is only detectable in the postnatalliver, thus showing 
developmental regulation at the translationallevel (360;361). DBP is 
involved in the regulation of several circadian-expressed genes in the 
brain and liver and is itself under circadian regulation by CLOCK, a major 
regulator of circadian oscillations (362-369). Although they are still 
rhythmic, dbp null mutant mice have disrupted circadian patterns in sleep 
and locomotor activity and expression of severalliver genes (e.g. cyp2a4) 
is also disrupted (363;364;366). GH has been shown to upregulate DBP 
mRNA and diurnal expression of GHR mRNA has been shown in mice 
(326;328). Interestingly, this variation in GHR expression is only seen in 
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the liver of the mice and required GH (328). These data suggest that GH 
and DBP cooperatively regulate GHR expression in the murine liver. There 
are three putative DBP sites in the 1.8 kb V1 promoter region. 
4.7. HNF-4 
Hepatocyte nuclear factor 4 (HNF-4) family has three members: HNF-4a, 
HNF-4~, and HNF-4y. Expression of HNF-4~ has only been shown in the 
Xenopus(370). HNF-4a and HNF-4y are 70% identical in their amino acid 
composition: the LBD and DBDs are identical while the A/B and the F 
domains differ slightly (371). They show similar distribution, being 
enriched in liver, and also expressed in kidney, pancreas, stomach and 
small intestine (270;372-374). However, HNF-4a mRNA is 10X more 
abundant in the liver than HNF-4y (372). 
We decided to study the effect of HNF-4a on the V1 promoter because of 
its relative abundance in the liver and it is the best studied member of the 
HNF-4 family. 
4.7.1. Protein domains, structure and proposed ligands of 
HNF-4a 
HNF-4a contains several domains: the A/B domain, a zinc finger DNA DBD 
(domain C), a hinge region (D), a large ligand binding (LBD) and 
dimerization domain (E), and a repressor domain (F) (Figure 36). The 
first 24 amino acids in the AlB domain code for activation function 1 (AF-
160 
1) that has been shown to interact exclusively with coactivators (Table 
11); sorne of these cofactors (e.g. CBP) have intrinsic HAT activity and 
have been implicated in chromatin remodelling. The DBD contains two 
zinc fingers, and this region is 100% conserved in vertebrates. 
The LBD contains a large AF-2 domain, 11 a helices and 2 J3 sheets, 
common features in nuclear receptors (375;376) (Figure 37). X-ray 
crystallography experiments of the LBD show that two conformational 
states are present in each homodimer of HNF-4a: the open state where 
helix 12 is extended out and co-linear with helix 10, and the closed state 
in which helix 12 is folded against the LB D, forming a hydrophobie pocket 
with helices 3 and 4 and allowing the interaction of coactivators and 
corepressors via their LXXLL motifs (376-378). Although crystallography 
experiments were carried out in the absence of ligand, C14-C18 fatty 
acids were found to be constitutively bound to the LBD in both states and, 
thus, the bound fatty acids are viewed as a cofactor rather than a 
traditionalligand for HNF-4a (Figure 37) (377;379). 
Nuclear receptors fall into two groups: members of the "classical" family 
are activated upon ligand binding, while members of the orphan receptor 
superfamily have no identified ligand (380). HNF-4a was considered an 
orphan nuclear receptor until recently when fatty acyl-CoA thioesters were 
identified as ligands for HNF-4a (381). 
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Figure 36: Protein domains of HNF-4a2. 
HNF-4a2 is one of the nine protein isoforms of HNF-4a. HNF-4a is a 
member of the nuclear receptor superfamily. Members of this family have 
five distinct domains, A-F; A/B: activation domain, contains the AF-l 
module; C: zinc finger DBD; D: hinge region; E: LBD, also contains AF-2 
module; F: NRD, contains a repressor sequence. AF-l and AF-2 modules 
have been shown to interact with coactivators. Numbers indicate amino 
acid residues. 
AF: activation function, DBD: DNA binding domain, LBD: ligand binding 
domain, NRD: negative regulatory domain; rep: repressor sequence; aa: 
amino acid. 
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Table Il: Coactivator and corepressor interactions of HNF-4a 
Domain Cofactor 
AF-1: Coactivators P160 (SRC-1, SRC-2, GRIP-1), 
CBPjp300, ADA2, PC4, TBP, 
TAFII31, TAFII80, TFIIB, TFIIH-p62 
AF-2: Coactivators SRC-1, SRC-2, SRC-3, 
CBPjp300,GRIP-1 
AF-2: Corepressors SMRT,SHP 
Activation function (AF-1) domain has been shown to only interact with 
coactivators, whereas AF-2 interacts with both coactivators and 
corepressors. SRC-1: (steroid coactivator 1), GRIP-1 (glucocorticoid, 
receptor interacting protein-1), CBP (CREB-binding protein), ADA2 
(alterationjdeficiency in activation), PC4 (positive cofactor), TBP (TATA 
binding protein), TAF (TBP associated factor), TFIIB (transcription factor 
lIB), SMRT (silencing mediator of retinoid and thyroid receptors), SHP 
(small heterodimer protein) (323;371;383). 
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Figure 37: Structure of the HNF-4 ligand binding domain. 
(A) A ribbon diagram of the homodimer reveals a "LBD" fold. Helices, 
shaded turquoise (1-9), yellow (10), or red (12), reveal two distinct 
conformations: open on the left and closed on the right. Strands are 
colored green, and the fatty acids (ffa) in the ligand binding pockets are 
colored magenta. (B) the ligand and elements of secondary structure are 
colored similarly in the schematic representations, with open and closed 
conformations in the same orientations for comparison. Figure and text of 
legend fram (377). 
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Figure 38: Ligand binding regions of HNF-4a 
Two ligand binding regions have been identified within the LBD of HNF-
4al: the high affinity acyl-CoA binding pocket (ACS) stretches across the 
E and F domains, and the low affinity fatty acid binding pocket (FAP) is 
located in the E domain. It has been suggested that cross-talk between 
the ACS and FAP regions regulates HNF-4(Xactivity. Acyl-CoA esters bind 
to the ACS and are hydrolysed by the thioesterase. The hydrolysed 
product then interacts with the FAP. Alternatively, free fatty acids present 
in the medium could be exchanged with fatty acids already bound to the 
FAP. RCOOH: free fatty acid; RCOSCoA: Acyl CoA ester; CoA: coenzyme 
A. Figure from (382). 
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Two ligand binding pockets have been reported for HNF-4a: a low affinity 
fatty acid binding pocket (FAP) and high affinity acyl-CoA binding site 
(ACS) (Figure 38) (382). Crosstalk between the two binding pockets 
regulates the activity of HNF-4a. 
HNF-4a also functions as an acyl CoA thioesterase, which is linked to its 
ability to bind acyl CoA substrates at high affinity (382). Ligand binding 
generally acts as a switch for corepressor-coactivator exchange for 
nuclear receptors but this ligand-dependent exchange has not yet been 
described for HNF-4a (383). 
4.7.2. Expression of HNF-4a and isoforms 
HNF-4a is highly expressed in the liver and, to a lesser extent, in the 
kidney, GI tract, and pancreas (384). There are nine isoforms due to 
alternative promoter usage (Pl and P2), a possible 30 bp inclusion in the 
F domain, and a potential truncation of the carboxy terminus (Figure 39) 
(385). The Pl promoter regulates expression from exon lA and produces 
isoforms a1-a6, whereas isoforms a7-a9 are transcribed from exon 10 
under the control of the P2 promoter. Among the Pl isoforms, isoform a2 
has a 30 bp insert in the C-terminus and is 10 amino acids longer than 
isoform al. Isoform a3 is truncated at the C-terminal end. Isoforms a4-
a6 are similar to isoforms a1-a3 except for the proposed two extra exons 
(lB and lC) in the N-terminus (385). 
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Figure 39: HNF-4a gene and mRNA isoforms. 
Expression of HNF-4a is under the control of two promoters (Pl and P2), 
giving rise to nine mRNA isoforms. See text for details. Figure adapted 
from (371). 
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P2 isoforms (a7-a9) are also similar to Pl isoforms a1-a3 except for the 
extreme N-terminus due to use of the P2 promoter and exon 1D. 
Pl and P2 isoforms are differentially expressed: Pl isoforms are highly 
expressed in human, rat and mouse adult liver, and adult-like hepatoma 
ceillines (351;386-388) whereas P2 isoforms are predominant in murine 
foetal liver and foetal-like hepatoma cells, undifferentiated cell types and 
stem cell populations (386;389). In contrast to the above data, one group 
has reported the expression of Pl isoforms in the human pancreas and 
rodent pancreatic cell lines, and low levels of P2 isoforms have been 
reported in mouse adult liver by RT-PCR (386). 
4.7.3. Actions of HNF-4a 
HNF-4a is an important regulator of the expression of severalliver-specific 
genes involved in regulating hepatic function, such as the metabolism of 
lipids, lipoproteins, carbohydrates, fatty aCids, amino aCids, blood 
coagulation, detoxification and haematopoiesis [reviewed in (371)]. It 
affects the transcription of target genes by binding as a homodimer to a 
DR-1 hexamer and recruits either coactivators to its AF-1 and AF-2 
domains or corepressors to the AF-2 domain, thereby mediating activator 
or repressor functions (Table 11) (384) . 
Tyrosine phosphorylation is required for its subnuclear localization and 
enhances DNA binding and subsequent activation potential (390). 
Serinejthreonine phosphorylation also enhances DNA binding and 
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transactivation in bacterial and COS cells (391). High AMP:ATP ratios 
stimulate phosphorylation of serine 304 by the AMP-activated protein 
kinase, decreasing HNF-4a stability and dimer formation, and, thus 
reducing binding activity (392). 
HNF-4a is constitutively active and forms dimers in the absence of added 
ligand; however, severa 1 physiologicalligands have been shown to 
modulate its activity. HNF-4a binds acyl-CoA substrates with high affinity 
and converts them into fatty acids that directly interact with the FAP, 
thereby modifying its activity (Figure 38). Acyl CoA thioesters of long 
chain fatty acids (LCFA) increase oligomerization and decrease binding of 
HNF-4a to its cognate element, while those of C14-18 promote dimer 
formation and DNA binding, thus activating HNF-4a (381;382;393). Other 
antagonist ligands include lipid lowering polyunsaturated fats and 
hypolipidaemic drugs (393). Dietary status also affects the activity of 
HNF-4a, thereby modulating its effect on target genes. For example, 
polyunsaturated fatty acids (PUFA) inhibit the binding of HNF-4a to its 
response element on the promoter of the glucose-6-phosphatase (G-6-P) 
gene and, thus, repress its transcription (394). G-6-P is a gluconeogenic 
enzyme that acts to increase the amount of glucose available for release 
into the bloodstream. These studies suggest that hepatic metabolic 
homeostasis is, in part, maintained by modulating the activity of H N F-4a 
on target genes. 
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4.7.4. Role of HNF-4a during early development 
In mice, HNF-4a is involved in formation of the primary layers of the 
embryo, organogenesis and the expression of early liver genes. HNF-4a is 
first detected in extra embryonic tissue and in the primitive endoderm of 
the E4.5 embryo (395). It is expressed in columnar visceral endoderm of 
the yolk sac at E5.5. Hepatic expression of HNF-4a first appears in the 
liver bud and hindgut at E8.5, when liver cells begin to proliferate and we 
first see the expression of liver-specific genes (e.g. AFP). The highest 
expression in liver is observed on day 18 and drops by day 20. There are 
low levels from birth throughout adult life due to the fact that P2 isoforms 
are no longer expressed and levels of Pl isoforms are decreased 
(383;386;395). HNF-4a is also expressed in the midgut (including the 
primordium of pancreas and gallbladder), the stomach, mesonephric 
tubules and the hindgut (intestine) ending at rectal-anus border (395). 
Homozygous mice knockouts are embryonically lethal and mice rescued 
with wild-type visceral endoderm develop a liver but fail to express severa 1 
specifie liver genes, including apolipoproteins (396;397). No homozygous 
mutants exist in the human population, presumably because the human 
knockout is also embryonically lethal. 
4.7.5. Role of HNF-4 a in adult liver 
Target hepatic genes of HNF-4a have been identified by the response 
elements on their promoters, their HNF-4a responses under in vitro test 
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conditions and their deregulation in HNF-4a defective models (Table 12) 
(371). Due to the lethality of the mice knockouts, conditional knockouts 
have been used to study the role of HNF-4a in adult mice. HNF-4a 
expression was barely detectable in the postnatal liver of these mice, they 
weighed less than their control Iittermates by 5 wk and had major defects 
in Iipid metabolism and by 8 wk, 70% of the knockout mice were dead 
due to as yet undefined causes (398). The expression of other LETFs is 
also affected in HNF-4a null mice. HNF-3f3 which is normally expressed at 
higher levels in the liver of female mice is unaffected in the female knock 
outs of HNF-4a, but is expressed in the male knock out mice at normal 
female Iiver levels, suggesting that HNF-4a negatively regulates the 
expression of HNF-3f3 in male mice (96). 
4.7.6. Transactivating properties 
HNF-4a has been shown to act as a transactivator on the majority of its 
target genes (371). Isoforms with the 10 amine acid insert in the C-
terminus (a2/a8) are stronger activators of transcription, reportedly 
because the insert exposes the AF2 domain to possible coactivator 
interactions (399). P2 isoforms are thought to be less potent 
transcriptional factors due to the fact that they lack the AF1 domain that 
interacts solely with coactivators (383;400;401). 
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4.7.7. Repressor properties 
HNF-4a can also act as a transcriptional repressor on severa 1 hepatic 
genes including human IGF-II, HMG-CoA synthase, liver-specific arginase, 
acyl-oxidase and itself HNF-4a (402-407). However for the HNF-4a and 
liver-type arginase genes, the mode of repression by HNF-4a is not known 
as HNF-4a does not bind to these promoters (403-405). 
HNF-4a has been shown to interact with SMRT and HDAC complexes that 
are involved in transcriptional repression (383;399). 
4.7.8. HNF-4 binding sites in the 1.8 kb Vl promoter region 
Studying the effect of HNF-4 on the hGHR V1 promoter was of particular 
interest since regulation of the liver-specific V1 is likely to involve a liver 
enriched transcription factor su ch as HNF-4a. In fact, six putative HNF-4 
binding sites were identified by computer assisted TF scanning programs 
in the 1.8 kb upstream of V1 (Figure 40A) and GH as weil as HNF-4a have 
been shown to be involved in the regulation of lipid, lipoprotein and bile 
acid metabolism [reviewed in (64;371)]. 
The HNF-4 site closest to the upstream V1 TSS is conserved across 
severa 1 species (ovine, bovine and murine) (Figures 20 and 40B,) 
(256;258;408-410). 
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Table 12: Hepatic target genes of HNF-4a. 
Gene 
Nutrient transport 
Lipid and retinol transport Apolipoproteins (AI, AIl, AN, CIII) 
intestinal and hepatic fatty acid 
binding proteins 
Other serum transport proteins Transferrin, transthyretin 
Nutrient metabolism 
Lipid and steroid metabolism 3-Hydroxy-3-methylglutaryl-CoA, 
P450 cytochromes (2A4, 2C1, 2D6, 
7), cholesterol 7-a hydroxylase 
Glucose metabolism Aldolase B, phosphoenol pyruvate 
carboxy kinase, liver-type pyruvate 
kinase 
Amino acid metabolism Tyrosine aminotransferase, 
Ornithine carbamylase 
Blood factors 
Coagulants Factor VII, VIII, IX, 5 
Anticoagulants Antithrombin III 
Other Erythropoietin 
Transcription factors HNF-1a, HNF-6, Fetoprotein 
transcription factor 
Immune system a1-Microglobulin and bikunin, 
Macrophage stimulating factor 
Growth factors and receptors Prolactin Receptor 
Adapted from (323;371). 
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Figure 40: Putative HNF-4 binding sites identified by Matinspector and 
Signal Scan software programs. 
Putative HNF-4 binding sites were identified by MatInspector and Signal 
Scan in (A) the 1.8 kb hGHR VI promoter (AF322015) and in (B) ovine 
(olA), bovine (b1A) (U15731) and mouse (mU) (NT_039747) 
homologous regions (223;256;258;411). 
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Table 13: Nucleotide sequences of the six putative HNF-4 sites in the 1.8 
kb V1 promoter. 
Comparison of the sequences of the putative HNF-4 sites in the V1 
promoter with the published consensus sequence from Siadek et al (371). 
The site 1 sequence is most like the consensus sequence (nucleotides not 
matching the consensus are in lower case type). (R): reverse strand. 
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HNF-4 
HNF-4 HNF-4 HNF4 2X HNF-4 
2.0kb 
Site Sequence 
Consensus GGGTCA A AGGTCN 
(Sladek et al, 2001) A TCT G G TCT 
AG G 
1 tGGGCA A AGGTCA 
2 (R) AGAaCA A AGGCaG 
3 tGGGCA t ttGGgG 
4 (R) tGGGCA G AaGaaC 
5 GGGGCA G AGGagG 
6 (R) AGGGCA A tGaGCA 
Comparing the six putative V1 HNF-4 binding site sequences to the 
previously published sequences for HNF-4 revealed that the site close st to 
the TSS (#1) is most similar to what has been defined as the consensus 
element (Table 13) (371). 
4.7.9. HNF-4a variant expression in human foetal and adult 
hepatocytes and ceillines (mRNA and protein) 
In order to characterize the mRNA transcripts expressed in human foetal 
and adult hepatocytes, as weil as in three human ceillines (HepG2, Huh7, 
and HEK293), primers were designed for specifie regions of the HNF-4 
gene and used in RT-PCR assays (Table 3). Transcripts arising from the 
Pl promoter were found in ail cell types and in both foetal hepatocytes 
and adult liver (Table 14). Cells from the hepatic lineage also expressed 
transcripts for HNF-4a with or without the extra 30 bp in the C-terminus, 
the C-terminal truncated isoforms and isoforms transcribed from the P2 
promoter. In contrast, HEK293 cells appear to be producing only the 
HNF-4a1 mRNA transcript. 
An HNF-4a antibody that can identify isoforms 1,2,4,5,7 and 8 detected 
HNF-4a2 in human foetal hepatocytes, adult liver and the two hepatoma 
ceillines while HEK293 cells had undetectable levels of HNF-4a protein 
(Figures 41 A&B). 
176 
Table 14: Expression of HNF-4a mRNA isoforms in human liver and 
ceillines. 
Primers were designed to specifie sites in the hHNF-4a gene, in order to 
characterise the different mRNA variants present in three human liver 
tissues and cell lines (Table 3). The results from RT-PCR analyses are 
tabulated. * (HepG2, Huh7), ** (HEK293), # (Isoforms 4,5,6 were never 
detected), (+: present; - not seen). 
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Variant # Foetal HumanAdult Hepatoma Cell Kidney Cell 
Hepatocytes (n=2-9) Liver (n=2-5) Lines* (n=2-4) Line ** (n=3-5) 
Pl promoter: exon lA 
Isoforms 1,2,3 + + + + 
P2 promoter: exon lD 
Isoforms 7,8,9 + + + -
W fout C-terminus 30 bp 
insert + + + + Isoforms 1,7 
C-terminus +30 bp insert 
Isoforms 2,8 + + + -
C terminus truncation 
Isoforms 3,9 + + + -
Figure 41: Detection of HNF-4a protein in human liver and ceillines by 
Western blot. 
(A) Western blot: 10 J.!g of nuclear Iysates were resolved on 12% SDS-
PAGE and immunoblotted with an HNF-4a antibody that recognises HNF-
4al,2,4,5,7,8. Calnexin was used as a loading control. (B) Extended 
exposure of Huh7, human adult liver (HAL) and human foetal hepatocytes 
(HFH) lanes to show HNF-4a2 as the major isoform expressed in HAL 
while HFH and Huh7 express both HNF-4a2 and a8 isoforms in equal 
amounts. HNF-4a was not detected (ND) in HEK293 cells. (C) Cumulative 
Western blot data expressed as mean or mean ± standard deviation, n=2-
11. The significance of the observed differences (compared to adult liver) 
was determined by Bonferroni's statistical test following ANOVA analyses. 
* p < 0.05, **p < 0.01. 
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Interestingly, foetal hepatocytes and hepatoma cell lines also expressed 
HNF-4a8 immunoreactive protein in approximately equivalent amounts to 
HNF-4a2. Quantitation of the relative amounts of total HNF-4 present in 
the samples reveals hepatoma cell types and foetal hepatocytes as having 
significantly higher amounts than adult liver and HEK293 cells (Figure 41 
C; * p< 0.05, ** p::; 0.01). Other groups have reported the expression of 
HNF-4a in hepatoma cell lines (387;388). 
Even though immunoreactive HNF-4a protein is expressed in human and 
rat kidney tubules (387;388), and we have found HNF-4a mRNA in 
HEK293 cells, there was no detectable HNF-4a protein in HEK293 cells by 
western blot. Isoforms from the Pl promoter have been shown to be 
transcriptionally more active than those from the P2 promoter (400). 
Thus, the different developmentally regulated isoforms are good 
candidates for a role in regulating the expression of V1-derived GHR 
mRNAs. 
4.7.10. Transient transfection assay studies on the effect of 
HNF-4a.l, a2 and aS on the VI promoter 
Based on the review of the literature, we hypothesised that HNF-4a would 
have a stimulatory effect on the V1 promoter and that there might be a 
differential effect of the Pl versus P2 isoforms. 
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Figure 42: Effect of HNF-4a1 on the transcriptional activity of V1 promoter 
constructs. 
HNF-4a1 (100 ng) expression vector was cotransfected with (A) 3' and (B) 
5' deleted Vl constructs in HEK293 cells, (C) HepG2 and Huh7 cells using 
CaP04• Cells were harvested 48 hr later and assayed as before. Data are 
presented as mean ± standard error, n=4-l1 experiments except for the 
HepG2 and Huh7 studies that were an n=l-2. The significance of the 
differences observed was determined by ANOVA, followed by Bonferroni's 
statistical test. * p < 0.05, ** P < 0.01, *** P < 0.001. , = HNF-4 
response element. 
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Initially, cotransfection studies were carried out with an HNF-4a1 
expression vector, as this is the HNF-4 a isoform that has been used in 
the majority of studies on the transcriptional activity of HNF-4a (Figure 
42). However, because we could not detect its protein expression in our 
human hepatic tissues, we subsequently changed to HNF-4a2 and aB, 
which we did find to be expressed at significant levels in the human 
hepatic tissues and ceillines (Figure 41). Transfections were carried out 
in HEK293 cells that did not express detectable endogenous HNF-4a 
protein. 
V1P1, the longest and most repressed construct, with ail six putative HNF-
4 sites, did not respond to HNF-4a1, a2 or aB (Figures 42A, 43A). The 
V7V1P1 construct, containing ail six sites but having lost NRR1, also did 
not respond to HNF-4a2 or aB (HNF-4a1 was not tested), suggesting that 
the NRR1 is not responsible for the lack of V1P1 response to HNF-4a 
(Figure 43A). There was also no response to the factors when the most 3' 
HNF-4 site was deleted (V7P1) (Figures 42A, 43A). Interestingly, the 
activity of the promoter region containing only the most 5' HNF-4 sites 
(#5 and #6) (VXPB) was markedly repressed by HNF-4a1 (p< 0.001), 
HNF-4a2 (p< 0.001) and, to a lesser extent, by HNF-4aB (p<O.Ol) 
(Figures 42A, 43A). Cotransfection of equal amounts of HNF-4a2 and aB 
were equally as effective in repressing VXPB (p< 0.01) (Figure 43A). 
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Loss of the S' 1.2 kb (sites #5 and #6 [V1P2]) led to a significant 
stimulation of transcriptional activity by ail three isoforms (HNF-4a1, a2 
[p< 0.05] and a8 [p< 0.01]) (Figures 42B, 43B). Deleting the #4 putative 
HNF-4 site (V1P3) caused a decrease in the stimulatory effect of the HNF-
4 factors, while deleting sites #2 and #3 (V1P4), leaving only the most 
consensus HNF-4 binding site, led to a highly significant responsiveness to 
ail three isoforms of HNF-4a1 and a2 (p< 0.001) and a8 (p< 0.01) 
(Figures 42B, 43B). 
As expected, the V1P5 construct with no HNF-4 sites had no response to 
any of the HNF-4a isoforms. The effect of HNF-4a1 on the V1 promoter 
constructs was also tested in HepG2 and Huh7 cells but no response was 
observed likely due to the high levels of endogenous HNF-4a in these cells 
(Figure 42C). 
P2 isoforms of HNF-4a contain one AF domain in the C-terminus, while 
the Pl isoforms have AF domains in both their N- and C-termini. On some 
gene promoters, the effects of Pl isoforms (e.g. al) are greater than P2 
isoforms Ce.g. a7), probably due to the fact that the latter lack the N-
terminal activation domain that has been shown to interact with 
coactivators (371;412). Since foetal hepatocytes and hepatoma ceillines 
express HNF-4a8 in addition to HNF-4a2 but not the V1 transcript, we 
hypothesised that the presence of HNF-4a8 would suppress the 
stimulatory effect of HNF-4a2 on V1 transcription. 
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Figure 43: Effect of HNF-4a2 and HNF-4a8 on the transcriptional activity 
of V1 promoter constructs. 
HNF-4a2 (100 ng), HNF-4a8 (100 ng) and HNF-4a2+a8 (50 ng+50 ng) 
expression vectors were cotransfected with (A) 3' and (B) 5' deleted V1 
constructs in HEK293 cells using polyfect. (C) 50 ng of HNF-4a2 and 
varying amounts of HNF-4a8 (50-200 ng) were cotransfected with V1P4, 
VXPB and V1P5 constructs into HEK293 cells. Cells were harvested 48 hr 
later and assayed as before. Data are presented as mean ± standard 
error, n=3-13 experiments. The significance of the differences observed 
was determined by ANOVA, followed by Bonferroni/s statistical test. * p < 
0.05, ** P < 0.01, *** P < 0.001. , = HNF-4 response element. 
183 
~[t A 
2.0kb 
Fold Change 
(relative to empty vector, M±SE, n=5-13) 
V1P1 
2.0kb 
H H V7~ VI 1 0 
-H H' 1 LUC; ':-1 -~~~~------'---------"---5 10 15 20 25 30 
~~:~l -H H t-1 LUC; 
V7P1 -H;ff: H,: ~} 1 LUC \. 1.7kb .: : . - V 
VXPB 
1.2kb 
B 
~ 1 LUC~ 
V1P1 .J:::L........f..~ f:]--~::~:-. 
2.0kb 
V1P2 
800bp 
o 
** 
5 
* 
** .~.~.~.~.~.~.~.~.~.~.~.~.~.~.~.~.~.~.~.~ ** 
** 
j:::': • 1 LUC; """""..-""",,,,,,,,,..-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,..-,,,".,,,,,,, 
V1P5 1 LUC) 
150bp 
* 
** 
*** 
30 
*** 
** 
** 
c 
2.0kb 
VXPB 
1.2kb 
---'----A 
"..-wr----
~ 1 LUC~ 
• Control 
V1PS 
1S0bp 
D HNF-4a.2 (50ng) 
~ HNF-4a.2 (50ng) + a. 8 (150ng) 
Fold Change 
(relative to empty vector, M±SE, n=3-10) 
o 2 4 6 8 10 12 14 16 18 
- - - - - - ** 
~------~** ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~--------~*** 
////////////////////////////////////////////////////////// 
~ HNF-4a.2 (50ng) +a8 (50ng) 
El HNF-4a.2 (50ng) + a.8 (200ng) 
* p< 0.05 
** p< 0.01 
*** p< 0.001 
Relative to control 
20 
To test this, increasing amounts of HNF-4a8 were cotransfected with a 
constant amount of HNF-4a2, using our most consensus HNF-4 binding 
site (VIP4) and the most S' sites (VxPs) as promoter vectors (Figure 43C). 
Increasing doses of HNF-4a8 had no significant effect on the response to 
HNF-4a2 with either of the promoter vectors. Thus, HNF-4a8 does not 
affect the activating or inhibitory potential of HNF-4a2, under our test 
conditions, contrary to what was hypothesised. 
4.7.11. Site directed mutagenesis of HNF-4 sites #1 
and #6 
To confirm that the proximal #1 and distal #6 putative HNF-4 sites are 
truly HNF-4a response elements, the sites were mutated (Table 6) and 
their responses to HNF-4a2 and a8 were tested in transient transfection 
assays: Mutagenesis of site #5 was not carried out because parallel EMSA 
and ChIP results indicated that this site was not functional (see below). 
Neither of the V1P4 HNF-4 mutant constructs (single and double) had a 
basal activity significantly different from the wild type VIP4 (4.7±O.8, 
n=10) (Figure 44). However, both mutant constructs showed no 
response to HNF-4a2 and a8. Significant repression of the 1.2 kb VxPs 
construct by HNF-4a2 and a8 was lost when the #6 HNF-4 site was 
mutated although, again, basal activities of both wild type and mutant 
constructs were similar (Figure 44). 
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Figure 44: Mutational analyses of HNF-4 sites #6 (most 5') and #1 
(most 3') in the proximal promoter of Vl. 
Constructs with either the (A) #6 or (B) #1 HNF-4 binding site mutated 
were cotransfected with HNF-a2 or aB; non-mutated constructs were 
transfected as controls. Data are presented as mean ± standard error, 
n=3-10 experiments. The significance of the differences observed was 
determined by ANOVA followed by Bonferroni's statistical test. * p< 0.05, 
** p< 0.01, *** p< O.OOI. 
, = H N F-4 response element, 1 V2 mutated H N F-4 response 
element, t mutated HNF-4 response element (Table 6). 
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These data strongly suggest that the #1 site is responsible for the 
stimulatory effects of HNF-a2 and a8 while the #6 site is responsible for 
the inhibitory response to HNF-a2 and a8. 
4.7.12. EMSA and EMSSA analyses of HNF-4 sites #1, #5 
and #6 
EMSA assays revealed that HNF-4a2 and a8 bind to the #1 site (Figure 
45A). Whereas bands that were formed with HEK293 nuclear extra ct 
proteins did not change with an HNF-4a antibody that recognises isoforms 
al, a2, a4, aS, a7 and a8, and, thus were non-specifie, the bands 
formed with proteins from HEK293 cells overexpressing HNF-4a2 and a8 
completely supershifted (Figure 45A). The partial and double mutants of 
this site showed only non-specifie binding that was not supershifted by the 
HNF-4a antibody (Figure 458). 
The #5 HNF-4 site did not bind HNF-4a2 or a8 as detected by gel 
supershift analysis (Figure 45C), while the #6 site specifically bound HNF-
4a2 and a8 and this binding was lost with the mutant probe (Figure 45D). 
Identical results were obtained when EMSA and EMSSA analyses were 
carried out with HEK293 nuclear extracts overexpressing either HNF-4a2 
or a8 (data not shown). 
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Figure 45: EM5A and EM55A analyses of HNF-4a proteins binding to 
putative HNF-4 sites #1, #5 and #6 in the V1 promoter. 
Double stranded oligonucleotides representing the (A, B) #1, (C) #5 and 
(D) #6 HNF-4 sites were radioactively labelled (aP32-ATP) and incubated 
with various nuclear extracts. Mutant oligonucleotides (Table 8) and a 
specific HNF-4a antibody that recognises HNF-4a2+8 were used to 
determine the specificity of binding. Nuclear extracts were from HEK293 
cells overexpressing HNF-4a2 + a8. Arrows indicate --. N5 = non-
specific, lw.·.· •.•• 1} 5 = shift, ... 55 = supershift bands. 
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4.7.13. ChIP analyses of HNF-4 sites #1, #5 and #6 
In vivo analysis of the HNF-4 sites by ChIP in Huh7 cells revealed that the 
proximal (#1) and most distal (#6) sites are bound byendogenous HNF-
4a; however, the distal site #5 is not (Figure 46). 
From the site directed mutagenesis, EMS/SA and ChIP data, we conclude, 
therefore, that #1 and #6 are functional HNF-4 sites and #5 is not. 
4.7.14. Discussion of the HNF-4a data 
The negative regulatory regions (NRR 1-3) previously identified during the 
deletional studies of the V1 promoter coincide with the presence of five 
(HNF-4 sites #1, #2, #3, #5 and #6) of the six identified HNF-4 sites. 
Cotransfection studies with HNF-4 a2 and a8 expression vectors showed 
that constructs containing just the two most 5' HNF-4 sites (in NRR3) 
were, in fact, repressed by both factors while the most proximal HNF-4 
site (#1) is highly stimulated. Sites #2-#4 remain to be investigated in 
detail. 
Studies by other labs have shown that regions homologous to our NRR2 
interact with liver nuclear proteins. Using footprinting analyses, Jiang et 
al. showed that bovine nuclear extracts from liver, spleen and kidney bind 
to two regions (258;268). The first, IV 23 bp footprint homologous to the 
S'end of NRR2 was weakly footprinted by nuclear proteins from liver, 
spleen and kidney. 
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Figure 46: In vivo ChIP analyses of proteins to three putative HNF-4 sites 
(#1, #5 and #6) in the V1 promoter region. 
(A) Position of primer pairs used for ChIP analysis (Table 9). (6) Huh7 
cells were crosslinked and the Iysates immunoprecipitated with HNF-4a or 
goat IgG (IgG con). Following the reversai of the crosslinks, PCR assays 
were performed across HNF-4 binding sites #1, #5 and #6 and a region 2 
kb upstream of HNF-4 site #6 as a control (control). Products were 
resolved on a 2% aga rose gel. The intensity of the bands in the IgG con 
and HNF-4a of site #5 are equivalent and therefore there is no 
enrichment of HNF-4a at this site. There is no band in the IgG con la ne 
of site #6 and a faint band in the HNF-4a lane of the same site; thus, 
HNF-4a is enriched at this site. However, HNF-4a cccupancy of site #6 is 
weaker compared to that of site #1. 
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MatInspector has identified no binding sites for transcription factors for 
this region. A second footprint (IV 20 bp), similar to a region in NRR2 that 
contains an HNF-4 site (#3) unique to the human, was specifie to bovine 
liver nuclear extracts. Rivers et al also showed that a region 
encompassing HNF-4 #3 (F2) in the V1 promoter was protected by HepG2 
nuclear proteins in footprinting analyses, implying that HNF-4 site #3 is 
possibly bound by HNF-4 proteins (268). 
Previous deletion promoter studies of the human V1 did not identify 
positive regulatory regions (268;269). However, footprinting analyses 
have identified two regions within the upstream positive region (PRR2) 
(Figure 19), between NRR2 and 3, that are bound by proteins in HepG2 
nuclear extracts (F3 and F4) (268). Our HNF-4 response element #4 is 
located within the F4 footprint, suggesting that endogenous HepG2 
nuclear proteins interacting at site #4 could be HNF-4, whereas F3 
contains a putative TATA box and a C/EBP site (268). A similar regulatory 
region in the ovine does not contain any HNF-4 sites (Figure 19) and has 
been shown to be repressive in Huh7 cells (253). 
PRR1, a 150 bp region containing the upstream V1 TATA/TSS complex as 
weil as IV 130 bp of its promoter, contains an HNF-4 site conserved in 
severa 1 species (Figure 19). The V1P4 construct containing this site (#1), 
was significantly stimulated by both HNF-4 a2 and a8. Ovine studies 
carried out in the laboratory of Dr. Timothy Adams identified a positive 
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regulatory region homologous to our PRR1 that contains an HNF-4 site 
although specifie studies with HNF-4 were not carried out (253). In the 
bovine, extensive studies have been carried out to determine the 
functional significance of the regulatory domain equivalent to the V1 HNF-
4 site #1 (258;270). Yeast one-hybrid experiments first identified HNF-
4a, HNF-4y and COUP-TFII as proteins interacting at this site, and this 
was then confirmed using bovine liver extracts in EMS/SAs and ChIP 
experiments (258;270). Ali three factors stimulated transcriptional activity 
of a 500 bp b1A promoter construct: the effeet of COUP-TFII was about 
15 fold higher than the HNF-4 factors. Deletion of the HNF-4 site ablated 
responses to HNF-4a and HNF-4y but there was still some response to 
COUP-TFI!. The -469 to -21 bp b1A construet contains a second putative 
HNF-4 site that is also present in the ovine but not in human or mouse but 
this site has not yet been investigated (Figures 20 & 40B). From Jiang et 
al. studies of b1A and the V1 studies carried out for my PhD research, 1 
conclude that the H N F-4 site present in PRR1 and conserved across four 
species is functional and stimulatory in the bovine and human GHR genes, 
and that this is likely to be true for the ovine as weil. It is difficult to 
speculate whether this is the case for the mouse L1 variant as this 
transcript is strongly upregulated only in the liver of pregnant mice and 
likely to be under additional regulatory mechanisms not common to other 
species expressing liver-specific variants of GHR (172;256;413). In fact, 
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studies of the mouse L1 promoter have identified a developmental 
enhancer element 3.5 kb upstream of the TSS that is only active in adult 
hepatocytes (256). This element binds NF-Y and MSY-1, a single stranded 
RNA binding protein. The amount of immunoreactive MSY-1 protein in the 
nuclei of non-pregnant mouse liver cells is much higher than in pregnant 
females and an MSY-1 expression vector repressed the activity of the 3.6 
kb L1 promoter construct by 50-60%, suggesting that it normally 
suppresses ml1 expression in non-pregnant mice (413). 
The importance of HNF-4a in the regulation of normal hepatic function 
has been demonstrated in liver-specific HNF-4a knock-out adult mice that 
show defects in hepatic lipid, lipoprotein and bile acid metabolism (398). 
These animais also weighed less compared to normal littermates (398). 
Studies in the rodent have clearly shown that expression of HNF-4a is 
under the control of two promoters: Pl and P2. Isoforms arising from the 
promoters are developmentally regulated, P2 isoforms being expressed 
only in the foetal hepatocytes and Pl isoforms in both foetal and adult 
hepatocytes (386;389). My immunoblotting data show, for the first time, 
a parallel situation in humans: the HNF-4a8 (P2) isoform was only 
expressed in the foetal hepatocytes while the HNF-4a2 (Pl) isoform was 
found in both foetal and adult hepatocytes, using an HNF-4a antibody 
specifie to the extreme C-terminus of HNF-4a. Other groups have 
reported the expression of the HNF-4a2 isoform in human adult 
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hepatocytes and hepatoma cells (HepG2, Huh7) using HNF-4a antibodies 
specifie to the N-terminus that distinguish between Pl and P2 isoforms 
(387;388). 
Since foetal hepatocytes and hepatoma ceillines express HNF-4a8 in 
addition to HNF-4a2, but not the Vl transcript, we initially hypothesised 
that the presence of HNF-4a8 would inhibit the stimulatory effect of HNF-
4a2 on Vl transcription in foetal and tumour hepatic cells. Previous 
studies suggest that there are functional differences between the Pl and 
P2 isoforms: P2 HNf-4a isoforms that possess only the Af-2 domain are 
less potent transcription factors (400;401) but are stronger activators of 
early genes (412). In addition, insertion of ten amine acids in the f-
domain of HNf-4al makes HNf-4a2 a more effective transactivator (414). 
Our observations of the effect of Pl and P2 HNF-4a isoforms on the Vi 
promoter did not reflect this: no significant differences in the potency of 
HNf-4 a2 (Pl isoform) and a8 (P2 isoform) on the hGHR Vi promoter 
were observed. Cotransfecting increasing amounts of HNf-4a8 with HNf-
4a2 did not alter the effect of HNf-4a2 on the promoter fragments. 
Thus, 1 disproved our hypothesis that P2 isoforms repress the activity of 
Pl isoforms and, thereby, inhibit the expression of the liver specifie Vi 
hGHR transcript in foetal hepatocytes and hepatoma celllines. 
Instead, 1 showed that HNF-4a2 and a8 could have both stimulatory and 
repressive effects on the same gene (hGHR) through two different HNf-4 
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sites, #1 and #6. In agreement with the inhibitory effects, HNF-4a1 has 
been shown to act as a repressor on the HMG-CoA synthase gene, the 
liver-specific arginase gene, the acyl-oxidase gene, the liver-specific 
promoter of the human IGF-II gene, and the HNF-4a Pl and P2 
promoters (403-407;415). Only one other example of the opposing 
effects of HNF-4a on the same gene via different sites has been reported: 
the human al-microglobulinjbikunin precursor (AMBP) gene that encodes 
two plasma glycoproteins (416). al-microglobulin is a retinal carrier 
protein and bikunin is a serine protease inhibitor protein (417;418). 
Although both proteins are unrelated in function, they are derived from 
the same precursor, AMBP, encoded bya single gene. ABMP expression is 
restricted to the liver and upregulated during the perinatal period, 
suggesting that this gene is under tissue and developmental regulation 
(418). Nine response elements (boxes) for the HNF family (HNF-1, HNF-
3, HNF-4) have been described in an enhancer region, IV 2.5 to 2.9 kb 
upstream of the TSS (416;419). Boxes 2, 7 and 8 are positive HNF-4 sites 
whereas HNF-4a1 exerts a negative effect through box 9 (416). The 
repressive effect is dependent on the absence of a functional box 8 and 
the presence of low HNF-4a: in conditions where HNF-4a is low, the 
occupancy of the low affinity box 8 will be low and, thus, the effect of box 
9 will be more pronounced (416). 
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The V1 promoter is similar to the ABMP gene in terms of multiple HNF-4 
sites in the promoter region and the expression is regulated in a 
developmental and tissue-specifie pattern. At the same time they are 
different in the sense that the HNF-4 sites in ABMP are located in an 
enhancer region over 2 kb upstream of the TSS, whereas the HNF-4 sites 
in the V1 promoter are both proximal and distal. 
HNF-4a2 and a8 both bind the same sites in the human V1 GHR 
promoter; this interaction is abolished by mutations in either one or both 
half sites of the direct repeat response element, showing that these are 
functional HNF-4 sites. The binding of Pl and P2 isoforms of HNF-4a to 
the V1 promoter suggests a regulatory role for HNF-4 in cells that express 
either one (adult hepatocytes) or both (foetal hepatocytes) of the 
isoforms. 
Another level of regulation may lie in their association with SMRT-HDAC 
complexes. The laboratories of Drs. Frances Siadek and Mary Weiss have 
shown that HNF-4a1 (Pl isoform) and HNF-4a7 (P2 isoform) interact with 
SMRT-HDAC complexes in vivo and in vitro, and that HNF-4a1 is more 
strongly repressed by SMRT (383;412;420). Studies have shown that 
both class 1 (HDAC 1-2) and class II (HDAC 4-6) HDACs are required for 
active repression (421). The availability of different HDACs in a cell could 
affect the activity of nuclear receptors: the deacetylase domain of SMRT 
specifically activates HDAC 3, and, thus, although SMRT-HDAC-4 
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complexes may assemble, HDAC3 interaction is also required in order for 
repression to occur. 
In addition, since no distinctive differences in HNF-4 binding sites have 
been identified that make it either inhibitory or stimulatory, activation or 
repression by HNF-4a is likely to be affected by other response elements 
in the region around it. In support of this, HNF-4a has been shown to 
repress PPAR activation of the mitochondrial HMG-CoA synthase gene, 
and HNF-4a repression of the human IGF-II gene is relieved by C/EBPa, 
suggesting competitive inhibition by other LETFs can occur at the same 
site (402;406). C/EBPa is expressed at very low levels in the rodent foetal 
liver and dedifferentiated epithelial cells and is upregulated in mature liver 
and in hepatomas (332). This could be the mechanism by which V1 
expression is augmented in the liver postnatally. 
The region containing the distal site #6 could be considered to be within 
the promoter of V7, which is upstream of the V1 exon, or to be a distant 
regulatory element of Vl. As a promoter region of V7, repression of HNF-
4 site #6 by both HNF-4a2 and aS, could be the mechanism regulating 
the suppression of V7 in the foetal liver and its low expression in adult 
liver. On the other hand, as a distal regulatory element for V1, it could 
account for the suppression of V1 expression in foetalliver and with 
increased expression of other LETFs such as CjEBPa around birth, these 
factors could alleviate the repression, and in cooperation with site #1, 
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upregulate V1 expression in the postnatalliver. Ali of these theories are 
yet to be investigated. 
The HNF-4 sites chosen for this study (#1, #5, #6) had sequences closest 
to the published consensus and the constructs containing these sites 
showed striking responses to HNF-4a1, a2 and aB. Site #1 (V1P4), with 
only 1 bp mismatch was highly stimulated, and sites #5 and #6, with only 
2 bp mismatches, were present in VXPB that was significantly inhibited in 
response to HNF-4a1, a2 and aB. Although site #2 was only a 2 bp 
mismatch and the promoter region (V1P3) was stimulated in response to 
HNF-4a1, a2 and aB, deletion of this site (including site #3) (V1P4) 
resulted in an increase in the magnitude of response, suggesting that site 
#2 (and possibly #3) is inhibitory. 
Site #4 is 4 bp off from the consensus, yet deletion of the site led to a 
slight decrease in both basal activity and responsiveness to HNF-4a1, a2 
and aB, suggesting that it may be stimulatory. Future experiments will 
investigate the functional significance of these three sites (#2, #3 and 
#4) and how ail six sites interact to regulate transcription of the V1 mRNA 
transcript. 
In summary, HNF-4a2 and aB have comparable potency on the hGHR 
gene, stimulating and repressing V1 promoter activity via different sites. 
The stimulatory site is conserved in the bovine, ovine and mouse and 
studies by Jiang et al. have shown that it is also functional in the b1A 
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promoter. The distal site #6 interacts with, and is repressed by, HNF-4a2 
and aS. Such duality in HNF-4a activity on the same gene may be 
important in the expression of V7 versus the Vl transcript in the adult 
liver and/or Vl repression in foetal liver and hepatomas. 
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CHAPTER 5: GENERAL DISCUSSION AND 
CONCLUSIONS. 
GH is an important regulator of postnatal growth and metabolism. It 
exerts its effects on target cells by interacting with its surface receptor, 
GHR. More than twelve mRNA transcripts of the hGHR have been 
identified, varying only in the 5'UTR sequence (224;241). Seven of the 
non-coding 5'UTR exons generating these mRNAs are grouped in two 
clusters which we have called modules A and B (59;223;224). 
Interestingly, mRNA variants arising from the exons in the two clusters 
are differentially regulated. While module A generated transcripts are 
ubiquitouslyexpressed, module B variants are only switched on in the 
postnatal hepatocyte, likely accounting for the increase in GHR mRNA and 
GH binding observed beginning ~ 3 months after birth (223;244;269). 
It has been of great interest to determine what mechanisms regulate the 
expression of these latter variants. Severa 1 mechanisms could be in 
operation. First, the structure of the chromatin could be modified in a 
developmental- and tissue-specifie manner. CpG islands have been shown 
to be involved in epigenetic regulation of the expression of several genes. 
However, the promoter regions of the module B exons did not contain any 
CpG islands or significant numbers of CpG dinucleotides. Second, 
developmental changes in the expression of transcriptional repressors in 
the foetal liver and non-hepatic cell types and/or transcriptional activators 
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in the postnatal liver could also be a mechanism by which the expression 
of module B mRNA variants are regulated. Whether these are acting to 
remodel the chromatin region relevant for module B exons' activation or 
are binding to already 'opened' chromatin regions remains to be 
determined. 
l began my studies by comparing the promoter activities of the exons in 
modules A and B. The cell types used did not express module B variants 
but they did produce module A variants and, thus, the fact that module A 
promoters were much more active than those from module B was not 
surprising. More intriguing was the fact that a 2 kb V1 promoter 
construct, containing the two TSS/TATA complexes and about 1.8 kb of 
the promoter region, was completely repressed in ail four cell lines. By 
removing 150-300 bp from the 3' end of this construct, promoter activity 
was significantly increased. Transcription factor scanning programs 
revealed two putative binding sites for the transcriptional repressors, Gfi-1 
and Gfi-1b. Both factors were shown to bind to the same sequence on 
the V1 promoter and both factors repressed its activity, as shown by 
transient transfection assays and site-directed mutagenesis. Even though 
our protein detection systems did not identify Gfi-1 and Gfi-1b 
immunoreactive proteins in the cell lines, mutation of one or both sites in 
the 300 bp proximal promoter of V1 significantly increased the basal 
activity of the construct. This suggests that endogenous repressors were 
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actively repressing V1 transcriptional activity through the Gfi-1j1b sites. 
We still have not ruled out the possibility that these factors could be Gfi-1 
andjor Gfi-1b, as the transient transfection assays have shown that small 
amounts of these factors (below the detection limits of our Western blots) 
strongly repress the activity of the V1 proximal promoter. 
GH has been shown to regulate transcription of its own receptor in the 
human hepatocyte (181;182;185;186;188). Severa 1 response elements 
have been described as GHREs [reviewed in (147)]. Wang et a/described 
a STAT5 site in the bovine b1A promoter through which GH regulates GHR 
in the hepatocyte (422). Although no consensus Stat response elements 
were detected in the 1.8 kb V1 promoter, a GAGA element is found ~ 20 
bp upstream of the conserved TATA box of the V1 promoter. GAGA 
elements in vertebrates have been shown to interact with severa 1 
unidentified endogenous GBPs (311;313-315). We discovered that the 
Drosophila GAF-519 protein strongly stimulates the activity of the 100 bp 
V1 proximal promoter through the GAGA element. The proximity of the 
proximal Gfi-1j1b site and the GAGA element led us to investigate the 
interaction of both factors. The effect of Gfi-1 was striking as it repressed 
~ 75% GAF stimulation of the 100 bp V1 proximal promoter when 
expressed at very low levels. This leads us to hypothesise that fine 
control of the expression of Gfi-1j1b and mammalian homologues of the 
Drosophila GAF will be important in modulating V1 expression. As so little 
201 
is known about the mammalian homologues of the Drosophila GAF, it is 
difficult to know what its role in the regulation of V1 promoter activity may 
be. However, from our knowledge of the function of GAF in Drosophila, 
we can speculate that they might involve antirepressor activities and/or 
boundary functions (295). While the downstream Gfi-1/1b site and the 
GAGA element are conserved across the species, bovine studies of the 
proximal 190 bp promoter of b1A show that a ubiquitous transcription 
factor, ZBP-89, is bound to its site just downstream of the GAGA element 
and overlapping the Gfi-1/1b site (267). Comparison with the consensus 
ZBP-89 sequence suggests that this is present in the ovine but not in the 
human or mouse (Figure 20). Thus, regulation of the Iiver-specific variant 
of hGHR through ZBP-89 may be restricted to ruminants. Whether either 
Gfi-1/1b or GBPs regulate ruminant Iiver-specific GHR expression has not 
been examined. 
In our search for a factor that could mediate the Iiver-specific expression 
of V1, we used computer-based TF scanning programs to analyse the 1.8 
kb promoter region of V1 for binding sites for members of the LETF 
family. Severa 1 response elements were identified including for C/EBP (3 
sites), DBP (3 sites), HNF-1 (3 sites), HNF-6 (1 site) and HNF-4 (6 sites). 
The HNF-4 site most proximal to the downstream TSS has a 1 bp 
mismatch with the published consensus sequence and has the potential to 
interact with HNF-4, COUP-TF and PPAR/RXR TFs. It is also conserved in 
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homologous regions in the bovine, ovine and mouse genes. This HNF-4 
site has been shown in the bovine to interact with and be stimulated by 
HNF-4al, HNF-4y and COUP-TF1! (258;270). HNF-4a and HNF-4y are 
expressed in hepatocytes; however, HNF-4y mRNA is 10X less abundant 
than HNF-4a mRNA (372). COUP-TF1! has been shown to be expressed 
in human liver mesenchymal and ductal cells but not hepatocytes (423). 
However, a recent paper using a ~-galactosidase marker driven by a 
COUP-TF1! pramoter did detect expression in murine hepatocytes, leaving 
the issue of whether COUP-TF1! could be involved in liver-specific GHR 
expression contraversial (424). 
We chose to study the raie of HNF-4a in regulating Vl transcription, in 
view of its abundance in the liver and its raie in regulating severa 1 hepatic 
genes [reviewed in (371)]. Nine isoforms of HNF-4a have been described 
(385). Two leader exons, exon lD and exon lA regulate the transcription 
of ail nine isoforms (386;389). The isoforms differ in the N-terminal and 
C-terminal regions. The leader exons also regulate the developmental-
and, to a lesser extent, the tissue-specificity of HNF-4a isoforms. Pl 
isoforms, transcribed fram exon lA are the predominant isoforms in 
postnatalliver (386-389). However P2 isoforms are more abundant in 
foetalliver, dedifferentiated cell types, stem cells and non-hepatic HNF-4a 
expressing tissues (e.g. pancreas and small intestine) (351;386-
389;401;425). Therefore, it appears that P2 HNF-4a isoforms are more 
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involved in the regulation of early genes and immature liver functions. 
We determined HNF-4a isoform expression in human liver and ceillines 
by RT-PCR and western blot analyses. The HNF-4a antibody used can 
detect HNF-4a isoforms 1,2,5,6,7 and 8. The results show that the P2 
isoform (HNF-4a8) is expressed in foetal hepatocytes and in the 
dedifferentiated hepatic ceillines, HepG2 and Huh7. The Pl isoform 
(HNF-4a2) was detected in both foetal and postnatalliver and also in 
HepG2 and Huh7 cells. 
Initially, we studied the effect of HNF-4a1 on V1 transcriptional activity. 
Subsequently, we switched to HNF-4a (2+8) as they were the isoforms 
we found to be expressed in the human tissues and cell lines. Transient 
transfection studies were conducted in HEK293 cells, as HNF-4a protein 
was not detectable. The V1 constructs tested contained a range of 1-6 
putative HNF-4 sites. Constructs containing the two distal HNF-4 
response elements were repressed by HNF-4a (1,2,8). The #1 site on its 
own was highly stimulated by HNF-4a. The contributions of the other 
sites were minor: sites #2 and 3 appeared to be slightly inhibitory whilst 
#4 was slightly stimulatory. Site-directed mutagenesis of sites #1 and #6 
confirm that they are responsible for stimulatory and repressed responses 
to the HNF-4a isoforms (1,2,3). EMSAjEMSSA and ChIP analyses show 
that HNF-4a (2+8) proteins interact with sites #1 and #6, but not site #5 
suggesting that the two major functional HNF-4 sites are #1 and #6. 
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Two pa radoxica 1 results were obtained from the HNF-4 studies. The first 
was that the highest levels of HNF-4a were found in the dedifferentiated 
hepatoma cell lines which didn't express Vi. This was most surprising as 
HNF-4a is a strong regulator of hepatic genes including, as l have shown, 
hGHR, and yet Vi was not expressed in these ceillines. The second was 
that ChIP analyses carried out in one of these ceillines (Huh7) showed in 
vivo occupation of the HNF-4 stimulatory response element (#1). Thus, 
occupation of a response element does not confer transcriptional activity. 
However, HNF-4 expression in HepG2 cells has been reported to be 
uncoupled from its effects on target genes and, thus, the protein may not 
be functional. 
Members of the nuclear receptor family to which HNF-4a belongs are 
activated upon ligand binding. Normally, HNF-4a has been shown to be 
constitutively active, and crystallography experiments have defined FFAs 
entrapped in its ligand binding pocket as essential cofactors (377). One of 
the features of hepatomas and hepatocarcinomas is defective lipid 
metabolism [reviewed in (426)]. Oleic aCid, an LCFA that has lipid 
lowering capabilities, has been shown to inhibit HNF-4a activity and is also 
found at high levels in the hepatoma cell line, HTC 7288c (381;427;428). 
Assuming that the fatty acid profile is similar in Huh7 and HepG2 cells, it is 
highly likely that the HNF-4a ligand binding pockets are occupied by 
antagonists in the hepatoma cells. This would explain the inability of the 
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high levels of HNF-4a in the hepatic tumour cells to stimulate VI mRNA 
expression. 
HNF-4a activity has been shown to be modified by dietary and energy 
status (392;394). Non-esterified fatty acids (NEFA) are transported into 
the cell by fatty acid transporters and converted into fatty acyl coenzyme 
A (FACoA) thioesters by the acyl coenzyme A synthetase (429). The 
FACoA thioesters will then interact with the ACS of HNF-4a and modulate 
its activity and subsequent activation of its target genes (382). Low 
energy status (high AMP:ATP ratios) activa tes the AMP-activated protein 
kinase which in turn phosphorylates HNF-4a and inhibits HNF-4a dimer 
formation, DNA binding, protein stability and subsequent transcriptional 
activity (392). GHR expression is also affected by nutritional status: 
during fasting (and starvation), wh en energy needs to be conserved, GHR 
mRNA expression is downregulated and during feeding it is upregulated 
(430). Thus, dietary status may affect hepatic GHR mRNA expression 
probably by modulating the activity of HNF-4a and its subsequent 
transcriptional activation of VI. 
The two aims of my PhD thesis were to carry out the screening of six 
putative hGHR promoter regions and then to characterise in more detail 
the promoter region of VI and to identify developmental- and liver-specific 
factors that regulate its expression. The use of celilines that do not 
express the VI mRNA variant complicates the identification of regulatory 
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regions in the context of normal postnatalliver. Nevertheless, l was able 
to define three negative and two positive regulatory regions in the V1 
promoter. 
l began to characterise developmental- and liver-specific regulators of V1 
expression: human foetalliver expresses both Pl and P2 isoforms of HNF-
4a, whereas only the Pl isoform is present in adult liver. Pl isoforms 
have been shown to be more potent transcription factors than P2 
isoforms, although l did not observe this in context of the HEK293 ceilline 
used for the transient transfection studies. l had hypothesised that P2 
isoforms (HNF-4a8) would suppress the activity of Pl isoforms (HNF-4a2) 
thus acting as a developmental switch. Unfortunately, l disproved this but 
speculate that other LETFs may act as foetal repressors or postnatal 
activators (e.g. C/EBPa). 
l also identified two transcriptional repressors and began to define their 
role in suppressing V1 expression. A GAGA element was also found to 
mediate stimulation of the 100 bp proximal promoter activity by the 
Drosophila GAF. Obviously, since no mammalian homologues of GAF are 
known, we cannot assess if this is a developmental regulator. But if GH 
changes the levels or activities of endogenous GBPs,as has been shown 
for other genes with GAGA elements, there may be a developmental 
mechanism involving GAGA. 
207 
Finally we found what appear to be similar levels of Gfi-i in foetal and 
postnatal tissues, making it unlikely that it is a developmental-specific 
regulator. However, we still need to assess if the ratios of GBPs and Gfi-i 
in foetal versus postnatal hepatocyte are significantly different. 
ln the section following, 1 discuss possible experiments that could be 
carried out in the future to conclude the study of the mechanisms 
regulating the tissue- and developmental-specific regulation of Vi 
expression. 
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CHAPTER 6: FUTURE DIRECTIONS 
The results of this project have opened up many interesting routes to 
explore. 1 will discuss future directions in module B-related experiments, 
especially those relating to the different factors that 1 have so far been 
investigated. Regulation of module A variants are being studied in the 
Goodyer lab at present by two PhD students: Yuhong Wei and Gurvinder 
Kenth. 
Gfi-l/lb and the Vl promoter 
Given that mutation of either one or both Gfi-ljlb sites in the 300 bp 
proximal promoter region of Vl increased basal activity of the promoter 
constructs, it would be interesting to see if the same mutations in the 
VlPl construct would increase its activity. This would pinpoint the 
elements regulating the repression of the VlPl promoter construct in the 
most 3' 300 bp region. 
ln addition, two other Gfi-ljlb sites were identified by Matinspector, 
upstream of the 300 bp proximal promoter of Vl (Figure 47). Since it has 
been established that Gfi-l and Gfi-lb are potent repressors of Vl, it 
would be of interest to investigate the contribution of these other sites to 
the overall regulation of the V7-Vl promoter by transient transfection 
assays and ChlP analyses of ail four sites in various types of cells and 
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tissues. In module B, the V8 exon has a putative Gfi-ljlb site ~ 50 bp 
upstream of a TATA box. This also should be tested. 
Dysregulation of Gfi-l expression in certain cell types is tumorigenic 
(277;278). In T-cells, Gfi-l has been shown to induce Iymphomas 
together with myc and pim, and inhibit p21 WAF, a cell cycle regulator 
(431-433). GHR mRNA expression and GH binding are reduced in hepatic 
tumours and liver cirrhosis, and Vl expression is low or undetectable 
(244;434-437). 50 far, no link has been made between GHR and Gfi-ljlb 
expression in cancers. It would be interesting to determine whether the 
changes in GHR expression are associated with deregulated Gfi-l and Gfi-
lb activity in the cancerous cells. 
GAGA element 
1 have shown that Drosophi/a GAF-519 stimulates the transcriptional 
activity of the Vl proximal promoter region through the GAGA element. 
EM5A results also show the interaction of endogenous GBPs with the 
GAGA element. To determine what GBPs are present in HEK293 as weil 
as other cell types, we could use the GAGA element as bait in yeast one-
hybrid assays; a cDNA library of choice (using data from EM5A 
experiments) could then be screened in order to identify any proteins that 
may be interacting. 
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Figure 47: Gfi-1j1b sites and GAGA elements within the V1 region. 
Two other Gfi-1b sites are located ""' 1.1 kb and 400 bp upstream of the 
TSS. A 3X GAGA element is found ""' 1.5 kb upstream of the TSS. A 
second 21 bp GAGA element is present""' 70 bp downstream of the TSS, 
within the V1 exon. 
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Cloning of the cDNA encoding the protein would determine if it is a 
mammalian homologue to the Drosophi/a GAF. Once the sequence is 
known, antibodies can be raised and used to determine whether there is a 
tissue- or developmental-specific expression pattern. The cDNAs can be 
used in transient transfection assays to determine functional activity on 
the Vl promoter. 
The function of the GAGA element as a GHRE in the proximal Vl promoter 
has also not been fully investigated. The effect of exposing different test 
cells to varying concentrations of hGH on the transcriptional activity of the 
Vl promoter should be studied to determine if there are GH effects on 
endogenous GBPs, as has been shown for the ATl receptor gene (313). A 
comparison of the different Vl promoter constructs would delineate any 
additional sequences that display responsiveness to hGH. In this way, 
although StatS response elements have not been detected by sequence 
analyses, alternative functional GHREs may be defined. Two other GAGA 
elements were identified by MatInspector, one in the 1.8 kb Vl promoter 
region, and the other within the Vl exon (Figure 47). These should be 
tested to determine if they have individual or "cooperative" activity. 
HNF-4a. 
HNF-4a interacts with both coactivators and corepressors, and Pl and P2 
isoforms of HNF-4a similarly repressed and activated Vl promoter activity. 
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Thus, determining cofactors interacting at each site by ChIP-on-ChIP 
analyses would shed light on the opposing effects of HNF-4a on the Vi 
promoter. In addition, only three of the six putative HNF-4 sites have 
been investigated to date. From the deletion promoter experiments, sites 
#2 and #3 have been hypothesised to be inhibitory, and site #4 
stimulatory. Using transient transfection assays, site directed 
mutagenesis, EMSA, EMSSA and ChIP analyses, the function of these sites 
and their contribution to the regulation of Vi (and V7) should be 
investigated. 
LETFS 
Severa 1 putative sites for multiple LETFs were identified by computer 
based TF screening. 
DBP is of major interest as it is expressed only in rat postnatal liver and it 
is involved in regulating the diurnal expression of several hepatic genes. 
However, preliminary data suggest that this is not the case in humans. 
We were able to detect DBP mRNA and immunoreactive protein in both 
human foetal hepatocytes and postnatal liver (438). The rat DBP protein 
is 87% homologous to the human DBP. Preliminary cotransfection 
experiments with either rat or human DBP did not yield any consistent 
results. However, severa 1 members of the PAR family of proteins (DBP, 
HLF and TEF) ail bind to the same site, including E4BP4, a transcriptional 
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repressor (439;440). Studies have shown that E4BP4 is also under 
circadian regulation and that expression of E4BP4 and DBP is antiphasic 
(440). It would be interesting to test the hypothesis that DBP and E4BP4 
are involved in regulating the postnatal diurnal expression of GHR mRNA 
in hepatocytes and that we have not observed DBP effects because of the 
presence of high levels of E4BP4 in our test cells. Since circadian rhythms 
are present in many celilines (441), it would be of interest to determine, 
in cells that have been synchronized, the nuclear proteins interacting with 
the DBP sites, using EMSA, EMSSA and ChIP analyses, as the collection of 
human hepatocytes at specifie times would be impossible. 
Expression of human IGF-II is under the control of four promoters: P1-P4. 
P2, P3 and P4 are highly active during foetal life, whilst Pl is not. Pl is 
switched on in the postnatal liver, and P2-P4 are down regulated. 
Rodenburg et al. showed that the Pl promoter activity was stimulated by 
CjEBPa, CjEBPP and HNF-3p in HEK293 and Hep3B cells whereas HNF-
4a1 suppressed its activity only in Hep3B cells (442). CjEBPa and CjEBPP 
also abolished HNF-4a1 mediated repression of the Pl promoter. There 
are three putative CjEBP sites in the 1.8 kb promoter region of V1. Using 
transient transfection assays, site-directed mutagenesis, EMSNEMSSA and 
ChIP analyses, the function of the three CjEBP sites should be 
investigated. As has been done with studies of the liver-specific Pl 
promoter of the human IGF-II gene, analyses of the interactions of other 
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LETFs (e.g. HNF-l, HNF-6) on the Vl promoter should also be carried out 
(442). 
A LOCUS CONTROL-like REGION (LCR-like)? 
LCRs have been described for the hGH, globin and apolipoprotein cluster 
of genes [(443;444) and reviewed in (445;446)]. These LCRs are located 
severa 1 kb upstream of the gene clusters and are involved in remodelling 
the chromatin downstream to allow for regulated gene expression. The 
LCR region of the apolipoprotein gene cluster is referred to as a hepatic 
control region (HCR) and contains binding sites for HNF-3 and HNF-4 
(446). 
The expression of module B variants is switched on in the same tissue and 
at the same developmental stage, suggesting that there is some common 
activation mechanism. One possibility is an upstream region that mimics 
an LCR, with one or more transcription factors that act at a simple locus 
to "open" the chromatin of module B. A second possibility is that there is 
a common postnatal liver-specific transcription factor or set of 
transcription factors for ail four exon promoters. Ali four contain TATA-
like boxes although those of V7, V4 and VS are not consensus TATA 
sequences. A comparison of the V7/Vl, V4 and VS promoter regions 
show some common putative elements (e.g. HNF-4) and unique sites (e.g. 
STAT6) that should be further investigated to test this hypothesis. 
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These suggested experiments are by no means exhaustive but they 
should provide greater insight into the mechanisms involved in regulating 
expression of this complex and intriguing gene that is essential to the 
postnatal growth of man. 
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CHAPTER 7: ORIGINAL CONTRIBUTIONS 
1. 1 have demonstrated that V1, V2, V3, V4, V7 and V8 5' UTR exons of 
the hGHR gene have individual promoter activities. 
2. By promoter deletion studies of the 1.8 kb promoter region of the V1 
exon, 1 have defined two positive regulatory regions, confirmed the 
presence of two negative regulatory regions and discovered a third 
negative regulatory element. 
3. 1 have determined that the third negative regulatory region (NRR1), 
the 250 bp proximal promoter region of V1, contains functional binding 
sites for the transcriptional repressors, Gfi-1 and Gfi-1b, as weil as a 
functional 4X GAGA element that could be stimulated by the Drosophi/a 
GAGA binding factor, GAF, as demonstrated by transient transfection 
assays and site-directed mutagenesis. Because the Gfi-1j1b site and 
the GAGA element in the 100 bp proximal promoter region overlap, 1 
tested the effects of Gfi-1 and GAF in competition experiments and 
found that the two factors interact. 
4. 1 have shown that isoforms of HNF-4a are developmentally regulated 
in the human hepatocyte as has been shown in the mouse: Pl (HNF-
4a2) and P2 (HNF-4a8) protein isoforms were detected in human 
foetal hepatocytes at equal amounts while human postnatal liver 
contains only the Pl (HNF-4a2) protein isoform. 
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5. 1 have investigated in detail three of the six putative HNF-4 sites 
identified by computer-based transcription factor scanning programs in 
the 1.8 kb promoter region of the V1 exon. 1 have demonstrated that 
the HNF-4a (a2+a8) effects on the V1 promoter are complex: both 
isoforms stimulated V1 transcriptional activity through an HNF-4 
response element (site #1) in the proximal promoter, and suppressed 
activity through a distal HNF-4 response element (#6). ChIP analyses 
suggest that in the Huh7 ceilline, where HNF-4a (a2 and a8) proteins 
are abundant, both the proximal (#1) and distal HNF-4 sites are bound 
by HNF-4a (a2+a8). Thus, 1 have shown that the hGHR promoter is a 
transcriptional target of Pl (a2) as weil as P2 (a8) HNF-4a isoforms 
and that their transcriptional effects are site specifie. 
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the report was found to be acceptable for ongoing conduct at the McGill University Health Centre. 
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The re-approval for the study was provided via expedited review of the Chair on May 16, 2006 and 
will be reported to the Research Ethics Board (REB) at its meeting of May 31, 2006. This decision 
will be entered accordingly into the minutes. The Research Ethics Board (REB) noted that no 
revision to the approved consent document aune 10,2003) is required at this cime. 
Ali research involving human subjects requires review at a recurring interval and the current study 
approval is in effect until May 16, 2007. It is the responsibility of the principal investigator to 
submit an Application for Continuing Review to the REB prior to the expiration of approval to 
comply with the regulation for continuing review of "at least once per year". 
However, should the research conclude for any reason prior to the next required review, you are 
required to submit a Termination Report to the Committee once the data analysis is complete to 
give an account of the study findings and publication status. 
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sponsored research activities that require US federal assurance are conducted under 
Federal Wide Assurance (FWA) 00000840. 
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~ A copy of the appropriate REB-approved consent document has been signed by each person 
who has volunteered as a subject of the research unless otherwise authorized by the REB. 
~ A copy of the signed document was offered to each subject, and each signed original is on file 
in a secure location. 
~ [fthe study involves an MUHC paüent receiving investigaüonal treatment on a research 
protocol, a copy of the Executive Summary, and of signed consent document was sent to the 
paüent's medical record and/or clinic file, and a "wallet card" was given to the subject. 
1 have reviewed the content 01 this report inc/uding the above statements, and assure the REB 
olitsac/) 
Signafu~~~-C/ Date: 11/21/05 
b) On behalf of the _____ h'\c-=-"..:-l+ __ Research Ethics Board (REB), 1 confirm that: 
~ the following decision was authorized by the REB: 
~ decision was provided following: 
C approval with conditions 
C continuing review tabled 
r: approval disallowed 
r other: 
C Full Board Review Cvbpedited Review 
~ duration of the REB approval is provided for (no.) : __ ) d. __ months or n NIA 
Name: REB position: 
Review date: 
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McGill Universitv Health Centre - Royal Victoria Hospital 
Consent Form 
Titfe ofthe study: Use of placental and fetai tissues for research 
Principal investigator: Dr. Cynthia Goodyer, Department ofPediatrics, McGill University 
Introduction: Vou are about to have a surgi cal operation. This form asks your permission for 
the placental and fetal tissues removed during the operation to be used for biomedical and gene 
research projects. These projects will be carried out at the Royal Victoria Hospital, or at other 
research institutions in Quebec or outside Quebec. 
Purpose of the study: The tissues will be used for research projects approved beforehand by the 
Research Ethics Committee of the Royal Victoria Hospital or the Research Ethics Committees at 
any other institution where research using the placental and fetal tissues is to be carried out. The 
projects (see list at the end of this form) have had a scientific review and are financed by 
Canadian and/or American govemment heaith research funding agencies, and/or pharmaceutical 
companies, and/or private sector foundations. 
Risks: There is no physical risk associated with your giving permission for the placental and 
fetal tissues to be used for research purposes. The use of these tissues for research will not change 
either the usual surgical procedures or your care. 
Advantages: There will not be any direct benefit ta you as a result of agreeing to the use of the 
placental and fetal tissues for research. It is hoped, however, that the research carried out on these 
tissues wiII help other persons in the future. 
Compensation: There is no financial compensation associated with your agreement that the 
tissues can be used for research. 
Nature of the participation: Vou are free to give or to refuse your permission that the placental 
and fetal tissues removed during surgery may be used for research. Whatever your decision, it 
wiII not affect the quality of care that you receive or your future care. Since aII tissues are 
obtained anonymously (without your name or any other form of identification), it is impossible ta 
communicate the results from the research projects in which the tissues were studied. 
Confidentialitv: Your medical file will remain confidential because we will collect the tissues 
anonymously; the researchers will not be able to link these tissues ta yOU. In addition, the tissues 
and anything resulting from these tissues will be destroyed when the research project is 
completed. The results arising from the research will be the responsibility of the project's 
principal investigator and will be kept for as long as they are useful. 
Persons to contact: If you have questions conceming the research projects, please cali Dr 
Cynthia Goodyer, the principal investigator, at the Montreal Children's Hospital (Tel: 514-412-
4400, extension 22481). If you have questions conceming your rights, you can call the 
Ombudsman at the Royal Victoria Hospital (Tel: 514-934-1934, extension 35655). 
June 10,2003 
2 
Summarv of the Research Projects using Human Placenta' and Feta' Tissues 
The placental and fetal tissues will be used in basic research studies of diseases that, as yet have 
no cure. At present, the researchers are using these tissues to better understand: 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
what genes are not functioning nonually in children who grow too slowly; 
how the kidney loses its ability to control calcium levels in the body; 
what changes in genes may cause people to have a higher risk of developing diabetes; 
how to identify those cells in the pancreas that can produce insulin and prevent diabetes; 
how brain cells fonu and communicate with each other; 
what controls the death ofbrain cells in people with Alzheimer's, prion ("mad cow") disease 
and foHowing a stroke; ,...-..... ------
how brain are injured and how they can be repaired in people with multiple sclerosis;~ a.
how brain tumors [onu; L" en fi) , 
how changes in the tissues that [orrn bone joints may cause arthritis; 0 a fiE B 
the effect of toxic factors in the environment on the development of fetal tissues; Z ~ OZ n~ 
how the lung develops. ~ o"!C ~ - §! : 
w _....::;'i-- ~ ~I' 
CONSENT 
0: .... N '1 <ê 9 tJ-·{~ 
- -Ct:"'" 
O:z:: <.> 2: 0 :t: LU u.. 
:::rI ~ :r. F.l 
Ùl ~ (J ':' 
O::wLk : 
..... :J:c(,i Z ..... LùP. 0 ..... (1) Q.. 
1 agree that the placental and fetal tissues removed during the surgical procedure may be lIi Or~ ~ 
biomedical or gene research purposes. l have had the opportunity to ask aIl of my questitm~I1'mt-------' 
these have been answered to my satisfaction. l have received a copy of this consent form. 
Participant Signature Date 
Study Nurse Coordinator Signature Date 
..., ~-~-------
MONTREAL CHllDRENIS HOSPITAL 
OF THE MUHC 
June 10, 2003 
Centre universitaire de santé McGiU -Hôpital Royal Victoria 
Formulaire de consentement 
Titre de J'étude: Utilisation de tissus placentaire et fœtal à des fins de recherche 
Chercheur principal: Dr Cynthia Goodyer, Département de Pédiatrie, Université McGi11 
Introduction: Vous allez recevoir une intervention chirurgicale. Le présent formulaire vise à obtenir votre 
consentement pour l'utilisation des tissus du placenta et du fœtus destinés à des projets de recherches 
biomédicales et de recherches sur les gènes réalisés à l'Hôpital Royal Victoria, ou à d'autres établissements 
de recherche au Québec ou à l'extérieur du Québec. 
But de l'étude: Les tissus prélevés seront utilisés dans le cadre de projets de recherche préalablement 
approuvés par le comité d'éthique à la recherche de l'Hôpital Royal Victoria ou d'un autre établissement où 
seront menés des projets de recherche qui utilisent les tissus placentaires et foetaux. Les projets de recherche 
dont il est question (voir liste ci-jointe) ont été évalués pour leur mérite scientifique et ils sont financés par 
des organismes gouvernementaux de la recherche de la santé canadiens/américains, et/ou des sociétés 
pharmaceutiques et/ou des fonds du secteur privé. 
Risques: il n . existe pas de risque physique associé à votre consentement à donner vos tissus du placenta et 
du fœtus dans le but de la recherche. L'utilisation des tissus à des fins de recherche ne changera en rien la 
procédure usuelle chirurgicale ou vos soins. 
Avantages: Il n 'y aura aucun bienfait direct résultant de votre consentement à l'utilisation de tissus du 
placenta et du fœtus destinés à la recherche. On espère cependant que les recherches effectuées à partir des 
tissus aideront d'autres personnes à l'avenir. 
Compensation: TI n'y a pas de compensation financière associée au consentement de l'utilisation des 
tissus dans le but de la recherche. 
Nature de la participation: Vous êtes entièrement libre de consentir ou non à ce que les tissus placentaire 
et fœtal prélevés lors de la procédure chirurgicale soient utilisés à des fins de recherche. Peu importe votre 
décision, cela n'affectera pas la qualité des soins que vous recevez ou vos soins à l'avenir. Puisque tous les 
tissus sont obtenus anonymement (sans votre nom ou autre forme d'identification), il est impossible de vous 
communiquer les résultats des projets de recherche auxquels les tissus ont été examinés. 
Confidentialité: Votre dossier médical demeurera confidentiel car nous recueiI1erons les tissus de façon 
anonyme. Les chercheurs ne pourront pas faire le lien entre ces tissus et vous. Par ailleurs, les tissus 
prélevés ainsi que tout ce qui ressort de ces tissus seront détruits lorsque le projet de recherche sera terminé. 
Les résultats découlant de la recherche seront sous la responsabilité de l'investigateur principal d'un projet 
et conservés aussi longtemps qu'ils seront utiles. 
Personne ressources: Si vous avez des questions concernant les projets de recherche, vous pouvez 
communiquer avec le Dr Cynthia Goodyer, l'investigateur principal, à l'Hôpital de Montréal pour enfants 
(514) 412-4400, poste 22481). Si vous avez des questions concernant vos droits, vous pouvez communiquer 
-- ·ec l'ombudsman de l'Hôpital Royal Victoria «514) 842-1231, poste 35655). 
Sommaire des projets de recherche gui utilisent les tissus humains du placenta et du fœtus 
Les tissus placentaire et fœtal seront utilisés envers des projets de recherches fondamentales sur des 
maladies qui, jusqu'à présent, sont encore incurables. Présentement, les chercheurs utilisent ces tissus pour 
mieux comprendre; 
• 
• 
• 
• 
• 
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Quels gènes fonctionnent anormalement chez les enfants avec une croissance retardée. 
Comment les reins perdent leur capacité de régulation du calcium dans le corps. 
Quelles différences au niveau des gènes prédisposent certaines personnes au diabète. 
Comment identifier les cellules du pancréas qui produisent l'insuline et préviennent lè diabète. 
Comment les cellules du cerveau se développent et communiquent entre elles. 
Comment les cellules du cerveau meurent chez les personnes atteintes de l'Alzheimer, les maladies 
du prion (vache folle), et accident vasculaire cérébral. 
• . Comment les cerveaux sont endommagés et pourraient être réparés chez les personnes a !tes de la 
• 
• 
• 
• 
sclérose en plaque. 
Comment les tumeurs cérébrales se développent. 
Comment les changements dans les tissus des articulations peuvent causer l'arthrite. 
Etudier les effets toxiques de l'environnement sur le développement des tissus fœtaux. 
Comment les poumons se développent. 
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material in your doctoral thesis. Please use the following 
acknowledgment: "Reprinted, with permission, from the Annual Review of 
Physiology, Volume 58 (c) 1996 by Annual Reviews 
www.annualreviews.org" 
This permission to reprint is for a one-time usage only and any 
subsequent use of this material requires submission of a new permission 
request. Fees for this noncommercial usage have been waived for you. If 
l can be of further assistance, please do not hesitate to contact me. 
Best wishes for success with your thesis. 
Sincerely, 
Laura Folkner 
Permissions Department 
ANNUAL REVIEWS 
A Nonprofit Scientific Publisher 
4139 El Cami no Way 
palo Alto, CA 94306 
Ph: 650.843.6636 
Fax: 650.855.9815 
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From: josafo@po-box.mcgill.ca [mailto: josafo@po-box.mcgill.ca 
Sent: Sunday, June 04, 2006 10:24 PM 
To: Permissions 
Subject: Permission to use figures for my PhD thesis. 
To whom it may concern: 
l am writing my PhD thesis and would like permission to use the 
following figures: 
Figures 1 and 2 from A nnual Review of Physiology 
Vol. 58: 187-207 (Volume publication date October 1996) 
Molecular Mechanism of Growth Hormone Action by C Carter-Su, -J 
Schwartz, and -L J Smit. 
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To: "Joy.osafo@mail.mcgill.ca'" <joy.osafo@maiLmcgill.ca>e 
Subject: RE: Obtain Permission 
Headers: Show AH H,~aders 
« ... OLE_Obj ... » 
Dear Ms Osafo 
We hereby grant you permission to reproduce the material detailed below in 
your thesis at no charge subject to the following conditions: 
1. If any part of the material to be used (for example, figures) has 
appeared in our publication with credit or acknowledgement to another 
source, permission must also be sought from that source. If such permission 
is not obtained then that material may not be included in your 
publication/copies. 
2. Suitable acknowledgment to the source must be made, either as a 
footnote or in a reference list at the end of your publication, as follows: 
"Reprinted from Publication title, Vol number, Author(s), 
Title of article, Pages No., Copyright (Year), with permission from 
Elsevier" . 
3. Reproduction of this material is confined to the purpose for which 
permission is hereby given. 
4. This permission is granted for non-exclusive world English rights 
only. For other languages please reapply separately for each one required. 
Permission excludes use in an electronic form. Should you have a specific 
electronic project in mind please reapply for permission. 
5. This includes permission for the Library and Archives of Canada to 
suppl Y single copies, on demand, of the complete thesis. Should your thesis 
be published commercially, please reapply for permission. 
Yours sincerely, 
« ... OLE_Obj ... » 
Natalie David 
Senior Rights Assistant 
Your future requests will be handled more quickly if you complete the online 
form at www.elsevier.com/permissions < http://www.elsevier.com/permissions > 
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Fax: 
Email Address: 
To use the 
ISSN/ISBN: 
following material: 
Title: 
Author(s) : 
Volume: 
Issue: 
Year: 
Pages: 
Article title: 
The int j of biochem n cell biology 
moroy t 
37 
3 
2005 
541 - 546 
The zinc finger transcription 
How much of the requested material is to be used: 
figures 1 and 2 
Are you the author: No 
Author at institute: No 
How/where will the requested material be used: 
Details: 
Additional Info: 
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Dear Ms Osafo 
We hereby grant you permission to reproduce the material detailed below in 
your thesis at no charge subject to the following conditions: 
l. If any part of the material to be used (for example, figures) has 
appeared in our publication with credit or acknowledgement to another 
source, permission must also be sought from that source. If such permission 
is not obtained then that material may not be included in your 
publication/copies. 
2. Suitable acknowledgment to the source must be made, either as a 
footnote or in a reference list at the end of your publication, as follows: 
"Reprinted from Publication title, Vol number, Author(s), 
Title of article, Pages No., Copyright (Year), with permission from 
Elsevier". 
3. Reproduction of this material is confined to the purpose for which 
permission is hereby given. 
4. This permission is granted for non-exclusive world English rights 
only. For other languages please reapply separately for each one required. 
Permission excludes use in an electronic form. Should you have a specific 
electronic project in mind please reapply for permission. 
5. This includes permission for the Library and Archives of Canada to 
supply single copies, on demand, of the complete thesis. Should your thesis 
be published commercially, please reapply for permission. 
Yours sincerely, 
« ... OLE_Obj ... » 
Natalie David 
Senior Rights Assistant 
Your future requests will be handled more quickly if you complete the online 
form at www.elsevier.com/permissions < http://www.elsevier.com/permissions > 
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Canada 
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Fax: 
Email Address: joy.osafo@mail.mcgill.ca 
To use the 
ISSN/ISBN: 
following material: 
Title: 
Author (s) : 
Volume: 
Issue: 
Year: 
Pages: 
Article title: 
Current biology 
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5 
3 
1995 
238 - 241 
Gaga over gaga factor 
How much of the requested material is to be used: 
figure 1 
Are you the author: No 
Author at institute: No 
How/where will the requested material be used: In a thesis or dissertation 
Details: 
Additional Info: 
- end -
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your thesis at no charge subject to the following conditions: 
1. If any part of the material to be used (for example, figures) has 
appeared in our publication with credit or acknowledgement to another 
source, permission must also be sought from that source. If such permission 
is not obtained then that material may not be included in your 
publication/copies. 
2. Suitable acknowledgment to the source must be made, either as a 
footnote or in a reference list at the end of your publication, as follows: 
"Reprinted from Publication title, Vol number, Author(s), 
Title of article, Pages No., Copyright (Year), with permission from 
Elsevier" . 
3. Reproduction of this material is confined to the purpose for which 
permission is hereby given. 
4. This permission is granted for non-exclusive world English rights 
only. For other languages please reapply separately for each one required. 
Permission excludes use in an electronic form. Should you have a specific 
electronic project in mind please reapply for permission. 
5. This includes permission for the Library and Archives of Canada to 
supply single copies, on demand, of the complete thesis. Should your thesis 
be published commercially, please reapply for permission. 
Yours sincerely, 
« ... OLE_Obj ... » 
Natalie David 
Senior Rights Assistant 
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Control of gene expression by 
How much of the requested material is to be used: 
Requesting permission to modify figure 2 for my PhD thesis. 
Are you the author: No 
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How/where will the requested material be used: 
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Additional Info: 
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Not original author to publish in a Dissertation. 
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Name: Joy Osafo 
Organization: MUHC-MCHRI 
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Address: 4060 St Catherine West 
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City, State and Postal Code: Montreal, Quebec h3z 2z3 
Country: Canada 
Phone: 514 937 7167 
Fax: 5144124478 
Email: jOy.osafo@mail.mcgill.ca 
Journal: Endocrinology 
Author Name: Goodyer CG 
Title: Organisation and evolutions of the human growth hormone receptor gene 5' flan king region 
Year: 2001 
Volume: 142 
Page Range: 1923-34 
Figure Modification: 
Figure Number(s): 9 
Prior Approval: The paper is from the lab in which 1 am doing my PhD. The modifications reflecl updates from the literature, as 
directed by my supervisor, Dr. Cindy Goodyer, the first author of the paper. 
Where will the figures appear: 
- Dissertation 
- Title: Regulation of the V1 variant of the human growth hormone receptor gene by Gfi-1, Gfi-1 b, a 
- Publisher: Joy Osafo 
The Endocrine Society grants permission to modify table/figure 9 from the selecled article stated above contingent upon the 
following conditions: 1) That you give proper credit to the author(s) and to include in your citation, the title of journal, title of 
article, volume, issue number, date, and page numbers. 2) That you include the statement Copyright 2001, The Endocrine 
Society. Please understand that permission is granted for one-time use only. Permission must be requested separately for future 
editions, revisions, translations, derivative works, and promotional pieces. 
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Title: Journal Publications Coordinator 
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TIN Number: 73-0531256 
was submitted by: joy.osafo@mail.mcgill.ca 
Not original author to publish in a Dissertation. 
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Organization: McGi/I University Health Centre, MCHRI 
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Journal: The Journal of Clinical Endocrinology & Metabolism 
Author Name: Amit t 
Title: A membrane-flXed, truncated isoform of the human growth hormone receptor. 
Year: 1997 
Volume: 82 
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Figure Reproduction: 
Figure Number(s): figure 6 
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- Publisher: Joy Osafo 
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upon the following conditions: 1) That you give proper credit to the author(s) and to include in your citation, the title of journal, 
title of article, volume, issue number, date, and page numbers. 2) That you include the statement Copyright 1997, The 
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2of3 
<mailto: joy~osafo@mail~mcgill~ca> 
Sent: Monday, June 05, 2006 12:41 AM 
To: healthpermissions@elsevier.com 
Subject: Obtain Permission 
This Email was sent from the Elsevier Corporate Web Site and is related to 
Obtain Permission form: 
Product: Customer Support 
Component: Obtain Permission 
Web server: http:,I /w-ww. else",rier. com <http://\ ... r ... ~ ... \1. el se"'"ier . corn > 
IP address: 10.10.24.149 
Client: Mozilla/5.0 (Windowsi Ui Windows NT 5.1i en-GBi rv:1.8.0.4) 
Gecko/20060508 Firefox/1.5.0.4 
Invoked from: 
http://www.elsevier.com/wps/finà/obtainpermissionform.cws_home?isSubmitteà=y 
es&navigateXmlFileName=/store/prod_webcache_act/framework_support/obtainperm 
ission.xml 
<http; ,1 /lAT'\""rw. else-vier. cOTn/\9ps/find/obtainperrnissionforrn. C\VS horne?isSu.bm.i tted= 
yes&~avigateXmlFileName=/store/prod_webc~che_act/framework=support/obtainper 
mission.xml> 
Request From: 
Ms Joy/K Osafo 
McGill University Health Centre, MCHRI 
4060 St Catherine West, Rm 514-1 
h3z 2z3 
Montreal 
Canada 
Contact Details: 
Telephone: 
Fax: 
Email Address: 
514 937 7167 
514 412 4478 
To use the following material: 
ISSN/ISBN: 
Title: 
Author(s) 
Volume: 
Issue: 
Year: 
Pages: 
Article title: 
Molecular and Cellular Endocrinology 
strous and van kerkhof 
197 
1-2 
2002 
143 - 151 
The ubiquitin-proteasome pathway 
How much of the requested material is to be used: 
Requesting permission to use figure 3 in my PhD thesis. 
Are you the author: No 
Author at institute: No 
How/where will the requested material be used: In a thesis or dissertation 
Details: 
Additional Info: 
thesis. 
Requesting permission to use figure 3 in my PhD 
6/712006 4:40 PM 
Mail :: lnbox: RE: Permission to use figures for my PhD thesis. http://webmai1.mcgill.calmessage.php?actionID=print_ message&in ... 
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Date: Tue, 06 Jun 2006 13:09:51 -0700 [06/06/2006 04:09:51 PM EDT) 
From: Permissions <Permissions@annualreviews.org> 
To: josafo@po-box.mcgill.ca 
Subject: RE: Permission to use figures for my PhD thesis. 
- __ - _._ -'·-0--·· •. _ •..• _ ......... _ .• _. __ ...... _ ............................. _ ... __ .. _ .• _ •. _. __ ....•. 
Dear Joy Osafo: 
Thank you for your request for permission ta reprint the figures cited 
in your e-mail below. We are happy ta grant you permission ta use this 
material in your doctoral thesis. Please use the following 
acknowledgment: "Reprinted, with permission, from the Annual Review of 
Physiology, Volume 58 (c) 1996 by Annual Reviews 
www.annualreviews.org" 
This permission ta reprint is for a one-time usage only and any 
subsequent use of this material requires submission of a new permission 
request. Fees for this noncommercial usage have been waived for you. If 
l can be of further assistance, please do not hesitate ta contact me. 
Best wishes for success with your thesis. 
Sincerely, 
Laura Folkner 
Permissions Department 
ANNUAL REVIEWS 
A Nonprofit Scientific Publisher 
4139 El Camino Way 
palo Alto, CA 94306 
Ph: 650.843.6636 
Fax: 650.855.9815 
lfolkner@annualreviews.org 
-----Original Message-----
From: josafo@po-box.mcgill.ca [mailto: josafo@po-box.mcgill.ca 
Sent: Sunday, June 04, 2006 10:24 PM 
Ta: Permissions 
Subject: Permission to use figures for my PhD thesis. 
Ta whom it may concern: 
l am writing my PhD thesis and would like permission ta use the 
following figures: 
Figures 1 and 2 from A nnual Review of Physiology 
Vol. 58: 187-207 (Volume publication date October 1996) 
Molecu1ar Mechanism of Growth Hormone Action by C Carter-Su, -J 
Schwartz, and -L J Smit. 
Thank you, Joy Osafo 
6/7/20064:37 PM 
L'Institut de recherche du Centre universitaire de santé McGi11 
The Research Institute of the McGi11 University Health Centre 
Santé et Sécurité au travail 
Occupationnal Health and Safety 
Ceci certifie que: 
This is to certify that: 
Joy Osafo 
A réussi avec succès le cours de transport de marchandises dangereuses pour les marchandises dangereuses de la 
classe 6.2 seulement, en conformité avec l'article 6.2 de la Loi et du Règlement sur le transport des marchandises 
dangereuses au Canada (Langage Clair). 
Has successfully completed the transport of dangerous goods trainning for dangerous goods of class 6.2 only, in 
compliance with part 6.2 of the Transport ofDangerous Goods Act and Regulations of Canada (Clear Language). 
Wednesday, April 07, 2004 
Dac Hien Vuong Coordonateur en santé et sécurité 
Hea/th and Safety Coordinator 
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A réussi avec succSS':;le cours en 
Has successfully ;owpleteda 
),f 
20 0eplember, 2002 
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HC) 
de radioprotedflon en laboratoires 
radiation safety course for 
MaU 
Maureen McQueen 
Officier de radioprotection 
Radiation Safety Otticer 
